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Introduction 
mTOR in normal physiology and disease 
The mammalian target of rapamcyin (mTOR) is a central regulator of cell 
growth that has been highly conserved through evolution from yeast to 
mammals. mTOR responds to growth factors, nutrients and energy levels to 
promote protein synthesis and proliferation under replete conditions and to 
conserve energy and promote survival during periods of stress or starvation. 
The importance of TOR for development is clearly illustrated by the embry-
onic lethality of TOR mutants in Drosophila melanogaster, Caenorhabditis 
elegans, and Mus musculus. TOR knockout embryos die shortly after implan-
tation due to impaired trophoblast differentiation and failure of embryonic 
stem cells to proliferate (1, 2). Dysfunction of mTOR signaling has also been 
implicated in a number of human diseases including obesity, type II diabetes, 
muscle atrophy, cardiac hypertrophy, neurodegenerative disorders such as 
Huntington’s and Alzheimer’s disease, and cancer (3). Current research ef-
forts are investigating the therapeutic potential of modulating mTOR signaling 
in the management of these disorders. 
mTOR signaling complexes 
The mTOR kinase carries out its function within the context of two structurally 
distinct multi-protein complexes, mTORC1 and mTORC2 (Figure 1). 
mTORC1 consists of mTOR in association with LST8 and Raptor. LST8 and 
mTOR are the only common components present in both TOR complexes. 
LST8 binds constitutively to the catalytic domain of mTOR and stimulates its 
kinase activity (4). Raptor acts as a scaffolding protein to bring mTORC1 
substrates such as p70S6K and 4E-BP1 within close proximity of the mTOR 
kinase domain. By phosphorylation of these substrates, mTORC1 plays a 
role in regulating the process of mRNA translation. A fourth partner of com-
plex 1, PRAS40, binds mTORC1 under conditions of serum or nutrient depri-
vation and acts as a negative regulator of mTORC1 (5). Phosphorylation of 
PRAS40 by Akt or mTOR itself appears to release its inhibitory effect on 
mTORC1 (6). 
 
mTORC2 contains mTOR, LST8, and Rictor in addition to the recently identi-
fied proteins SIN1 and PRR5/Protor (7, 8). Much less is known about the up-
stream regulation and function of this complex, although it is currently an 
area of active research. This complex has downstream substrates that are 
distinct from those of mTORC1, most likely as a consequence of the unique 
proteins present in this complex. Importantly, mTORC2 is responsible for 
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phosphorylation of Akt at serine residue 473 (9) and is involved in the organi-
zation of the actin cytoskeleton via phosphorylation of protein kinase C-alpha 
(PKCα) (10). 
 
 
Figure 1. Members of the two multi-protein mTOR complexes. mTOR forms a part of two struc-
turally and functionally distinct protein complexes termed mTORC1 and mTORC2. mTORC1 
consists of mTOR in association with LST8 and Raptor. PRAS40 can bind to mTORC1 under 
certain conditions such as serum or nutrient starvation. mTORC1 regulates mRNA translation via 
its downstream targets p70S6K and 4E-BP1. mTORC2 comprises mTOR, LST8, and Rictor. 
Sin1 and PRR5 have also recently been found to associate with mTORC2. Akt and PKCα have 
been identified as mTORC2 substrates. Rapamycin, the small molecule inhibitor of mTOR, spe-
cifically targets mTORC1. 
Regulation of mTOR by growth factors 
mTORC1 is activated by the binding of various growth factors to their respec-
tive receptors located at the cell surface. Best described is the action of insu-
lin and insulin-like growth factors which stimulate mTORC1 by way of the 
phosphatidylinositol-3-kinase (PI3K) pathway (Figure 2). There is some evi-
dence that mTORC2 may also be activated by growth factors via PI3K, al-
though little else is currently known about signaling upstream of mTORC2 
(9). In addition to insulin, a number of other growth factors such as vascular 
endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and 
epidermal growth factor (EGF) can also activate PI3K signaling. 
 
Activation of the pathway begins by binding of the appropriate ligand to its 
receptor, which stimulates the kinase activity of the receptor to phosphorylate 
key tyrosine residues within the intracellular domain. Type 1a PI3K is then 
recruited to these phospho-tyrosine residues by direct binding of SH2 do-
mains present in its p85 regulatory subunit. In some cases, the interaction 
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between p85 and the receptor is indirect and occurs via substrate adaptor 
proteins such as the insulin receptor substrates IRS1 and IRS2 (11). Binding 
of PI3K has a dual function in that it releases the inhibitory function of p85 on 
the p110 catalytic subunit and also positions PI3K in close proximity to the 
plasma membrane where its substrate, phosphatidylinositol 4,5 bisphosphate 
(PIP2), resides. Phosphorylation of PIP2 by PI3K generates phosphatidyl-
inositol 3,4,5 triphosphate (PIP3) which stimulates the recruitment of kinases 
such as PDK1 and Akt to the plasma membrane via interaction with their 
pleckstrin homology domains. PI3K signaling is controlled by the phos-
phatase PTEN, which can dephosphorylate PIP3 to PIP2 and limits further 
downstream activation of the pathway.  
 
Akt activation requires phosphorylation on two residues; Thr308 which is 
phosphorylated by PDK1 when the two kinases are brought into close prox-
imity at the plasma membrane by PIP3, and Ser473 which is phosphorylated 
by the mTORC2 complex (9, 12). Phospho-Akt has numerous direct down-
stream targets that promote survival and growth, one of which is tuberous 
sclerosis complex 2 (TSC2). TSC2 forms a complex with TSC1, and together 
this complex is an important negative regulator of mTORC1. Akt activation 
leads to inhibition of the TSC1/TSC2 complex and thus activation of 
mTORC1. When TSC2 is phosphorylated by Akt, it becomes bound by 14-3-
3 proteins which sequester it to the cytosol and away from membrane-bound 
TSC1 (13). The TSC1/2 complex acts to downregulate mTORC1 activity by 
stimulating Rheb, a small Ras-like GTPase that interacts with mTORC1, to 
hydrolyze GTP to GDP. The activity of Rheb is determined by its guanine 
nucleotide binding state; Rheb in a GTP-bound form strongly stimulates 
mTORC1 activity while GDP-bound Rheb is inactive. Therefore, upon mito-
gen exposure, signaling through the PI3K/Akt pathway represses the function 
of TSC1/2, allowing GTP-bound Rheb to accumulate, and resulting in the 
activation of mTORC1. A recent report by Sato et al. has shed light on the 
mechanism of mTORC1 activation by Rheb-GTP (14). They show that Rheb 
does not induce autophosphorylation of mTOR (ie mTOR kinase activity) but 
that Rheb enhances the binding of substrates to mTORC1 by increasing their 
access to Raptor. 
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Figure 2. The mTOR signal transduction pathway. Activity of the mTOR-Raptor complex 
(mTORC1) is positively regulated by extracellular growth factors and by amino acids. Binding of 
growth factors to a cell surface receptor sets off a signaling cascade through the PI3K-PDK1-
Akt pathway to the TSC1/2 complex. For complete activation of Akt, phosphorylation of Ser473 
by mTOR-Rictor (mTORC2) is required. Currently little is known about the upstream regulation 
of mTORC2. TSC is a major negative regulator of mTORC1 which is inactivated by Akt which 
promotes sequestration of TSC2 by 14-3-3 proteins. Hypoxia and low energy levels, on the 
other hand, can stimulate TSC2 via REDD1 and AMPK respectively. This stimulates the TSC1/2 
complex to activate GTP hydrolysis by Rheb, leading to accumulation of GDP-bound Rheb and 
inhibition of mTORC1. Hypoxia can also promote Rheb-GDP in a TSC-independent manner via 
BNIP3. Accumulation of GTP-bound Rheb positively regulates activity of mTORC1. Amino ac-
ids, by activation of the Rag heterodimer, allow activation of mTORC1 by Rheb-GTP. Down-
stream targets of mTORC1 include 4E-BP1, p70-S6K and eEF2K which all function in some 
aspect of mRNA translation. 
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Deregulation of PI3K and mTOR in cancer 
In cancer, mutagenic events often occur in genes whose encoded proteins 
function in the PI3K signaling pathway, thus resulting in constitutive activation 
of mTOR and uncontrolled proliferation in the absence of mitogenic signals. 
Activating mutations in PI3K subunits, mutation or amplification of various 
growth factor receptors and loss of PTEN expression are common events 
reported in human malignancies that play a role in the deregulation of PI3K 
signaling. One such mutation involves the epidermal growth factor receptor 
(EGFR) whereby genomic deletion of exons 2-7 results in expression of a 
truncated form of the receptor called EGFRvIII. This EGFR variant lacks a 
portion of the extracellular ligand-binding domain and exhibits constitutively 
elevated kinase activity in the absence of ligand. EGFRvIII expression is re-
ported in 50% of gliomas, and is also common in breast, prostate and non-
small cell lung cancer, but is not found in normal tissue (15). Clinical studies 
have demonstrated a correlation between EGFRvIII expression and poor 
prognosis for patients with glioblastoma. Signaling downstream of EGFRvIII 
is also different compared to wild-type EGFR, with a preferential activation of 
the PI3K pathway and relatively less stimulation of the MAPK and STAT3 
signaling pathways (16). Current interest lies in combining EGFR targeted 
therapies with mTOR inhibitors, as this treatment strategy seems to be par-
ticularly effective towards tumors which develop resistance against EGFR 
antagonists (17, 18). 
Regulation of mTOR by cellular energy levels 
Protein synthesis consumes a large proportion of the total cellular energy 
(estimated at 20-45% in mammalian cells), thus it is crucial that the rate of 
mRNA translation be linked to the ATP supply. Since mTOR is a key regula-
tor of protein synthesis, it is not surprising that mTOR activity is coupled to 
cellular energy status. This connection is mediated by AMPK, a kinase that 
responds to changes in the ratio of AMP to ATP. It is important to note that 
the energy dependent regulation of mTOR signaling is dominant to other 
pathways such as insulin or amino acid stimulation, so that mTOR cannot be 
activated by other sources if energy levels are not permissive. AMPK be-
comes activated in a multi-step process that is initiated by the binding of two 
AMP molecules to the γ-subunit. This induces a conformational change that 
allows the subsequent phosphorylation of the α-subunit on Thr172 by LKB1 
(19). In contrast, under energy replete conditions when the ATP:AMP ratio is 
high, binding of ATP to AMPK inhibits its activation by preventing this phos-
phorylation event. Experiments utilizing the AMP mimetic 5-aminoimidazole-
4-carboxamide 1-β-D-ribonucleoside (AICAR) have shown that increased 
AMPK activity correlates with dephosphorylation of mTORC1 targets (20).  
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The mechanism that mediates the repression of mTOR by AMPK involves 
the phosphorylation of TSC2 on multiple sites by AMPK. These phosphoryla-
tion events stimulate the inhibitory activity of TSC2 towards Rheb and mTOR 
(21), in contrast to the inactivating phosphorylation of TSC2 by Akt in re-
sponse to growth factors. A possible second mechanism occurs by direct 
phosphorylation of mTOR by AMPK on Thr2446, however the consequence 
of this phosphorylation event on mTOR function is not clear (22). More re-
cently, Gwinn et al. found that AMPK phosphorylates Raptor on 2 serine resi-
dues (Ser722 and Ser792) in response to energy stress (23). Cells with intact 
AMPK signaling normally undergo cell-cycle arrest during energy stress, 
however they found that cells unable to phosphorylate Raptor continue to 
proliferate and ultimately undergo apoptosis. This demonstrates the require-
ment of Raptor phosphorylation by AMPK for mTORC1 inhibition and cell-
cycle arrest induced by energy stress (23). 
Regulation of mTOR by amino acids 
Given that mTORC1 stimulates processes that use large amounts of amino 
acids, such as ribosome biogenesis and mRNA translation, it is physiologi-
cally advantageous for mTOR to respond to the availability of essential amino 
acids that mammalian cells are unable to synthesize themselves. Amino ac-
ids pay a key role in maintaining basal levels of mTOR signaling. In particu-
lar, the intracellular concentration of leucine, an essential branched-chain 
amino acid, positively regulates mTORC1 activity through a pathway parallel 
to the insulin signaling network (24). Leucine uptake is mediated by the 
SLC7A5-SLC3A2 amino acid antiporter which was recently shown to import 
leucine while exporting glutamine (25). Thus when cells are starved for 
glutamine, extracellular leucine cannot enter the cell and as a result, 
mTORC1 cannot be activated even in the presence of growth factors. The 
intracellular sensor of leucine or other amino acids which influence mTORC1 
activity remains unknown, although it has been shown that the Rag family of 
small GTPases are involved in transmitting the amino acid input to mTORC1 
(26, 27). Amino acids stimulate GTP loading of the Rags as well as their 
binding to Raptor. While this association does not stimulate mTOR kinase 
activity in vitro, there is evidence that it promotes mTORC1 relocation to 
vesicles that contain Rheb. Thus Rags may position mTORC1 at an optimal 
location to receive growth factor signals via Rheb when amino acids are pre-
sent. 
 
Vps34, a class 3 PI3K member, may also be involved in regulating mTORC1 
under conditions of amino acid or glucose starvation, although the mecha-
nism is currently unknown. Recent research provides evidence that Vps34 
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acts at a point downstream of TSC2 and upstream of mTORC1 and shows 
that Vps34 is required for the insulin stimulation of mTORC1 targets (28, 29). 
However, the involvement of Vps34 in regulating TOR signaling has been 
brought into question as it was not found to hold true in a Drosophila model 
(30). 
Regulation of mTOR signaling by oxygen  
Oxygen is a crucial regulator of cellular metabolism. When oxygen levels be-
come limiting, cells rapidly activate adaptive mechanisms to reduce energy 
expenditure by inhibiting energy-intensive processes such as mRNA transla-
tion (31). This effect occurs in part through inhibition of mTORC1 as can be 
seen upon exposure of cells to low oxygen (hypoxia) which reduces 
mTORC1 activity towards 4E-BP1 and p70S6K (32). Downregulation of 
mTOR signaling can thus be considered as a component of the cellular re-
sponse to hypoxia.  
 
A key aspect of the hypoxia response involves the hypoxia-inducible factor 
(HIF) family of transcription factors which orchestrate the transcriptional 
changes required for hypoxia tolerance. HIFs are rapidly activated by post-
transcriptional mechanisms when oxygen levels drop below normal and sub-
sequently promote the expression of genes whose products promote angio-
genesis, anaerobic metabolism, cell motility and invasion. These processes 
function to improve tissue oxygenation and to maintain cellular ATP produc-
tion in the absence of oxygen. BNIP3 and REDD1 are transcriptional targets 
of HIF which act to inhibit mTORC1 activity under hypoxia. REDD1 promotes 
the dissociation of TSC2 from 14-3-3 proteins, thereby restoring the inhibitory 
function of TSC2 towards Rheb and mTORC1 (33). BNIP3 acts downstream 
of TSC2 by interacting with Rheb directly and decreases the amount of active 
GTP-loaded Rheb (34).  
 
Apart from the HIF-dependent regulation of mTORC1 there are also HIF-
independent mechanisms which downregulate mTORC1 activity. For exam-
ple PML, the promyelocytic leukemia tumor suppressor, also prevents the 
association of Rheb with mTORC1 but does so by co-localizing with mTOR in 
the nucleus under hypoxic conditions (35). Severe or long-term hypoxia also 
contributes to mTORC1 regulation indirectly by activating the energy stress 
pathway via AMPK as described in the previous section. Energy levels de-
crease under hypoxia since cells must rely on anaerobic glycolysis to gener-
ate ATP, a much less efficient method than the oxygen consuming process of 
oxidative phosphorylation. However, moderate hypoxia is able to activate 
AMPK very quickly (within 30 minutes) under serum-deplete conditions, 
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which correlates with inhibition of mTORC1 (36). This appears to be a con-
sequence of rapidly decreasing ATP levels under hypoxia when growth fac-
tors are not present.  
 
The fact that hypoxia influences mTOR through multiple mechanisms sug-
gests that it may be particularly important for adaptation to this stress. 
Possible link between folliculin and mTOR 
An interesting new connection has been made between mTORC1 signaling 
and folliculin, a protein of unknown function. Germline mutations in the gene 
encoding folliculin cause a rare genetic disease called Birt-Hogg-Dubé (BHD) 
syndrome. The characteristic features of BHD include benign skin tumors 
originating from the hair follicles (fibrofolliculomas) on the face and upper 
torso, lung cysts leading to spontaneous pneumothorax, and an increased 
risk of developing renal carcinoma (37). Mutations in the BHD gene are inher-
ited in an autosomal dominant fashion and have been characterized in a 
number of families. The majority of reported human mutations are either 
frameshift or nonsense mutations that are predicted to cause protein trunca-
tion and result in haploinsufficiency (38). It is thought that folliculin acts as a 
typical tumor suppressor. Evidence to support this idea comes from renal 
tumors of BHD patients that have lost expression of the remaining wild-type 
allele, as well as loss-of-heterozygosity that has been reported at this locus in 
sporadic kidney tumors (39, 40). BHD syndrome displays phenotypic similari-
ties with several familial hamartoma syndromes such as Peutz-Jeghers syn-
drome, Cowden syndrome and Tuberous Sclerosis Complex. These diseases 
are characterized by benign tumors that develop in multiple tissues and ele-
vated risk of malignant cancer. Hamartoma syndromes all share a common 
upregulation of mTORC1 signaling, so it is a logical assumption that folliculin 
is also somehow connected to mTOR. The link between folliculin and 
mTORC1 has recently been confirmed in a kidney-specific BHD knock-out 
mouse where strong activation of Akt/mTORC1 and MAPK pathways was 
observed (41). How exactly folliculin is regulating mTORC1 is still not clear, 
although there is some evidence to suggest that folliculin associates with 
AMPK via two recently identified interacting proteins, FNIP1 and 2 (42, 43). 
Folliculin may therefore be involved in energy and/or nutrient sensing through 
the AMPK and mTOR pathways.  
Regulation of mRNA translation by mTOR  
The result of stimulating mTORC1 activity is manifested in cellular changes 
such as increased cell growth (cell size and mass), increased proliferation, 
Thesis_Weppler_v12_fc.pdf
Chapter 1 
 18 
angiogenesis, and increased survival (44). These downstream effects are all 
thought to be mediated by mTORC1’s regulation of mRNA translation. 
 
The process of mRNA translation involves the sequential decoding of mRNA 
by the ribosome into protein. Ribosomes are composed of 2 subunits, termed 
the ‘small’ 40S subunit and the ‘large’ 60S subunit, which together are com-
prised of 85-90 distinct proteins and four different ribosomal RNA molecules 
(45). The ribosome catalyzes the formation of peptide bonds between amino 
acids of the newly synthesized protein. Translation can be divided into three 
distinct stages: initiation, elongation, and termination. All stages require addi-
tional translation factors which transiently associate with the ribosome and 
allow separate regulation of the various stages. For most mRNAs, initiation 
begins by recruiting the 40S ribosomal subunit to the 5’ cap structure of the 
mRNA (Figure 3). This occurs following formation of the eIF4F complex con-
sisting of eIF4E (the cap-binding protein), eIF4G (a large scaffolding protein 
which is crucial for binding of the ribosome), and eIF4A (an RNA helicase) 
(46). As discussed later, mTOR plays an important role in regulating the 
availability of eIF4E to participate in this complex. Together with the methio-
nyl-tRNA and certain initiation factors, the 40S subunit scans along the 5’ 
untranslated region (UTR) for the start codon. During elongation, the poly-
peptide chain is assembled in a stepwise fashion according to the reading 
frame of the mRNA.  
 
Elongation requires two translation factors, eEF1 and eEF2. eEF2 is also 
regulated by mTOR and is required for translocation of the ribosome to the 
next codon in the mRNA (45). Termination occurs when the ribosome en-
counters a stop codon, resulting in the release of the polypeptide chain and 
ribosomal subunits. It is common for multiple ribosomes to initiate translation 
of an mRNA molecule in succession, which allows the simultaneous produc-
tion of several peptides from a single mRNA. This structure is termed a 
‘polyribosome’ or ‘polysome’ and can be isolated to determine which mRNAs 
are actively synthesizing protein at any given time or condition. 
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Figure 3. mTORC1 regulation of mRNA Translation. Initiation of translation begins by assem-
bling the eIF4E-eIF4G-eIF4A complex at the 5’ cap of the mRNA. This process is stimulated by 
mTORC1 via inhibition of the eIF4E binding protein (4EBP). This initiation complex recruits the 
40S ribosomal subunit which scans the 5’ UTR for the AUG start codon where the 60S ribosomal 
subunit joins to form a functional ribosome. Elongation is also stimulated by mTORC1 by activa-
tion of the eEF2 elongation factor which is required for translocation of the ribosome along the 
mRNA. Upon encountering a stop codon, translation is terminated by releasing the nascent pep-
tide and ribosomal subunits. 
Translational control and cancer 
There is increasing evidence that aberrant regulation of mRNA translation 
can contribute to cellular transformation and malignancy. In numerous can-
cers, general protein synthesis rates are significantly elevated in comparison 
to normal tissue (47, 48). In addition, many tumor suppressors and onco-
genes have been identified which control protein synthesis. Finally, strong 
genetic support of this hypothesis comes from studies which show that ex-
perimental overexpression of eIF4E can cause malignant transformation (49, 
50) and from an animal model of B-cell lymphoma that demonstrates eIF4E is 
tumorgenic in vivo (51, 52). How then might increased mRNA translation 
cause cancer? Not all mRNAs respond the same way to increases in transla-
tion initiation. Some mRNAs, many of which encode proteins influencing pro-
liferation, apoptosis, angiogenesis, and metastasis, have long 5’UTRs with 
complex secondary structure and show much greater dependency on eIF4E 
and other cap-dependent initiation factors for their translation. For example, 
c-Myc, cyclin D1, ornithine decarboxylase (ODC), matrix metalloproteinase-9 
(MMP-9), and vascular endothelial growth factor (VEGF) all fall within this 
group of mRNAs whose translation rates respond to availability of the eIF4F 
initiation complex and whose expression is linked to the defining hallmarks of 
cancer (53, 54). Therefore, prolonged upregulation of translation initiation can 
Thesis_Weppler_v12_fc.pdf
Chapter 1 
 20 
promote malignancy through the differential expression of mRNAs involved in 
transformation and tumor progression.  
Stress adaptation by translation regulation 
Eukaryotic cells possess a variety of mechanisms to dynamically regulate 
gene expression, so that appropriate proteins can be made available to cope 
with diverse cellular environments and to perform tissue-specific functions. 
These include epigenetic, transcriptional, post-transcriptional, translational, 
and post-translational processes which all play a role in determining the final 
proteome composition of a cell at any particular time. Under rapidly changing 
environmental conditions, translation regulation is particularly important as it 
allows cells to immediately adjust the production of particular proteins from 
the existing pool of mRNA transcripts. Transcriptional regulation, by compari-
son, takes much longer to implement changes at the level of protein expres-
sion, since mRNA must first be transcribed, processed and transported to the 
cytoplasm before new proteins can be synthesized. A simple analogy is to 
think of translational regulation like carrying an umbrella with you in case it 
should rain. At the first sign of inclement weather, by raising the umbrella you 
will stay relatively dry. Should conditions worsen or continue for longer peri-
ods of time, you may consider going home to get your raincoat (transcrip-
tional regulation). 
Downstream effectors of TORC1 signaling 
The role of mTOR in the regulation of mRNA translation is brought about by 
the actions of three well described direct downstream effectors of mTORC1: 
S6K, 4E-BP, and eEF2 kinase.  
S6K 
In order for the S6 kinases (S6K1 and S6K2) to become activated they must 
be phosphorylated on multiple sites. mTORC1 associates with the S6 
kinases through an interaction between Raptor and the TOR-signaling (TOS) 
motif located at the amino terminus of S6K. This interaction with TORC1 
promotes the phosphorylation of S6K at Thr389 by mTOR (55). Phosphoryla-
tion at this site is required for subsequent phosphorylation by PDK1 at 
Thr229 located in the activation loop of the catalytic domain (56). Once phos-
phorylated at Thr229, S6K is fully activated and can phosphorylate its own 
downstream targets, such as ribosomal protein S6 (a part of the 40S ribo-
somal subunit). S6 phosphorylation correlates with increased protein synthe-
sis and since S6 is located at the mRNA binding site of the ribosome, it is 
hypothesized to be involved in positively regulating translation (57, 58). How-
ever, there is little evidence that demonstrates that S6 phosphorylation actu-
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ally stimulates translation. One theory that has since been disproved is that 
S6K controls the translation of a subset of mRNAs that contain a 5’ terminal 
oligopyrimidine (TOP) tract. 5’ TOP mRNAs include a number of ribosomal 
proteins and translation elongation factors and the translation of these 
mRNAs correlates strongly with mTORC1 activity (59). However, S6K1/S6K2 
knockout mice still retained translation of 5’ TOP mRNAs which could be 
blocked using rapamycin, an mTORC1 inhibitor (60). Therefore, there ap-
pears to be another mTORC1-dependent protein involved in the regulation of 
5’ TOP translation other than the S6 kinases. However, recent evidence has 
shown that while TOP translation is dependent on mTOR, knock-down of ei-
ther raptor or rictor has only a slight inhibitory effect, therefore suggesting 
that mTOR may regulate TOP translation through a novel pathway with only 
a minor contribution of mTORC1 (61). Nevertheless, the role of mTOR in 5’ 
TOP translation is clear and demonstrates how mTOR signaling can stimu-
late ribosome biogenesis through increased production of ribosomal proteins.  
 
Of course, functional ribosomes also require a rRNA component. mTOR is 
also able to control rDNA transcription by a link between S6K and the UBF 
rDNA transcription factor (62). Thus, mTORC1 signaling to S6K will ultimately 
increase the total translational capacity of the cell and lead to an increase in 
cell size and mass. 
 
Not long ago, S6K1 was shown to phosphorylate eIF4B and facilitate its re-
cruitment into translation initiation complexes (63). This target of S6K may 
perhaps be physiologically more important than S6 in regulating translation. 
eIF4B stimulates the RNA helicase activity of eIF4A. Data suggest that phos-
phorylation enhances eIF4B activity and promotes the translation of mRNAs 
containing secondary structure (64). 
 
A negative feedback loop of the PI3K/Akt/TORC1 pathway has also been 
described which involves phosphorylation of the insulin-receptor substrates 
IRS1 and IRS2 by S6K (65). This serves to downregulate insulin stimulation 
of the PI3K pathway. However, if chronically activated, this negative feedback 
loop may contribute to insulin resistance and the onset of obesity or diabetes. 
4E-BP 
The eIF4E binding proteins (4E-BP1, 2 and 3) are a group of translational 
repressor proteins which compete with eIF4G for an overlapping binding site 
on eIF4E, so that when 4E-BP is bound to eIF4E, it prevents formation of the 
eIF4F complex and recruitment of the 40S ribosome for translation initiation 
(46). In this way, 4E-BPs are important for the repression of cap-dependent 
translation by mTOR under sub-optimal growth or stress conditions. Trans-
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genic mice lacking 4E-BP1 and 4E-BP2 display elevated insulin resistance 
and sensitivity to diet-induced obesity, demonstrating a role for 4E-BPs as 
“metabolic brakes” (66). 
 
The interaction between 4E-BP and eIF4E is regulated by a complex series 
of phosphorylation events. Hypo-phosphorylated 4E-BPs bind eIF4E with 
high affinity, whereas hyper-phosphorylated 4E-BPs rapidly dissociate (67). 
The 4E-BPs also rely on a TOS motif for interaction with Raptor and 
mTORC1, just as the S6Ks. Evidence suggests that mTORC1 is responsible 
for phosphorylation of 4E-BP1 on Thr37 and Thr46 in response to nutrient 
signaling (68). Phosphorylation of 4E-BP1 occurs in a hierarchical manner 
such that phosphorylation of Thr37 and Thr46 is required to prime subse-
quent phosphorylation of Thr70, followed by Ser65 (69). Thr70 and Ser65 are 
responsive to insulin and growth factors and respond to inhibition by rapamy-
cin. However, in vitro kinase assays do not confirm mTOR as the kinase that 
directly phosphorylates these residues (68). Therefore it seems likely that an 
mTORC1-associated or mTORC1-controlled kinase is required for phos-
phorylation of these sites.  
eEF2 
In addition to regulating translation initiation, mTORC1 also influences the 
elongation step of protein synthesis via eEF2. Association of eEF2 with the 
ribosome is controlled by phosphorylation of Thr56 in its GTP-binding domain 
(70). Phosphorylation of this residue is catalyzed by eEF2 kinase and inhibits 
the binding of eEF2 to the ribosome, thus impairing its activity. mTOR signal-
ing negatively regulates eEF2 kinase activity by multiple inhibitory phosphory-
lation events. One of these sites (Ser 366) has been shown to be a direct 
target of S6K1 (71). Phosphorylation of two additional sites (Ser78 and 
Ser359) is also dependent upon mTORC1, although the kinase(s) directly 
responsible has yet to be identified (72). Therefore, by blocking the inhibitory 
effect of eEF2 kinase upon eE2F, mTOR can promote translation elongation. 
mTOR inhibitors in cancer therapy 
The mTOR kinase was discovered as the result of studies conducted in yeast 
investigating a macrolide compound with antifungal properties called rapamy-
cin, what would later become known as the first mTOR inhibitor (73). Rapamy-
cin was first isolated from the bacterium Streptomyces hygroscopicus obtained 
from a soil sample collected on Easter Island (Rapa Nui) in the early 1970s 
(74). Due to the immunosuppressant properties of rapamycin, its development 
as an antifungal agent was not pursued. However, this same property made 
rapamycin attractive for the treatment of graft rejection after organ transplanta-
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tion. As a laboratory tool, rapamycin enabled the elucidation of the mTOR 
pathway and has shed light on the potential of mTOR inhibitors for the treat-
ment of a broad range of disorders including cancer, inflammatory and cardio-
vascular diseases. A number of rapamycin analogs with superior pharmacoki-
netic properties have been developed, for example RAD001 (Novartis), 
CCI779 (Wyeth) and AP23573 (Ariad), all of which are currently undergoing 
clinical testing for the treatment of various malignancies (44). FDA approval 
has been granted to mTOR inhibitors for use in solid organ transplants and in 
drug-eluting stents for cardiovascular disease. 
 
The mechanism of rapamycin’s inhibitory action is distinct from other small-
molecule kinase inhibitors and also contributes to its remarkable specificity.  
In order to be biologically active, rapamycin must bind initially to a cytoplas-
mic receptor protein, FKBP12. This complex then interacts with the FRB 
(FKBP12-rapamycin binding) domain of mTOR (Figure 4). Since the FRB 
domain lies outside of the catalytic domain, rapamycin-FKBP12 is not thought 
to function by direct inhibition mTOR catalytic activity but rather by means of 
steric hindrance whereby the association of mTOR with raptor is disrupted 
and thus substrate acquisition to mTORC1 is impaired (75). The FRB domain 
is unique to mTOR and is not found in similar kinases of the PI3K-related 
kinase family, therefore contributing to rapamycin’s specificity. Another clini-
cally relevant advantage is that the interaction between rapamycin-FKBP12 
and mTOR is extremely stable, thus making the blockade of mTORC1 signal-
ing essential irreversible once the complex has formed (76, 77). For reasons 
that are not clear, rapamycin-FKBP12 binds only to mTOR proteins that re-
side in mTORC1 (i.e. mTOR present within the mTORC2 complex is unable 
to bind rapamycin-FKBP12 directly). One possibility is that components of 
mTORC2 may physically block binding of rapamycin-FKBP12 to mTOR when 
in this complex. However, chronic treatment of cells with rapamycin can indi-
rectly inhibit mTORC2 function by binding to newly synthesized mTOR pro-
tein and limiting the pool of mTOR molecules available for assembly into 
mTORC2 (78).  
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Figure 4. Inhibition of mTOR by rapamycin. The FRB domain of mTOR serves as the high-
affinity binding site for the rapamycin-FKBP12 complex. Other important mTOR domains include 
the N-terminus HEAT domains which mediate protein-protein interactions and the kinase domain 
(KD) which harbors the catalytic site. The FAT and FATC domains are conserved regions found 
in protein which are members of the PI3K-like kinase (PIKK) family.  
 
Aims of this thesis 
In this thesis, I examine various aspects related to mTOR signaling in cancer 
with a focus on its role in the tumor microenvironment. The general aims of 
this thesis are to elucidate how mTOR signaling and the regulation of mRNA 
translation contribute to the response of tumor cells to microenvironmental 
stresses such as hypoxia or to cancer therapy, in order to exploit mTOR as a 
potential therapeutic target. 
Specific objectives 
Hypoxia is a common feature of solid tumors that contributes to mTOR regu-
lation and modulates mRNA translation by both mTOR-dependent and inde-
pendent mechanisms. Chapter 2 describes why hypoxia adversely affects 
patient prognosis and how we can exploit the unique properties of hypoxic 
tumors for cancer treatment. In chapter 3, the mechanisms regulating mRNA 
translation inhibition under hypoxia are characterized. By examining cells cul-
tured under hypoxic conditions, the dynamic changes in global mRNA trans-
lation, as well as several patterns of gene-specific changes in translation are 
quantified.  
 
In chapter 4, we investigated the involvement of a signaling molecule up-
stream of mTOR (EGFRvIII) in tumor progression and response to therapy. A 
stable cell line model was generated and used to assess the impact of 
EGFRvIII on radiation sensitivity, in vivo tumor growth, and survival under 
hypoxia. 
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Chapter 5 addresses the potential of mTOR as a therapeutic target in cancer 
using an animal model. In order to determine if mTOR inhibition could im-
prove the local tumor control brought about by radiotherapy, rapamycin was 
given in combination with fractionated radiation to mice carrying glioblastoma 
xenografts. 
 
In chapter 6 we characterized the regulation of mRNA translation initiation 
mediated by the mTORC1 target 4E-BP1. In this study, a parallel mTORC1-
independent pathway that signals to 4E-BP1 is described. 
 
A number of genetic syndromes that are characterized by benign hamartoma 
tumors, display overactive mTOR signaling. In chapter 7, we present an in-
teresting case of Birt-Hogg-Dubé syndrome in which we investigated the in-
volvement of mTORC1 in tumor tissue from the patient. In addition, prelimi-
nary data suggesting the involvement of mTORC2 are presented in the dis-
cussion. 
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Abstract 
There is overwhelming evidence that solid human tumors grow within a 
unique microenvironment. This environment is characterized by an abnormal 
vasculature, which leads to an insufficient supply of oxygen and nutrients to 
the tumor cells. These characteristics of the environment limit the effective-
ness of both radiotherapy and chemotherapy. Measurement of the oxygena-
tion status of human tumors has unequivocally demonstrated the importance 
of this parameter on patient prognosis. Tumor hypoxia has been shown to be 
an independent prognostic indicator of poor outcome in prostate, head and 
neck and cervical cancers. Recent laboratory and clinical data have shown 
that hypoxia is also associated with a more malignant phenotype, affecting 
genomic stability, apoptosis, angiogenesis and metastasis. Several years 
ago, scientists realised that the unique properties within the tumor micro-
environment could provide the basis for tumor-specific therapies. Efforts that 
are underway to develop therapies that exploit the tumor microenvironment 
can be categorised into three groups. The first includes agents that exploit 
the environmental changes that occur within the microenvironment such as 
hypoxia and reduced pH. This includes bioreductive drugs that are specifi-
cally toxic to hypoxic cells, as well as hypoxia-specific gene delivery systems. 
The second category includes therapies designed to exploit the unique prop-
erties of the tumor vasculature and include both angiogenesis inhibitors and 
vascular targeting agents. The final category includes agents that exploit the 
molecular and cellular responses to hypoxia. For example, many genes are 
induced by hypoxia and promoter elements from these genes can be used for 
the selective expression of therapeutic proteins in hypoxic tumor cells. An 
overview of the various properties ascribed to tumor hypoxia and the current 
efforts underway to exploit hypoxia for improving cancer treatment will be 
discussed.  
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Introduction 
Hypoxia is present in solid human tumors 
During the past 10 years, it has become evident that solid human tumors very 
often contain regions that are deficient in oxygen. The presence of hypoxia 
has been demonstrated in cervical cancer [1,2], squamous cell carcinoma 
(SSC) of the head and neck [3,4], melanoma [5,6], breast [7,8] and more re-
cently in prostate cancer [9]. The oxygen levels are typically very heteroge-
neous both among patients and within individual tumors. Oxygenation status 
has primarily been measured using either polarographic oxygen electrodes 
(Eppendorf) or biochemical techniques that rely upon the antibody detection 
of nitroimidazole-based adducts within hypoxic tissue (pimonidazole, EF5, 
EF1). Electrode pO2 data have been used extensively in clinical studies and 
are often referred to as the ‘gold standard’ for determining tumor oxygenation 
status. However, these electrodes show no discrimination of cell type or vi-
ability and thus will record readings from less significant (radiobiologically 
speaking) tissue. Since pimonidazole and EF5 are selectively reduced only in 
viable hypoxic cells, they have a theoretical advantage for determination of 
relevant hypoxia. This may also explain why Eppendorf pO2 values do not 
always correlate with the nitroimidazole-based hypoxia marker studies [10–
12]. Reliable methods of identifying patients with hypoxic tumors will be in-
creasingly important in the coming years as therapies targeting this aspect of 
the microenvironment approach use in the clinic. 
Hypoxia is associated with poor prognosis 
The presence of hypoxic cells in human tumors is considered as one of the 
multifactorial causes of tumor treatment resistance. Experimental and clinical 
evidence suggest that the hypoxic fraction in solid tumors reduces sensitivity 
to conventional treatment modalities, influences growth, and may increase 
malignant progression. Importantly, tumor hypoxia has been clinically dem-
onstrated to predict an adverse treatment outcome in the radiotherapeutic 
management of cancer of the head and neck, uterine cervix and soft-tissue 
sarcomas [2,4,13–16]. In head and neck cancer in particular, there is strong 
evidence that hypoxia is associated with poor outcome of radiotherapy in 
terms of locoregional control, disease-free survival and overall survival [13]. 
This poor prognosis due to hypoxia is independent of known prognostic pa-
rameters such as clinical stage. In some cases, the prognostic value of hy-
poxia was shown to be independent of the treatment modality. Patients with 
hypoxic tumors in one series had a worse prognosis when treated with sur-
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gery alone [2]. This result implies that hypoxia may be associated with more 
advanced or aggressive tumors. 
Mechanisms for worse prognosis 
Treatment resistance 
For many years, the importance of hypoxia in solid tumors was linked solely 
to the fact that hypoxic cells are intrinsically more resistant to treatment. For 
ionizing radiation, the dose required to produce the same amount of cell kill-
ing is up to 3 times higher for hypoxic cells compared with well-oxygenated 
cells [17]. Chemotherapeutic drug resistance in hypoxic cells is also partially 
caused by reduced toxicity in the absence of molecular oxygen. Some 
agents, such as bleomycin, require free radicals in their mechanism of cell 
killing. Chemotherapeutic drug resistance can also be caused by the hypoxia-
induced inhibition of cell cycle progression and proliferation, since a number 
of drugs specifically target highly proliferating cells. Proliferation decreases 
as a result of decreasing oxygen levels [18], and it has been shown that the 
drug toxicity falls off as a function of distance from blood vessels [19]. Fur-
thermore, chemotherapeutic drug delivery to hypoxic areas is challenged 
since tumor hypoxia itself arises from insufficient and distorted vasculature. 
Thus the effective dose to hypoxic regions may be much less than to other 
parts of the tumor [19,20]. 
Increased malignancy 
Recently, data have suggested that conditions within the tumor micro-
environment, most notably hypoxia, can influence patient prognosis by 
means other than treatment resistance. These data have come from both the 
laboratory and the clinic. 
Laboratory data 
There is a wealth of data from the laboratory that implicates hypoxia as a 
contributor to the malignant phenotype. Hypoxia has been implicated in pro-
moting metastasis, angiogenesis, and selection of cells with a more malig-
nant phenotype. 
Metastasis 
Several experimental models have shown that tumor hypoxia is associated 
with an increased ability to form metastases. Young and coworkers demon-
strated many years ago that murine tumor cells exposed to severe hypoxia 
increased their metastatic potential [21]. Similarly, in the murine KHT-C fi-
brosarcoma model, hypoxic primary tumors exhibit a significant increase in 
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pulmonary metastases [22]. Other in vitro experiments utilising the vasculosa 
area of early chick embryos to grow human glioblastoma cells demonstrated 
that microvessel density was significantly increased under hypoxia, and that 
migration of tumor cells outside of the main tumor mass occurred only under 
hypoxic conditions [23]. 
 
Hypoxia is able to promote tumor metastasis in two ways: (1) by inducing the 
expression of gene products involved in the metastatic cascade and (2) by 
providing selection pressure for a more aggressive phenotype (see next sec-
tion). The initiation of metastasis is a multistep pathway that involves three 
major processes: degradation of the basement membrane and extracellular 
matrix (ECM), modulation of cell adhesion molecules, and cell migration. Hy-
poxia plays a role in influencing several of these areas, thereby making it an 
attractive target to control tumor progression. 
 
The importance of matrix metalloproteinases (MMPs) in tumor invasion and 
metastasis is widely accepted. This family of enzymes is capable of degrad-
ing constituents of the basement membrane and ECM, including fibrillar col-
lagen, but may also contribute to metastasis through interactions with cell 
adhesion molecules and migration through the ECM [24]. Several studies 
have shown that MMP expression is associated with poor prognosis and de-
creased overall survival [25–27]. Canning and co-workers have shown that 
MDA-MB-231, a highly metastatic breast carcinoma cell line, displays re-
duced secretion of tissue inhibitor of metalloproteinase-1 (TIMP-1) and in-
creased expression of MMP-9 under hypoxic conditions in vitro [28]. In addi-
tion, the increased invasion of MDA-MB-231 cells through matrigel filters un-
der hypoxia can be markedly reduced by addition of a MMP inhibitor. Simi-
larly, in a rabbit model of myocardial infarction, cardiac myocytes show in-
duced MMP-3 and MMP-9 expression, but downregulate TIMP-1 expression 
following infarction [29]. This pattern of MMP expression could be duplicated 
in vitro by culturing myocytes under hypoxic conditions, thus it seems that 
hypoxia is responsible for modulating MMP expression in several pathologi-
cal conditions. 
 
Activation of MMPs under hypoxia may be mediated by increased expression 
of urokinase-type plasminogen activator receptor (uPAR). uPAR is a cell sur-
face receptor responsible for the binding and activation of urokinase-type 
plasminogen activator (uPA). Activated uPA is able to convert plasminogen 
into plasmin, which can then act directly in ECM degradation, and initiate the 
MMP activation cascade [24]. Cell surface associated uPAR is upregulated 
under hypoxia in vitro, and also contributes to invasiveness [30]. Hypoxia 
mediates this increased expression by increasing both transcription and sta-
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bility of uPAR RNA [31]. There is also evidence that the association of uPAR 
with its ligand is directly involved in migration, independent of uPA-mediated 
proteolysis, which in combination with ECM degradation can markedly en-
hance invasion [32].  
 
Most research regarding the regulation of cell adhesion molecules by hypoxia 
has focused on endothelial cells with respect to angiogenesis, with relatively 
few studies having been conducted using tumor cells themselves. One such 
study revealed that cell surface integrins and other adhesion molecules, such 
as CD44 and N-CAM, were transiently downregulated upon exposure to hy-
poxia, leading to an associated decrease in adhesion to ECM components 
that returned to normal levels after reoxygenation [33]. If similar changes 
should occur in vivo, this could have a significant effect on the migration of 
malignant cells from a hypoxic environment to a new site of tumor growth.  
 
In addition to its pro-inflammatory properties, interleukin-8 (IL-8) has been 
associated with the tumorigenicity, angiogenesis, and metastasis of numer-
ous tumors including melanoma, prostate, bladder, pancreas and ovarian 
cancer. In vitro exposure of several different cell types to hypoxia leads to 
elevated levels of both IL-8 mRNA and protein [34,35]. The hypoxic regula-
tion of IL-8 mRNA involves increases in both the stability and transcription of 
the message and is dependent upon the cooperation of the AP-1 and NF-B 
transcription factors. In vivo analysis by immunohistochemistry and in situ 
hybridisation of tumor sections has localised IL-8 expression adjacent to ne-
crotic zones, lending even further evidence to the argument that IL-8 expres-
sion is regulated by hypoxia within the tumor micro-environment [34,36]. IL-8 
expression is often correlated with an aggressive phenotype and has the abil-
ity to cause nonmetastatic cell lines transfected with IL-8 cDNA to become 
highly tumorigenic and invasive [37,38]. IL-8 transfected cells show upregula-
tion of MMP-2 and MMP-9 mRNA, collagenase activity, and increased inva-
siveness through Matrigel-coated filters. 
Selection 
Hypoxia-mediated selection of tumor cells with a diminished apoptotic poten-
tial under hypoxic conditions has been suggested as an important biological 
mechanism for tumor progression [39]. Graeber and colleagues used embry-
onic fibroblasts derived from wt and p53-deficient mice to investigate the role 
of p53 in hypoxia-induced apoptosis and showed that oncogenic transforma-
tion predisposed cells to hypoxia-induced killing through an apoptotic path-
way modulated by p53. They also demonstrated that apoptotic regions were 
more prevalent in p53+/+ tumors than in p53–/– tumors and that apoptotic ar-
eas colocalised with hypoxic regions, distal to adjacent blood vessels. Based 
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on the observation that in a mixture of transformed p53–/– and p53+/+ cells in a 
1 to 1000 ratio, p53–/– cells had overtaken p53+/+ cells after multiple rounds of 
hypoxia and aerobic recovery, they concluded that hypoxia could also select 
for apoptosis-resistant cells. Drawn primarily from these experimental results, 
a mathematical model has recently been developed that describes the effects 
of alternating periods of hypoxia and normoxia on tumors that contain wild-
type and mutant p53 cells [40]. Based on independent experimental results, 
the model can predict the time it takes for a subpopulation of mutant p53 tu-
mor cells to become the dominant population within defined tumor regions, 
both in vitro and in vivo, and provides a qualitative insight into the behaviour 
of mixed populations of wild-type and mutant cells growing under normoxic 
and hypoxic conditions. By studying the role of the human papilloma virus 
(HPV) E6 and E7 genes in sensitising human cervical epithelial cells to hy-
poxia, Kim and colleagues [41] consolidated the results of Graeber and col-
leagues and extended the relevance of these observations made in geneti-
cally manipulated rodent cells to human neoplasia. Furthermore, studies us-
ing three-dimensional cultures of human multicell spheroids have also shown 
that tumor cells bearing mutant p53 are able to sustain longer periods of cel-
lular proliferation in hypoxic conditions than those with the wild-type gene 
[42]. 
 
The selective pressure resulting from hypoxia is not limited to the selection of 
cells with reduced apoptotic potential. It has also been shown to provide a 
possible selection force for cells that have altered oncogenic pathways that 
result in a switch to a more angiogenic phenotype [43].  
 
By promoting the clonal expansion of cells with reduced apoptosis and in-
creased angiogenesis, hypoxia can contribute to the development and malig-
nancy of tumors. Recent clinical results showing that hypoxic cervical can-
cers with a low apoptotic index are highly aggressive strongly support this 
basic experimental concept [44]. 
Angiogenesis 
Tumor progression requires the formation of new blood vessels—the process 
of angiogenesis—in order to provide nutrients and remove catabolites from 
the expanding tumor mass. Angiogenesis is also essential for the efficient 
dissemination of primary tumor cells during metastasis. The early steps of 
angiogenesis and tumor metastasis are nearly identical, as both processes 
involve degradation of the ECM and directed migration of either vascular or 
neoplastic cells. In addition, angiogenesis requires proliferation of the migrat-
ing endothelial cells. Therefore, it is not surprising to find that many of the 
molecules that facilitate tumor cell invasion during metastasis are also in-
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volved in angiogenesis (i.e. MMPs, the uPA system and cell adhesion mole-
cules), and may also be regulated by hypoxia in this function.  
 
Initiation of angiogenesis begins when cells within the tumor micro-
environment respond to hypoxia by the production of the vascular endothelial 
growth factor (VEGF) [45]. In vitro studies by Rofstad’s group have shown 
that D-12 melanoma cells expressing low VEGF levels under aerobic condi-
tions significantly increase VEGF secretion under hypoxia, and demonstrate 
increased angiogenesis and metastatic efficiency in mice [46]. In addition to 
VEGF, hypoxia is also responsible for inducing the expression of the VEGF 
receptors (VEGFR1 and VEGFR2) through HIF-1 mediated transcription [47]. 
Thus, it would seem that hypoxia efficiently promotes an angiogenic signal by 
regulating both the VEGF ligand and its receptors.  
 
Basic fibroblast growth factor (bFGF), like VEGF, is a potent angiogenic fac-
tor, but its expression in endothelium does not appear to be directly regulated 
by hypoxia. bFGF binds with high affinity to heparan sulphate proteoglycans 
in the ECM where it remains sequestered in an inactive form until released by 
the FGF binding protein (FGF-BP). Upon mobilisation by FGF-BP, bFGF can 
exert its biological effects by signaling through one of its four receptor tyro-
sine kinases [48]. Hypoxia may play an indirect role in upregulating bFGF 
activity by inducing FGF-BP through the p38 signal transduction pathway [49, 
50]. Hypoxia can also regulate the amount of extracellular bFGF available to 
stimulate endothelial cells by inducing its secretion, along with that of platelet-
derived growth factor, from macrophages that infiltrate the tumor micro-
environment [51]. 
 
Integrins αvβ3 and αvβ5 are expressed on the angiogenic endothelium where 
they mediate adhesion with ECM components such as vitronectin. Human 
umbilical endothelial cells (HUVECs) exposed to 1% oxygen show increased 
expression of αv and β3 subunits, while β5 expression remained constant 
compared with aerobic controls [52]. A concomitant increase in the attach-
ment to fibrinogen, an αvβ3-mediated process, was also observed under hy-
poxia. There is evidence that this integrin regulates matrix degradation 
through the binding of proteolytically active MMP-2, which facilitates collagen 
degradation in vitro [53]. Cell–matrix interactions can augment VEGF signal 
transduction through complexes of αvβ3 and VEGFR-2, whereby binding of 
vitronectin to its receptor results in increased VEGFR-2 kinase activity [54]. 
Clinical data 
Several clinical studies support the association between hypoxia and malig-
nancy. Data in primary uterine cervical carcinoma [1,2,15,55], soft-tissue sar-
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coma [4,56] and SSC of the head and neck [3,13,14,57–61] showed that tu-
mor hypoxia was prognostic for poorer outcome, irrespective of the treatment 
modality. Different end-points were evaluated, locoregional control, disease-
free survival, disease-specific survival or overall survival. In the study of 
Brizel and colleagues [13], 63 patients with head and neck cancer receiving 
primary radiotherapy underwent pre-treatment polarographic tumor oxygen 
measurement of the primary tumor or a metastatic neck lymph node. The 
median pO2 for the primary lesions was 4.8 mm Hg, and it was 4.3 mm Hg for 
the cervical nodes. Hypoxia adversely affected 2-year local control (30 versus 
73%, P=0.01), disease-free survival (26 versus 73%, P= 0.005), and survival 
(35 versus 83%, P=0.02). 
 
In general, tumor hypoxia does not depend on clinical tumor size, clinical 
stage, histological type, grade, extent of necrosis, or patient haemoglobin 
levels, and is therefore an independent predictor of outcome. Based on these 
results, it has been proposed that tumor hypoxia may directly influence ma-
lignancy and that the poor prognosis of hypoxic tumors is not simply a result 
of resistance to therapy [2,14]. Indeed, tumor hypoxia has been shown to 
promote lymph-vascular space involvement and parametrial infiltration in 
SCC of the uterine cervix [2]. Moreover, positive correlations between the 
lactate concentration of the primary tumor and the incidence of lymph node 
metastases have been demonstrated in cervical carcinoma [62] and in carci-
noma of the head and neck [63]. High lactate level is indicative of extensive 
anaerobic metabolism and, hence, poor oxygenation in the tumor tissue [64].  
 
There is substantial evidence that hypoxia is associated with clinical metas-
tases and several mechanisms have been suggested. Nordsmark and col-
leagues demonstrated an inverse relationship between the tumor cell poten-
tial doubling time (Tpot) and the median tumor pO2 in human soft tissue sar-
comas [56]. The authors suggested that a high proliferation rate was confined 
to more hypoxic tumors. In human cervical carcinoma, a low apoptotic index 
was associated with highly aggressive tumors [44]. Although experimental 
studies suggest that apoptotic cell kill is compromised in hypoxic tumors due 
to TP53 mutations [39], no association between mutant TP53 and hypoxia 
could be found in human soft-tissue sarcomas [16] or in cervical cancers [65]. 
In cervical cancers, a high incidence of metastases in squamous cell carci-
noma of the uterine cervix is associated with poor oxygenation of the primary 
tumor and not with vascular density [66]. 
 
The exact mechanisms by which tumor hypoxia leads to distant metastases 
are still to be elucidated. Some suggestions for improving treatment strate-
gies come from the study of Rofstad and colleagues in SCC of the uterine 
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cervix treated with radiotherapy. The authors argue that treatment failure was 
primarily a result of hypoxia-induced radiation resistance rather than hypoxia-
induced lymph-node metastasis, suggesting that novel treatment strategies 
aiming at improving tumor oxygenation or enhancing the radiation sensitivity 
of hypoxic tumor cells may prove beneficial to improve radiation therapy of 
advanced cervical carcinoma [67]. 
Gene expression 
The multiple roles assigned to hypoxia, including the induction of angiogene-
sis, apoptosis and metastasis, likely result in large part from changes in gene 
expression that accompany hypoxia. A significant number and wide variety of 
hypoxia-induced genes have been described. Changes in the expression of 
many of these genes serve to counteract hypoxia and increase oxygenation, 
while others affect the cellular adaptation to decreased oxygen levels or me-
diate death signal pathways.  
 
Upregulation of growth factors and hormones such as vascular endothelial 
growth factor (VEGF) [68], platelet-derived endothelial cell growth fac-
tor/thymidine phosphorylase (PDECGF/TP) [69] and erythropoietin (EPO) 
[70] results in endothelial cell proliferation and increased red blood cell pro-
duction and serves to restore oxygen availability. Expression of the VEGF 
receptor Flt-1 is also induced in endothelial cells under hypoxic conditions 
[71]. Induction of the messenger molecule nitric oxide synthase (NOS) under 
hypoxia has been postulated as a mechanism to stimulate vasodilation result-
ing in increased blood flow [72].  
 
As an adaptation to oxygen deprivation, cells need to shift their adenosine 
triphosphate (ATP) production from oxidative phosphorylation to anaerobic 
glycolysis. Thus, the activity of glycolytic enzymes such as phosphoglycerate 
kinase-1 (PGK-1) [73] and pyruvate kinase M (PK-M) [74] is increased during 
hypoxia, and the expression of glucose importer proteins (GLUTs) [75,76] are 
also induced.  
 
Several genes involved in regulating cell survival, metabolism and prolifera-
tion have been reported to be induced by hypoxia, including c-jun [77], insu-
lin-like growth factor-2 (IGF-2), IGF-binding protein 1 and 3 (IGFBP-1 and 
IGFBP-3), transforming growth factor β (TGF-β) [78], placental growth factor 
(P1GF) [79], urokinase receptor [80], tyrosine hydroxylase (TH) [81], p27Kip1 
[82] and p21Waf1 [83]. 
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The regulation of gene expression under hypoxia has been shown to occur 
through many different mechanisms, including transcription, mRNA stability, 
translation and post-translational modifications. VEGF expression in particu-
lar is controlled at several levels by hypoxia, including increased transcription 
initiated by the transcription factor HIF-1 [84], enhancement of message sta-
bility by association with an RNA-binding protein HuR [85], and by increased 
production of a required chaperone protein ORP150 [86]. The 5'UTR of 
VEGF mRNA has also been shown to contain a functional internal ribosomal 
entry site (IRES), which facilitates cap-independent translation. This may 
serve as an advantage under hypoxic conditions where translation is low and 
competition for cap-dependent translation factors is high [87–89]. 
 
Cells exposed to hypoxia upregulate the expression of several transcription 
factors, including hypoxia-inducible factor (HIF-1) [90], p53 [91], AP-1 [92], 
C/EBPβ [93], early growth response 1 (Egr-1) [94] and nuclear factor κB 
(NFκB) [95]. Perhaps the most important within this group is HIF-1, which 
induces the expression of more than 30 known genes (for a review see 
Ref.[96]), including EPO [90,97], VEGF [98], NOS2 [99], Flt-1 [100], GLUT-1 
and GLUT-3, PK-M [101] and IGF-2. The transcription of the HIF-1-
responsive genes is stimulated through the binding of HIF-1 and other tran-
scriptional activators to a hypoxia responsive element (HRE) in the gene 
promoter [102–105]. 
 
The HIF-1 transcription factor itself, is regulated by a post-translational 
mechanism. HIF-1 is a heterodimer consisting of the two subunits, HIF-1α 
and HIF-1β (identical to the aryl hydrocarbon receptor nuclear translocator 
(ARNT)) which are both ubiquitously expressed [71,106]. HIF-1β protein is 
stable, while HIF-1α is targeted for ubiquitination by the von Hippel-Lindau 
tumor suppressor protein (VHL) and rapidly degraded by the proteasome un-
der well-oxygenated conditions [107–109]. VHL recognises a hydroxylated 
prolyl residue (P564) in the HIF-1α protein, which remains unhydroxylated 
under hypoxic conditions [110,111]. Thus, HIF-1α is stabilised during hypoxia 
and can dimerise with its partner HIF-1β to induce the transcription of HRE-
responsive genes. 
How do we combat hypoxia? 
The realisation that hypoxia is a common characteristic of human tumors that 
adversely effects patient prognosis suggests that targeting hypoxia will be an 
effective means of improving treatment. Scientists and clinicians alike are 
using two fundamentally different approaches to tackle the problems of hy-
poxia. The first approach is to improve or restore normal tumor oxygenation, 
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and the second approach is to exploit the unique property of tumor hypoxia 
for targeting treatment to the tumor. The success of these two approaches 
will ultimately depend upon the relative importance of hypoxia in treatment 
resistance and malignancy. 
Improve oxygenation 
Attempts to increase the oxygen supply to the hypoxic yet potentially viable 
tumor cells has been a major goal of experimental and clinical research for 
over 40 years. Various strategies have been considered including hyperbaric 
or increased oxygen breathing, the administration of hypoxic cell sensitisers, 
and, more recently, erythropoietin to improve the haemoglobin level and to 
avoid repeated transfusions. Although most of the early attempts to over-
come hypoxia have led to mixed results, in head and neck cancer a large 
meta-analysis of these trials has shown that oxygen modification results in a 
significant improvement in local control and disease-specific survival 
[112,113]. 
Erythropoietin (EPO) 
EPO is a glycoprotein hormone produced by the kidney in response to tissue 
hypoxia that stimulates red blood cell production in the bone marrow. Cur-
rently, there is active interest in using recombinant human EPO in patients 
with low haemoglobin (Hb) levels in order to improve tumor oxygenation. The 
hypothesis is that some hypoxic tumors may result from low Hb levels in 
anaemic patients. Hb concentration has been shown to be an important 
prognostic factor for the outcome of various cancer types treated by radio-
therapy. Most of the clinical studies published have shown better tumor con-
trol in patients with higher Hb levels than in patients with Hb in the lower part 
of—or below—the normal range. There seems to be a good documentation 
for the effect of Hb on radiation response in carcinoma of the uterine cervix 
[114–117], in head and neck cancer [118–122], in bronchogenic carcinoma 
[123–125], in bladder carcinoma [126–129] and prostate carcinoma [130]. 
Overall, patients with low haemoglobin levels have lower local control and 
survival. The only prospective study on the effect of transfusion on tumor 
control is a small study in carcinoma of the cervix [131]. Patients who were 
transfused to maintain their Hb level above 135 g/l showed significantly im-
proved local control rates. 
 
Recombinant human EPO (r-HuEPO) has been evaluated in normal subjects, 
as well as in subjects with various anaemic conditions. In oncology, EPO is 
known to increase the Hb level in cancer patients without interfering with their 
course of radiation therapy. In a study by Lavey and colleagues [132], the 40 
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participating patients had a Hb value <135 g/l and a malignant tumor located 
above the diaphragm without evidence of distant metastasis for which they 
were scheduled to undergo a 5–8 week course of daily radiation therapy. Half 
the patients also received 150–300 mg/kg of EPO subcutaneously (s.c.) three 
times per week starting 0–10 days prior to the first dose of radiation. The 
EPO and control groups did not differ significantly in patient age, gender, tu-
mor type, initial Hb, erythropoietin or iron bioavailability. The Hb level in-
creased more than 6% during radiation therapy in all 20 of the EPO patients, 
but in only 2/20 of the control patients (P<0.001). The Hb rose from a mean ± 
standard deviation (S.D.) of 119±13 g/l to >140 g/l during radiation therapy in 
80% of the EPO group compared with 5% of the control group (P<0.001). 
The mean change in Hb concentration during radiation (an average rise of 
5% per week) in the EPO group was significantly higher than in the control 
group (P<0.001).  
 
Abels and colleagues also showed that approximately 50–60% of anaemic 
cancer patients receiving chemotherapy responded with a Hb rise of at least 
20 g/l to EPO therapy given three times weekly at a dose of 150 I.U./kg over 
a period of 12 weeks [133]. In a subsequent open-label dose titration study, 
doses up to 300 IU/kg, were sometimes required, demonstrating the relative 
resistance to the effect of EPO in these patients. In another study, 60 anae-
mic patients treated with neoadjuvant radio-chemotherapy and EPO experi-
enced more pathological responses compared with that of a historical control 
group (67% versus 27%) [134]. At the moment, several phase III trials are 
running to test the hypothesis that an increase of Hb with EPO during radio- 
or chemo-therapy has the ability to improve outcome. 
ARCON 
The ARCON protocol (accelerated radiotherapy combined with carbogen and 
nicotinamide) is currently being evaluated in the clinic. Carbogen (95% 
O2+5% CO2) is used to reduce diffusion limited or chronic hypoxia, and 
nicotinamide is added to reduce acute hypoxia resulting from temporary vas-
culature shutdown [135–140]. The use of these agents simultaneously has 
indeed been shown to increase the radiation damaging effect in a variety of 
rodent tumor models [141–145]. 
 
Increased oxygenation of tumors treated with carbogen and nicotinamide has 
been demonstrated in patients [140]. Promising results have been obtained in 
several non-randomised clinical studies using this combination in conjunction 
with accelerated irradiation. The Nijmegen radiotherapy group reported a sig-
nificant beneficial effect for the treatment of stage T3–T4 SCC laryngeal tu-
mors compared with historical conventional radiation therapy data, both in 
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terms of locoregional control and survival [146,147]. Phase II clinical results 
obtained for bladder carcinoma also showed a significantly increased local 
control and overall survival from the triple combination treatment, when com-
pared with previous experiences using standard radiotherapy [148]. 
 
However, these positive findings were not confirmed by a phase I/II study of 
the European Organization for Research and Treatment of Cancer (EORTC) 
that involved head and neck SCC tumors of various localizations [149]. 
EORTC studies involving non-small cell lung cancer [150], and glioblastoma 
were also negative [151]. A randomised phase III clinical trial will be started 
shortly to ultimately determine the success of this protocol. 
Radiosensitisers 
Many years have been dedicated to the search and development of com-
pounds that could substitute for oxygen at the time of radiotherapy. This ap-
proach was based on the concept that these compounds could mimic the 
effects of oxygen at the time of radiation delivery, thereby increasing DNA 
damage and restoring radiosensivity. However, most of the compounds de-
veloped could not be administered to patients at effective concentrations with 
acceptable toxicity. None the less, hypoxic sensitisers continue to be devel-
oped and used in some instances. Nimorazole, a 5-nitroimidazole derivative, 
has been widely used as an antimicrobial agent against Trichomonas 
vaginalis and other protozoa including Entamoeba histolytica and Giardia 
intestinalis with little reported toxicity. Similarly, significant or chronic toxicity 
has been absent from the phase I and II studies involving the use of nimora-
zole [152,153]. In a large double-blind randomised phase III trial in Denmark, 
nimorazole was reported to significantly improve the effect of radiotherapy of 
supraglottic and pharyngeal tumors, while the toxicity of the drug was mild 
[154]. This result was highly significant, and nimorazole has now been incor-
porated into the standard treatment of most head and neck cancer patients in 
Denmark. 
Exploit the microenvironment 
The second approach in combating hypoxia is fundamentally different from 
attempts to restore or replace oxygen. In this scenario, the unique property of 
tumor hypoxia is used as an advantage for targeting cancer treatment. There 
are three primary means by which this targeting is currently being attempted. 
The first is to target the lack of oxygen per se, for example by using bioreduc-
tive drugs that are only toxic in the absence of oxygen. The second is to ex-
ploit the unique features of the tumor vasculature that are both responsible 
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for and a consequence of tumor hypoxia. Finally, one can target the known 
molecular and cellular biological responses to hypoxia.  
Exploit hypoxia per se 
Bioreductive drugs 
Bioreductive drugs are compounds that are reduced by biological enzymes to 
their toxic, active metabolites. They are designed such that this metabolism 
occurs only or preferentially in the absence of oxygen. The use of these 
drugs in combination with traditional therapies has the potential to greatly 
improve treatment outcome by increasing cytotoxicity to the hypoxic fraction.  
Tirapazamine (TPZ) is the leading compound in this class of agents and has 
shown promising results in a number of clinical trials when used in combina-
tion with cisplatin and/or radiotherapy [155–157]. A wide number of cell lines 
are sensitive to TPZ, regardless of their p53 status, and require 50–150 times 
higher dose for the same toxicity under aerobic conditions [158]. The mecha-
nism of this preferential toxicity is mediated by an enzymatically catalysed 
one-electron reduction of TPZ, which yields a highly reactive radical capable 
of causing cell death by producing various types of DNA damage [159]. In the 
presence of oxygen, the TPZ radical is rapidly oxidized back to the non-toxic 
parental compound, thus minimizing toxicity to well-oxygenated tissues. Pre-
clinical in vitro testing has shown TPZ to have a synergistic effect on cell kill 
when given prior to cisplatin [160]. This synergism reflects the findings in 
animal studies [158,161] and clinical trials [162,163] showing that this com-
bined chemotherapy potentiates the antitumor efficacy of cisplatin without 
increasing systemic toxicity. The mechanism of this synergism has yet to be 
elucidated, but has been postulated to involve the inhibition of cisplatin-
induced DNA cross-link repair [160,164]. 
 
Another promising bioreductive drug nearing clinical trial is AQ4N, a prodrug 
that is activated by reduction in hypoxic cells producing a stable product 
(AQ4) that intercalates within DNA and blocks topoisomerase II action. A key 
advantage to this drug is that the active AQ4 is stable, thus allowing diffusion 
to aerobic regions where it can act to produce a ‘bystander’ effect, or be ef-
fective in areas of transient/acute hypoxia [165]. In murine tumor models, 
AQ4N is not effective as a single agent, but shows substantial antitumor ac-
tivity when combined with methods to increase the hypoxic fraction (physical 
clamping or hydralazine), radiation, or anticancer drugs [166,167]. 
Gene therapy 
Poor prognosis for many cancer patients prescribed conventional drug or ra-
diation treatments has increased interest in clinical protocols based on gene 
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therapy. The aim is to transfer genetic material to the tumor cell or its micro-
environment in quantities sufficient to obtain a therapeutic level of expres-
sion. However, strategies devised to date have limited efficiency, most nota-
bly due to deficiencies in the delivery systems employed. A recent approach 
to this problem employs the concept of targeting anaerobic bacteria to the 
hypoxic/necrotic areas of solid tumors. An association between bacteria and 
tumors dates back more than 100 years ago when William Coley found that 
certain patients who contracted bacterial infections recovered remarkably 
well from certain cancers. Currently, Clostridium spp. [168,169] and attenu-
ated Salmonella typhimurium auxotrophs [170,171] are being investigated at 
several research centres as systems to deliver anti-tumor compounds spe-
cifically to the tumor site. The latter strain grows under aerobic and anaerobic 
conditions, with selectivity for tumors reported as a consequence of its 
auxotrophic nature. The specificity of clostridia for tumors resides in its obli-
gate requirement for anaerobic conditions, giving Clostridium an advantage 
over Salmonella. Intravenously (i.v.) injected spores of a non-pathogenic 
clostridial species have been shown to localise to, and germinate in, the hy-
poxic/necrotic regions of solid tumors. Although growth alone in the tumor is 
not sufficient for therapeutic efficacy, the possibility now exists to engineer 
Clostridium spp. to produce a variety of therapeutic proteins with anticancer 
properties. Clostridia can thus be used as highly selective in-situ cell factories 
able to produce and secrete antitumor therapeutics specifically at the tumor 
site. Moreover, it has been shown that the immune response does not hinder 
repeated administration of clostridial spores, that colonization can be im-
proved using vascular targeting treatment using Combretastatin A4-
phosphate (CA-4P) (see next section) and that gene expression can be 
stopped at any time using suitable antibiotics [172]. We [173] and others 
[174,175] demonstrated that it is possible to express therapeutic proteins, not 
only in vitro, but also in vivo after administration of the recombinant clostridia 
to tumor-bearing animals [176]. Moreover, the specificity of this gene delivery 
system can be further increased, by placing the therapeutic gene under the 
regulation of a radio-induced promoter, leading to spatial and temporal con-
trol of gene expression [177]. Taken together, these experiments demon-
strate that the principle of using the Clostridium vector system, or other an-
aerobic bacteria such as Bifidobacterium [178], is feasible and holds consid-
erable promise for tumor-specific therapy. 
Exploit tumor vasculature 
Abundant evidence has demonstrated that solid tumors require an expansion 
of the blood supply to provide their oxygen and nutritional requirements. Yet 
in tumors, this process of angiogenesis results in disproportional and inade-
quate vascular architecture, with vessels that are structurally and functionally 
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different from those in normal tissues [179–181]. Consequently, this abnor-
mal intra-tumoral vessel network, which elicits a high rate of endothelial cell 
proliferation [182], offers an ideal target for novel therapeutic strategies, such 
as anti-angiogenesis and vascular targeting.  
Anti-angiogenesis  
Angiogenesis is a complex biological process that offers potential therapeutic 
targets at many points [183]. The target population most often consists of 
actively dividing and migrating vascular endothelium from established normal 
host and tumor vessels. Many of the current strategies for therapeutic anti-
angiogenesis involve the blockade of angiogenic growth factors and the sup-
pression of endothelial cell recruitment through small molecule receptor 
blockers, specific antibodies or the use of endogenous inhibitors. The five 
classes of angiogenesis antagonists in current clinical trials include mole-
cules that block matrix breakdown, inhibit endothelial cells directly, block acti-
vators of angiogenesis, inhibit endothelial specific integrin/survival signalling 
and distinct mechanisms of action. Due to the large number of currently in-
vestigational anti-angiogenic approaches, we limit our discussion to a select 
number of drugs currently subject to clinical investigation.  
 
The initial step in the angiogenic process is the degradation of the basement 
membrane surrounding the endothelial cells [184]. MMPs play a critical role 
in the degradative process [185]. Thus, inhibitors of MMPs are an obvious 
choice for anti-angiogenic strategies. Synthetic molecules such as marimas-
tat, prinomastat, and BAY 12-9566 have been investigated as such agents. 
Unfortunately, phase III clinical trials using these inhibitors alone or in combi-
nation with chemotherapy have demonstrated no clinical efficacy [186]. The 
apparent explanation for this observation is that MMPs may be more impor-
tant in the early stages of cancer and may not be required once the metasta-
ses have been established. Another method to target the enzymatic break-
down of the basement membrane and surrounding tissue is to disrupt the 
uPA system [187]. The urokinase inhibitor penicillamine is currently being 
tested in a phase II clinical trial for glioblastoma.  
 
Molecules that inhibit endothelial cell migration and proliferation include the 
endogenous molecules angiostatin and endostatin [188], as well as the po-
tent teratogen thalidomide. Angiostatin, a fragment of the precursor plasmi-
nogen was the first isolated tumor-derived angiogenesis inhibitor [189]. 
Treatment of experimental animals with angiostatin causes regression of the 
primary tumor, prevents angiogenesis and metastatic growth [189,190]. En-
dostatin is a C-terminal fragment of collagen type XVIII [191]. Interestingly, 
the activity of endostatin and angiostatin are synergistic when combined sug-
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gesting different molecular targets [192]. Both of these molecules are cur-
rently the subject of phase I clinical trials. Thalidomide has also been shown 
to have anti-angiogenic properties and in vitro data suggest that it also inhib-
its endothelial cell and tumor cell proliferation [193,194]. Recent reports from 
phase II clinical trials have shown encouraging results [195,196].  
 
VEGF, its receptor and its signalling pathway are attractive targets for anti-
angiogenic strategies. A series of compounds that target this pathway includ-
ing small molecule inhibitors of the VEGF-R, such as SU5416 [197], SU6668 
[198], a ribozyme that degrades VEGF mRNA (angiozyme) [199] and anti-
bodies directed against VEGF [200,201] or VEGF-R (PTK-787/ ZK22584) 
[202] have been developed and are under clinical investigation. 
 
Interactions between tumor cells and the ECM are vitally important for inva-
sion and migration. In particular, αvβ3 and αvβ5 integrins, serve as major 
receptors for ECM-mediated cell adhesion and migration [203]. These in-
tegrin molecules have been demonstrated to be upregulated during repair, 
retinal neovascular-isation and tumor neo-angiogenesis [204–206]. This ad-
hesion event is mediated by an arg-gly-asp (RGD) peptide motif and small 
peptides containing such a motif have been demonstrated to inhibit integrin 
function [207]. Angiogenesis is inhibited both by antibodies directed against 
these integrins and by peptide antagonists that block integrin–extracellular 
matrix interactions. A humanised monoclonal antibody directed against αvβ3, 
designated Vitaxin [208,209] and a small molecule blocker of αvβ3, 
EMD121974 are currently the subject of clinical investigation. 
 
A number of anti-angiogenic strategies work through mechanisms distinct 
from those described above. CAI is an inhibitor of calcium influx [210] cur-
rently in phase I studies in combination with paclitaxel against solid tumors. 
Interleukin-12 (IL-12) is a multifunctional cytokine determined to be anti-
angiogenic [211–213] by inducing interferon gamma and interferon-γ-
inducible 10 kDa protein (IP10) [214]. Furthermore, the group B streptococ-
cus toxin, CM101 that selectively targets proliferating blood vessels has 
completed phase I trials with encouraging results [215].  
Vascular targeting 
The concept of ‘vascular targeting’ was championed many years ago 
[181,216] and has recently become a very active area of research. This con-
cept refers to the use of agents that exploit vasculature features that are 
unique within the tumor. Several advantages of targeting the vasculature 
have been presented including: (i) potential efficacy against any solid tumor 
since the main target is the endothelial cell lining, (ii) lack of treatment-
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induced resistance, since endothelial cells are genetically stable, (iii) acces-
sibility of the drug and target, and (iv) indirect killing of many thousands of 
tumor cells from vessel damage and subsequent nutrient deprivation. This 
approach would also result in killing of those cells that are at intermediate 
levels of hypoxia, resistant to classical therapies [217]. Five different ap-
proaches to vascular targeting have been attempted in clinical settings (see 
Table 1).  
 
The specificity of hyperthermia and photodynamic therapy for vasculature is 
somewhat limited as is the accessibility of these modalities for a variety of 
tumor sites. Flavone acetic acid (FAA) has been shown to be active in a vari-
ety of murine tumors [218–220]. This activity was accompanied by the induc-
tion of tumor necrosis factor α (TNFα), blood flow changes and the induction 
of haemorrhagic necrosis. However, changes in blood flow were not ob-
served in patients and therefore this agent was ineffective in clinical trials 
[221,222]. Its structural analogue, the 5,6-dimethylxanthenone 4-acetic acid 
(DMXAA) compound, appears to induce TNFα more strongly in tumors than 
in normal tissues and to exert specific anti-tumor activity independently in 
humans [223,224]. DMXAA is presently being tested in a phase I trial both in 
the United Kingdom and New Zealand. 
 
Various tubulin-interfering drugs have also been reported to provide anti-
tumor activity through vasculature shutdown and the induction of haemor-
rhagic necrosis. This was demonstrated for the tubulin-binding drugs vincris-
tine and vinblastine (both well known chemotherapeutics), colchicine, as well 
as the structurally similar compound homoharringtonine [218,220,225]. How-
ever, these effects were only observed at doses near the maximum systemi-
cally tolerable concentrations. 
 
More recently, the combretastatin family of tubulin-binding compounds with 
more selective anti-tumor activity has been introduced [226]. CA-4P has been 
selected from this family for preclinical and clinical evaluation [219,227–232]. 
A single CA-4P dose of 1/3 to 1/10 of the maximum tolerable dose (rat or 
mouse experiments, respectively) results in rapid blood vessel damage, and 
subsequently tumor necrosis. The efficacy is somewhat tumor-dependent—
being more effective in the mouse KHT sarcoma [230] and the WAG/Rij rat 
rhabdomyosarcoma [232] models than the mouse C3H mammary carcinoma 
[219]. Typically CA-4P results in central tumor necrosis, leaving a viable rim 
of cells on the edge of the tumor. CA-4P also appears to be much more ef-
fective in large tumors (>7 cm3) compared with small (<1 cm3) tumors [232]. 
The mechanism of action of CA-4P seems to result from a cell shape change 
that occurs in newly formed endothelial cells, resulting in blood vessel occlu-
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sion and total vascular shutdown [229,233]. Currently, a limited number of 
phase I clinical studies in the United States and the United Kingdom are ex-
amining the impact of CA-4P on tumor physiology, as well as general compli-
ance and normal organ function. 
 
Table 1 Vascular targeting strategies with demonstrated preclinical antitumor activity 
Hyperthermia Damage to endotherlial cells with subsequent al-
teration of micro-haemodynamics and vascular 
stasis 
e.g. Refs. [246–
248] 
Photodynamic ther-
apy 
Aims to target directly the tumor cells, but also 
induces tumor cell loss through the destruction of 
intratumoral microvasculature 
e.g. Refs. 
[249,250] 
Tumor necrosis  
factor α  
(TNFα) 
Vascular damage and subsequent blood flow fail-
ure with acute haemorrhagic intratumoral necrosis; 
also true for drugs that mediate their action through 
TNFα induction, such as flavone acetic acid (FAA) 
and its analogue DMXAA 
e.g. Refs. 
[218,225,251] 
Antibody-directed 
Targeting 
Targeting tissue factor to initiate thrombosis within 
the tumor with the formation of central necrosis 
e.g. Refs. [252] 
Tubulin interfering 
Agents 
Acute endothelial cell collapse, vessel damage and 
blood flow reduction with rapid major haemorrhagic 
necrosis 
e.g. Refs. 
[219,229,232, 253] 
DMXAA, 5,6-dimethylxanthenone 4-acetic acid. 
 
Exploit the biological responses to hypoxia 
The final strategy being pursued to target hypoxia is based on exploiting the 
recently understood biological responses to hypoxia. As described earlier, 
cells respond to hypoxia by modulating the expression of many genes. These 
changes in gene expression, in turn, cause a cellular and tissue response to 
hypoxia that affects both the cellular sensitivity to treatment and the proc-
esses of metastasis and angiogenesis. By targeting the early steps in the 
activation of these pathways, one may develop more specific and effective 
types of therapy. 
 
Various biological responses to hypoxia can be viewed in a generalised se-
quence of four successive steps (see Fig. 1). The first step is carried out by 
an oxygen sensor—a protein that is capable of sensing and responding to 
reduced levels of oxygen. Activation of the sensor causes a molecular re-
sponse consisting of the activation of downstream signalling pathways. This 
molecular response, in turn, leads to a cellular response, and finally a tissue 
or tumor response. In the past several years, we have learned much about 
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one of the main hypoxic biological response pathways in mammalian cells—
that involving the HIF-1 transcription factor. This pathway serves as a good 
example of this general response sequence and for how this knowledge can 
be translated into new cancer therapies.  
 
Two recent reports suggest that the oxygen sensor in the HIF-1 pathway is a 
prolyl hydroxlyase [110,111]. This enzyme, designated HIF-PH, requires oxy-
gen for its activity (hydroxylation of proline residues). In this example, the mo-
lecular response to hypoxia is initiated as a result of reduced hydroxylation of 
a proline residue in the HIF-1α subunit (P564). Reduced hydroxylation pre-
vents the recognition of HIF-1α by the VHL ubiquitin ligase, thereby prevent-
ing ubiquitination. As a result, HIF-1 is stabilised and can transactivate its 
many targets, such as EPO, VEGF and GLUT-1. These changes in gene ex-
pression lead to a cellular response that may consist of increased glycolysis 
in the tumor cells or activation of endothelial cell proliferation and migration 
by binding of VEGF to its receptor. Finally, this leads to a tumor or tissue re-
sponse that consists of increased angiogenesis, and to increased survival of 
tumor cells resulting from a switch to anaerobic metabolism [234]. 
 
The important part of this illustration is that a detailed biological understand-
ing of this pathway offers a plethora of options for targeting cancer treatment 
to the tumor. For example, an attractive molecular treatment would be one 
based on augmenting the activity of the oxygen sensor itself. Since the multi-
ple cellular and tissue effects stem from this one initial protein, it provides a 
very specific and potent treatment target. There are already many examples 
of research directed against the second level of this pathway. Several com-
pounds designed to alter the activity of HIF-1 [235,236], VHL [237], or the 
ubiquitin system itself [238–240] are being explored in cancer treatment. At 
the level of the cellular response, antibodies and inhibitors of both VEGF and 
its receptor Flk-1 have been developed (as discussed under the anti-
angiogenesis strategies). Recent reports suggest that inhibiting the ability of 
tumor cells to shift to glycolysis would also be advantageous [234,241]. Fi-
nally, targeting treatment to the cellular or tissue response of this pathway 
would consist of the more generalised anti-angiogenesis and hypoxia-
targeted therapeutics (both discussed earlier). It is clear that as one moves 
downwards in this pathway from the oxygen sensor to the cellular and tissue 
responses, the targets become less specific in nature. 
 
Elements of this pathway can be exploited as well as inhibited. For example, 
the DNA recognition sequence for the HIF-1 transcription factor is well de-
scribed. This HRE can be inserted within gene therapy constructs, to limit the 
expression of therapeutic proteins to hypoxic areas of tumors [242–245]. 
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Dachs and colleagues [243] established the potential for tumor hypoxia to be 
exploited for targeted gene expression by showing that the HRE from the 
mouse PGK-1 gene could be used to drive expression of heterologous genes 
within the mass of a solid tumor.  
 
The HIF-1 pathway is relatively well understood and serves as a good exam-
ple of how knowledge of the biological responses to hypoxia can translate 
into new therapies. However, there are numerous other molecular and cellu-
lar responses to hypoxia that are independent of HIF-1, perhaps each with 
unique oxygen sensors. Continued research into the basic molecular and 
cellular responses of hypoxia will undoubtedly contribute further to the devel-
opment of novel hypoxia-based cancer therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Biological responses to hypoxia can be viewed in terms of four successive steps. The 
HIF-1 pathway serves as an example of such a response. The first step is to sense that oxygen 
is limiting and in the HIF-1 pathway this is carried out by an oxygen-dependent prolyl hydroxy-
lase. The second step is the initiation of a molecular response through the activation of down-
stream signalling pathways. In this example, this results in the activation of several classes of 
genes as a result of stabilisation of the HIF-1α subunit. A cellular response occurs due to these 
changes in gene expression, in this case resulting in a switch to anaerobic metabolism and se-
cretion of angiogenic factors. Finally, a tumor/tissue response occurs. In the HIF-1 pathway, this 
may be the induction of angiogenesis in the tumor micro-environment together with increased 
survival and proliferation of the tumor cells. Each of these steps in the biological response to 
hypoxia is an opportunity for targeting therapy as indicated below each box. 
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Abstract 
Hypoxia has recently been shown to activate the endoplasmic reticulum 
kinase PERK, leading to phosphorylation of eIF2α and inhibition of mRNA 
translation initiation. Using a quantitative assay, we show that this inhibition 
exhibits a biphasic response mediated through two distinct pathways. The 
first occurs rapidly, reaching a maximum at 1–2 h and is due to phosphoryla-
tion of eIF2α. Continued hypoxic exposure activates a second, eIF2α inde-
pendent pathway that maintains repression of translation. This phase is char-
acterized by disruption of eIF4F and sequestration of eIF4E by its inhibitor 
4E-BP1 and transporter 4E-T. Quantitative RT-PCR analysis of polysomal 
RNA indicates that the translation efficiency of individual genes varies widely 
during hypoxia. Furthermore, the translation efficiency of individual genes is 
dynamic, changing dramatically during hypoxic exposure due to the initial 
phosphorylation and subsequent dephosphorylation of eIF2α. Together, our 
data indicate that acute and prolonged hypoxia regulates mRNA translation 
through distinct mechanisms, each with important contributions to hypoxic 
gene expression. 
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Introduction 
The presence of hypoxic and anoxic areas in human tumors is well docu-
mented, and is prognostic for poor outcome (reviewed in Harris, 2002; Wout-
ers et al, 2002). The clinical importance of tumor hypoxia results from its abil-
ity to protect cells against both radiation and chemotherapy and from the fact 
that it can provide a selection pressure for apoptotically resistant cells (Grae-
ber et al, 1996). Furthermore, the cellular response to hypoxia causes impor-
tant changes in gene expression that affect cell behavior and influence pa-
tient prognosis. There has been particular focus on changes mediated 
through the family of hypoxia-inducible transcription factors (HIFs). HIF-1 and 
HIF-2 promote transcription of more than 60 putative downstream genes (for 
a review see Semenza, 2003) that affect hypoxia tolerance, energy homeo-
stasis, angiogenesis and tumor growth. Although the transcriptional response 
to hypoxia is clearly very important (Ryan et al, 1998; Tang et al, 2004; Leek 
et al, 2005), tumor cells also experience short, transient exposures to hypoxia 
and/or anoxia that occur over time frames too fast for an effective transcrip-
tional response. Transient changes in oxygenation occur owing to the ab-
normal vasculature found in most tumors, characterized by immature, leaky 
and improperly formed vessels. Perfusion of these vessels can change dy-
namically in time, leading to rapid but transient episodes of severe hypoxia in 
the tumor cells dependent upon them (Bennewith and Durand, 2004; 
Cardenas-Navia et al, 2004). Consequently, post-transcriptional responses 
are presumably important for adaptation to cycling oxygenation in tumors. 
 
Control of mRNA translation during hypoxia is emerging as an important cel-
lular response to hypoxia (Koumenis et al, 2002; Koritzinsky et al, 2005; 
Wouters et al, 2005). As protein synthesis is energy costly, inhibition of 
mRNA translation may represent an active response to prevent loss of en-
ergy homeostasis during hypoxia. Indeed, it has been shown that overall 
mRNA translation is severely but reversibly inhibited during hypoxia 
(Koumenis et al, 2002; Erler et al, 2004; Bi et al, 2005) with kinetics that pre-
cede ATP depletion (Lefebvre et al, 1993). Furthermore, regulation of mRNA 
translation can have a significant and rapid impact on individual gene expres-
sion. This is because the sensitivity of individual genes to changes in overall 
translation varies widely and in a manner that reflects the molecular mecha-
nisms responsible for controlling translation (Johannes et al, 1999; Harding et 
al, 2000). Regulation of gene expression through control of mRNA translation 
is important during various pathologies including cancer (Holland et al, 2004). 
The mechanisms responsible for inhibiting translation during hypoxia are not 
yet fully understood.  
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We have previously investigated the involvement of the endoplasmic reticu-
lum (ER) kinase PERK in the hypoxia-induced downregulation of protein syn-
thesis (Koumenis et al, 2002). PERK is activated as part of the evolutionarily 
conserved unfolded protein response (UPR) (reviewed in Schroder and 
Kaufman, 2005). It phosphorylates eIF2α, a subunit of eIF2, which in its GTP-
bound form recruits the aminoacylated tRNA to the 40S ribosomal subunit. 
The exchange of GDP for GTP is mediated by the guanine nucleotide ex-
change factor eIF2B. Ser51-phosphorylated eIF2α inhibits eIF2B, resulting in 
inhibition of translation initiation. eIF2α phosphorylation results in a set of mo-
lecular events collectively termed the integrated stress response. These in-
clude the inhibition of global mRNA translation in conjunction with induced 
expression of the transcription factor ATF4 and its downstream target genes 
(Harding et al, 2003). We showed that hypoxia rapidly activated PERK, which 
led to reversible phosphorylation of eIF2α (Koumenis et al, 2002). Hypoxia-
induced inhibition of protein synthesis was severely attenuated in cells with-
out functional PERK. After prolonged periods of hypoxia, PERK-deficient 
cells did show partial inhibition, suggesting that protein synthesis is regulated 
through additional mechanisms. 
 
Another candidate mechanism for inhibiting translation during hypoxia is dis-
ruption of the cap-binding protein complex eIF4F, which consists of eIF4E, 
eIF4A and eIF4G (for recent reviews see Gebauer and Hentze, 2004; Holcik 
and Sonenberg, 2005). eIF4E participates in a protein bridge between the 
mRNA and the ribosome by its simultaneous interaction with the mRNA 5' 
cap structure and the large scaffolding protein eIF4G, which in turn interacts 
with eIF3 that is bound to the 40S ribosomal subunit. eIF4E is regulated 
through a set of binding proteins (4E-BPs) that bind reversibly to eIF4E in 
their hypophosphorylated form, and this obstructs the interaction between 
eIF4E and eIF4G. The 4E-BP1 protein becomes hyperphosphorylated in re-
sponse to a number of stimuli, such as insulin, hormones, growth factors, 
mitogens and cytokines, as a result of activation of the PI3-kinase/Akt/mTOR 
pathway (Hay and Sonenberg, 2004). 
 
It remains unclear to what degree the lack of eIF4F assembly contributes to 
inhibition of translation during tumor hypoxia. Several studies have investi-
gated the combined consequences of ischemia/reperfusion on eIF4F-related 
proteins in rat brains (reviewed in DeGracia et al, 2002). Proteolysis of eIF4G 
was reported during ischemia and reperfusion in vivo (Neumar et al, 1998; 
Martin de la Vega et al, 2001), but not in neuronal cells cultured in vitro (NGF 
differentiated PC12 cells) (Martin et al, 2000). The reports addressing the 
expression and phosphorylation status of eIF4E during ischemia are conflict-
ing, but 4E-BP1 dephosphorylation has been demonstrated both in vivo and 
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in vitro (Martin et al, 2000; Martin de la Vega et al, 2001). The acuteness and 
complexity of ischemia/reperfusion stress and the high sensitivity of neurons 
to deprivation and reconstitution of both oxygen and nutrients are distinct 
properties of this model system and thus difficult to extrapolate to tumor hy-
poxia. In rat hepatocytes, 4E-BP1 becomes dephosphorylated and associ-
ates with eIF4E rapidly (15-60 min) upon mild hypoxia, but this could not ex-
plain the observed down-regulation of protein synthesis (Tinton and Buc-
Calderon, 1999). More recently, it was reported that hypoxia could influence 
4E-BP1 phosphorylation by affecting the activity of mTOR (Arsham et al, 
2003). Serum-starved and hypoxic human embryonic kidney cells failed to 
activate mTOR, phosphorylate 4E-BP1 and dissociate 4E-BP1 from eIF4E in 
response to insulin treatment. Nonetheless, it remains unknown whether hy-
poxia alone is sufficient to disrupt the eIF4F complex and to what extent this 
influences overall translation during hypoxia. Here we show that hypoxia in-
duces a biphasic inhibition of mRNA translation characterized by transient 
phosphorylation of eIF2α and subsequent dissociation of eIF4F. These two 
mechanisms operate independently of each other and both have important 
consequences for gene expression during hypoxia 
Materials and methods 
Cell culture 
Exponentially growing cervical carcinoma HeLa cells (American Type Culture 
Collection CCL-2), lung adenocarcinoma A549 cells, normal human fibro-
blasts (AG1522) or MEFs that were WT or had a homozygous knock-in muta-
tion for eIF2α (S51A) (Scheuner et al, 2001) were grown on glass dishes or 
chamber slides in DMEM media supplemented with 10% fetal calf serum. 
The MEF media also contained MEM nonessential amino acids and 55 μM 2-
mercaptoethanol (all Sigma-Aldrich). For preparation of extracts and viability 
assessments, see Supplementary data.  
Hypoxic conditions  
Cells were transferred to a hypoxic culture chamber (MACS VA500 mi-
croaerophilic workstation, Don Whitley Scientific). The composition of the at-
mosphere in the chamber consisted of 5% H2, 5% CO2, 0.0% O2 and residual 
N2.  
Thesis_Weppler_v12_fc.pdf
Chapter 3 
 70 
m7GTP resin precipitation  
A 1 mg portion of HeLa extract was incubated with 25 µl of m7GTP sepha-
rose resin (Amersham Biosciences) for 3 h at 4°C. The resin was washed, 
boiled in Laemmli buffer and the polypeptides were resolved by SDS-PAGE.  
Western blotting  
Cell extracts were boiled in Laemmli buffer and polypeptides were resolved 
by SDS-PAGE and transferred onto 0.2 μm nitrocellulose membranes (Am-
ersham Corp.). For primary antibodies, see Supplementary data. Detection of 
peroxidase-coupled secondary antibodies was performed with Enhanced 
Chemiluminescence (Amersham Corp.).  
Immunofluorescence  
Cells were fixed with 4% paraformaldehyde and permeabilized in 4% para-
formaldehyde and 0.1% Triton X-100. For antibodies, see Supplementary 
data. Cells were mounted in the ProLongTM Antifade Kit (Molecular Probes) 
and analyzed with a Zeiss inverted LSM 410 laser scan confocal microscope.  
Polysomal fractionation and analysis  
Polysomal fractionation and analysis were performed as described previously 
(Koritzinsky et al, 2005); see Supplementary data.  
RNA isolation and reverse transcription  
RNA isolation and reverse transcription were performed as described previ-
ously (Koritzinsky et al, 2005); see Supplementary data.  
Quantitative PCR analysis  
Real-time PCR was performed in either ABI 7700 or ABI 7500 (Applied Bio-
systems). For primers and probes, see Supplementary data. Unfractionated 
samples were normalized by 18S rRNA signal. Samples from polysome frac-
tions were normalized by 18S rRNA measured by PCR divided by 18S rRNA 
measured by spectrometry during fractionation, corrected for loading. This 
facilitated correction for any differences in RNA isolation or reverse transcrip-
tase efficiency between samples. The abundance of every gene was calcu-
lated relative to a master reference using standard curves. 
Supplementary data 
Supplementary data are available online at www.embojournal.org. 
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Results 
Kinetics of translation inhibition  
To determine the effects of hypoxia on mRNA translation initiation in HeLa 
cells, we examined the association of ribosomes with mRNA at various time 
points. In this assay, the number of ribosomes found within the ‘polysomal’ 
fraction of mRNA (mRNA containing two or more ribosomes) is a reflection of 
de novo protein synthesis. This technique is advantageous to other methods 
such as 35S incorporation, which requires prior amino-acid starvation, a pro-
cedure that can itself influence translation initiation (Kimball and Jefferson, 
2000). Figure 1A shows that at all time points examined, hypoxia causes a 
large decrease in polysomal mRNA and a corresponding increase in free ri-
bosomes and ribosomal subunits. The reduction in translation is not influ-
enced by cell death, as cell viability remains above 90% following 16 h of hy-
poxia (data not shown). Furthermore, the inhibition of translation is com-
pletely reversible upon reoxygenation (data not shown).  
 
To assess quantitatively overall mRNA translation from the polysome profiles, 
we calculated the percentage of rRNA participating in polysomes and defined 
this as the overall translation efficiency. This value is reduced from 62 to 24% 
after 1 h of hypoxia, and then recovers somewhat stabilizing at ~30% (Figure 
1B). The drop in translation reproducibly exhibited this biphasic response with 
maximum inhibition after 1-2 h, followed by a small recovery. The magnitude 
of inhibition is comparable to that observed following complete disruption of 
the cellular redox environment with 1 mM dithiothreitol (DTT) (17%) (data not 
shown). 
 
Analysis of the polysome profiles in Figure 1A shows that hypoxia also causes 
a change in the distribution of the polysomal mRNA, with proportionally less 
signal in the higher molecular weight fractions. This indicates that the average 
number of ribosomes per mRNA transcript is also decreased during hypoxia, 
reflecting a reduction in translation initiation efficiency even for those transcripts 
that remain translated. From the polysome profiles, we calculated the average 
number of ribosomes per translated transcript (i.e. mRNAs containing two or 
more ribosomes) at different time points during hypoxia (Figure 1C). The kinet-
ics of this parameter follow in large part that of the overall translation.  
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Figure 1. Hypoxia inhibits mRNA translation. HeLa cells were exposed to 0.0% O2 for 0–16 h 
and cell lysates were separated on a sucrose gradient. (A) The optical density (OD) at 254 nm is 
shown as a function of gradient depth for each time point. Actively translated mRNA is associ-
ated with high-molecular-weight polysomes deep in the gradient. (B) Translation efficiency in 
HeLa cells as a function of time in 0.0% O2. As a measure of overall translation efficiency, the 
relative amount of rRNA participating in polysomes was estimated. This fraction is proportional to 
the integrated area under the curve containing polysomes, as marked in (A). (C) The average 
number of ribosomes per mRNA in the polysomes as a function of time in 0.0% O2. This was 
calculated by differential integration of the profiles in (A). 
 
 
eIF2α regulates translation during acute hypoxia  
The eIF2α kinase PERK is at least partly responsible for protein synthesis 
inhibition during acute hypoxia, as measured by radioactive labeling of newly 
synthesized proteins (Koumenis et al, 2002). Thus, we hypothesized that the 
rapid inhibition and subsequent partial recovery in translation is due to 
changes in eIF2α phosphorylation. Indeed, we found that the phosphorylation 
of eIF2α is greatest after 1-2 h and then decreases by 8 h of hypoxia in sev-
eral cell lines (Figure 2A). ATF4 protein levels also increase and then de-
crease during hypoxia in a manner that mirrors eIF2α phosphorylation. The 
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dynamics of eIF2α phosphorylation and ATF4 protein induction thus correlate 
with the initial inhibition of translation and its subsequent recovery. 
 
To assess the requirement of eIF2α phosphorylation for translation inhibition 
during hypoxia we examined the response of mouse embryo fibroblasts 
(MEFs) derived from eIF2α knock-in mice containing an S51A mutation 
(Scheuner et al, 2001). As expected, these cells were defective in phosphory-
lation of eIF2α during hypoxia (Figure 2B). The translation efficiency in wild-
type (WT) MEFs is similar to that in HeLa cells, with a rapid drop during acute 
hypoxia followed by a partial recovery (Figure 2C). In contrast, S51A MEFs 
display a substantial defect in their ability to inhibit translation during the initial 
phase. Nonetheless, after 16 h of hypoxia, both cell lines show a similar loss 
in translation efficiency. These data indicate that eIF2α phosphorylation is 
indeed necessary for inhibition of translation during acute hypoxia, but not at 
later times. 
 
When the polysome profiles are analyzed in terms of the average number of 
ribosomes per translated transcript, S51A MEFs exhibit an even stronger de-
fect in their response during acute hypoxia. Despite a small but detectable 
drop in translation efficiency during the first 4 h of hypoxia (Figure 2C), S51A 
MEFs show no decrease in the average number of ribosomes per translated 
transcript (Figure 2D). The same result was found in cells treated with DTT, a 
known activator of PERK that causes eIF2α phosphorylation. In contrast, WT 
MEFs show a strong reduction in average ribosomes per transcript during 
both acute hypoxia and DTT treatment. Interestingly, after 8 h of hypoxia, the 
average number of ribosomes per translated transcript increases again to-
ward normal levels in WT cells and is equivalent to that in S51A MEFs by 16 
h. These data provide further evidence that the inhibition of translation that 
occurs after acute and prolonged hypoxia is mechanistically distinct. 
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Figure 2. Inhibition of translation during acute hypoxia is dependent on eIF2α. HeLa cells, A549 
cells, human normal fibroblasts (NF) and WT or S51A MEFs were exposed to 0.0% O2 for 0–16 
h, 1 mM DTT or serum starvation (SS) for 1 h. Cell lysates were separated by SDS-PAGE. Im-
munoblots for (A) HeLa, A549 and NF or (B) MEFs were performed using antibodies against 
total or phosphorylated eIF2α, ATF4 and β-actin. In (A), optical densitometry for phosphorylated 
eIF2α or ATF4 normalized by total eIF2α is also shown. Total eIF2α expression has previously 
been shown to be constant during hypoxia (Koumenis et al, 2002). (C) Cell lysates were sepa-
rated on a sucrose gradient, and OD at 254 nm was recorded. Translation efficiency as a func-
tion of time in 0.0% O2 in WT and S51A MEFs was estimated as in Figure 1. (D) Average num-
ber of ribosomes per mRNA in the polysomes in WT and S51A MEFs as a function of time in 
0.0% O2 was calculated as in Figure 1. 
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Disruption of the eIF4F complex during hypoxia  
The assembly of the cap-binding complex eIF4F is a common control point 
for translation initiation and was thus a likely candidate for maintaining low 
rates of translation during prolonged hypoxia. We examined the levels of 
eIF4E and proteins that associate with it as an active complex (eIF4GI) or as 
an inactive complex (4E-BP1). Figure 3A shows that the levels of eIF4E do 
not change during hypoxia. In contrast, 4E-BP1 (Figure 3B) shows both a 
small induction at 8 h and a strong dephosphorylation after 16 h of hypoxia. 
This protein runs as different migrating bands representing different phosphory-
lation levels (Pause et al, 1994). The fastest migrating band is substantially 
increased after 16 h of hypoxia, and represents the hypophosphorylated 4E-
BP1, which is known to have a higher affinity for eIF4E. A small decrease in 
the abundance of the scaffold protein eIF4GI (Figure 3C) was observed after 8 
h, consistent with a decrease in its rate of synthesis measured in a microarray 
study using polysomal RNA (unpublished data). Overexposure of the blots in-
dicated no reproducible changes in the cleavage of eIF4G. The influence of 
hypoxia on 4E-BP1 phosphorylation appears to be largely independent of 
eIF2α phosphorylation, as it is not differentially affected in the WTand S51A 
MEFs (unpublished data). However, until the relative contributions of various 
upstream signaling pathways to 4E-BP phosphorylation under hypoxia are bet-
ter understood, it is premature to conclude that no connection between eIF2α 
and eIF4F exists.  
 
To more strictly assess the influence of hypoxia on eIF4F, we investigated the 
association of eIF4E with eIF4GI and eIF4GII as well as with its inhibitor 4E-
BP1 in HeLa cells. During aerobic conditions where translation is efficient, 
eIF4E is associated with large amounts of both eIF4GI and eIF4GII, and only a 
small amount of 4E-BP1 (cap lanes in Figure 4A and B). Cap-associated 
eIF4G migrated somewhat slower than the overall pool of eIF4G, suggesting a 
possible modification of this phospho-protein when bound to the cap. In con-
trast, after 4 or 16 h of hypoxia, there is a dramatic loss in binding to both 
eIF4GI and eIF4GII, indicating dissociation of the eIF4F complex. At 16 h, this 
dissociation correlates with a large increase in binding between eIF4E and 4E-
BP1, consistent with the increase in the hypo-phosphorylated levels of 4E-BP1 
at this time. It also correlated with decreased phosphorylation of eIF4E (Sup-
plementary Figure S1) at 16 h, but the physiological significance of this re-
mains unclear. However, although dissociation of eIF4G and eIF4E is complete 
after 4 h of hypoxia, a corresponding change in eIF4E phosphorylation or 
eIF4E/4E-BP1 association is not seen at this time point. This suggests that a 
mechanism distinct from 4E-BP1 dephosphorylation may also inhibit eIF4F 
during hypoxia. 
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Figure 3. Expression of eIF4E, 4E-BP1 and eIF4GI during hypoxia. HeLa cells were exposed to 
0.0% O2 for 0–16 h and cell lysates separated by SDS-PAGE. Immunoblots were performed 
using antibodies against actin, (A) eIF4E, (B) 4E-BP1 and (C) eIF4GI. The phosphorylation 
forms of 4E-BP1 have different electrophoretic mobilities and are represented by several bands
on the immunoblot. Full-length eIF4GI runs at about 220 kDa; the blot is overexposed to detect
cleavage products. 
 
 
Figure 4. eIF4F is disrupted during prolonged hypoxia. HeLa cells were exposed to 0.0% O2 for 
0–16 h and cell lysates probed for the presence of various eIF4E complexes. Lysates were 
incubated with an m7-cap analogue (‘Cap’) or uncapped resin as a negative control. Im-
munoblots were performed with antibodies against actin, (A) eIF4GI, eIF4E, 4E-BP1 and (B) 
eIF4GII. ‘Cap’: proteins bound to the capped resin; ‘Resin’: proteins bound to the uncapped 
resin; ‘C-FT’: unbound fraction after incubation with capped resin; ‘R-FT’: unbound fraction after 
incubation with uncapped resin. 
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Translocation of eIF4E by 4E-T  
A potential cause of eIF4F disruption that has not been well characterized is 
the translocation of eIF4E to the nucleus or to cytoplasmic bodies of mRNA 
processing (P-bodies). A 5-20% fraction of eIF4E is known to localize to the 
cell nucleus (Lejbkowicz et al, 1992). The shuttling protein 4E-T is the only 
known regulator of eIF4E localization and is capable of binding and transport-
ing it to the cell nucleus (Dostie et al, 2000). eIF4E also colocalizes with 4E-T 
in P-bodies, where mRNA is degraded or stored (Andrei et al, 2005). Hypoxia 
caused a redistribution of both eIF4E and 4E-T from predominantly cyto-
plasmic staining under aerobic conditions to substantial nuclear staining dur-
ing hypoxia (Figure 5A–C). This redistribution occurred progressively over 
time in hypoxic conditions, correlating with the gradual dephosphorylation of 
4E-T (Figure 5D). In addition, hypoxic cells exhibit significant eIF4E and 4E-T 
staining in the perinuclear area, which may be associated with the nuclear 
envelope or the ER. Interestingly, hypoxia also increased the number of 4E-T 
speckles, which have been described as P-bodies (Ferraiuolo et al, 2005). 
Gene-specific regulation of translation  
As translation efficiency is highly gene specific, we anticipated that individual 
genes would show different patterns of translation efficiency during acute and 
prolonged hypoxia. To investigate this, we fractionated polysomal mRNA and 
subsequently measured the mRNA abundance of individual genes by quanti-
tative RT-PCR (Figure 6A). We first confirmed that concomitant with an in-
crease in polysome association, the non/subpolysomal abundance de-
creased (Supplementary Figure S2). Subsequently, we quantified both the 
transcript recruitment and distribution within the polysomes (expressed as the 
relative fraction of translated transcripts and the average number of ri-
bosomes per translated transcript, respectively). 
 
We first measured the translational profile of the housekeeping gene β-actin 
(Figure 6B). In aerobic cells, it is efficiently translated with a majority of the 
mRNA in polysome fractions 5 and 6. After 1 h of hypoxia, there is a marked 
reduction in translation, as evidenced by a shift toward the lower polysome 
fractions, which recovers considerably by 16 h. The drop in translation effi-
ciency at 1 h is due to reductions in the relative fraction of translated mRNA 
and in the average number of ribosomes per translated transcript (Figure 6B). 
At later time points, only the average number of ribosomes per transcript re-
mained low. The kinetic changes in translation efficiency for β-actin are simi-
lar to those observed for overall translation efficiency. 
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Figure 5. 4E-T and eIF4E relocal-
ize during hypoxia. HeLa cells 
were treated with 0.0% O2 for 0-16 
h. Cells were stained with DAPI 
and (A) a polyclonal antibody 
against eIF4E, (B) a polyclonal 
antibody against 4E-T or (C) a 
monoclonal antibody against 
eIF4E and a polyclonal antibody 
against 4E-T. Cells were visual-
ized by confocal microscopy and 
individual pictures merged to de-
termine colocalization. (D) Cell 
lysates were separated by SDS-
PAGE and immunoblots per-
formed using antibodies against 
4E-T. The ratio of the individual 
bands was quantified with optical 
densitometry. A cross-reacting 
band is indicated (*). 
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Figure 6. Gene-specific regulation of translation during hypoxia. HeLa cells were exposed to 
0.0% O2 for 0-16 h and cell lysates were separated on sucrose gradients. (A) Fractions were 
collected as indicated, RNA was isolated and reverse transcribed. Thereafter, the total mRNA 
abundance of (B) β-actin, (C) CAIX, (D) ATF4, (E) CHOP and (F) GADD34 was determined 
using real-time quantitative PCR. The left panel shows total mRNA levels from unfractionated 
samples, normalized by 18S rRNA signal. The following three panels use black, gray and white 
bars to represent the gene abundance in polysome fractions following 0, 1 or 16 h hypoxia, 
respectively. The last two graphs show components of translation efficiency. This includes the 
relative fraction of transcripts in polysomes (i.e. corrected for total mRNA abundance) and the 
average number of ribosomes per mRNA. Graphs show the average from two independent 
experiments, and the histograms show the results from one representative experiment. 
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Many proteins are induced at the transcriptional level by hypoxia and we 
suspected that these genes might be preferentially translated during hypoxia. 
We investigated the translation of the HIF-1 target gene carbonic anhydrase 
IX (CAIX), which is important for tumor cell growth and survival during hy-
poxia (Robertson et al, 2004). Figure 6C shows an ~500-fold transcriptional 
induction of CAIX during hypoxia. Polysome analysis indicates that, similar to 
β-actin, CAIX is initially efficiently translated but severely inhibited after 1 h of 
hypoxia. A significant restoration of the polysome distribution occurs after 16 
h and thus ensures protein synthesis at this time where there is also signifi-
cantly more cellular mRNA. As for β-actin, the initial inhibition of CAIX trans-
lation is due to a drop in the recruitment of the mRNA into polysomes and in 
the number of ribosomes per transcript. However, during prolonged hypoxia, 
the mRNA recruitment recovers and lower translation efficiency is attributed 
only to a small reduction in the average number of ribosomes per transcript. 
 
ATF4 is a central transcription factor mediating the UPR following ER stress. 
Both thapsigargin (which causes ER stress) and 16 h of hypoxia result in 
eIF2α phosphorylation and translational induction of ATF4 in a PERK-
dependent manner (Harding et al, 2000; Blais et al, 2004; Bi et al, 2005). Un-
der normal conditions, the translation efficiency of this gene is low, with most 
of the mRNA found in fractions 1-3 (Figure 6D). In direct contrast to β-actin 
and CAIX, its translation is substantially increased during acute hypoxia, due 
to increased recruitment into the polysomes and an increase in the average 
number of ribosomes per transcript. In agreement with Blais et al (2004), we 
also observed a further increase in ATF4 translation efficiency during pro-
longed hypoxia.  
 
An important transcriptional target of ATF4 is the C/EBP transcription factor 
CHOP (Fawcett et al, 1999), which induces cell cycle arrest and apoptosis 
during ER stress. Figure 6E shows that CHOP is regulated both transcrip-
tionally and translationally by hypoxia. Translation is only moderately inhib-
ited during acute hypoxia, as shown by a drop in the average number of ri-
bosomes per transcript. However, this reduction is much smaller than aver-
age overall reduction (Figure 1C) and the reductions observed for both β-
actin and CAIX. After 16 h of hypoxia, translation of CHOP is stimulated, as 
indicated by a recovery in the number of ribosomes per transcript and a 
marked increase in the fraction of translated mRNA. 
 
Recovery from ER stress requires the GADD34 gene, which is induced in a 
PERK-dependent (Novoa et al, 2001) and CHOP-dependent (Marciniak et al, 
2004) manner. GADD34 stimulates the activity of PP1c to dephosphorylate 
eIF2α. We found that, like CHOP, GADD34 is regulated both transcriptionally 
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and translationally during hypoxia. Interestingly, its translation efficiency is 
highest after 4 h of hypoxia, which coincides with the start of recovery from 
eIF2α phosphorylation and overall translation inhibition (Figure 6F). In con-
trast, GADD34 mRNA is unable to completely bypass the translation inhibi-
tion after 16 h. 
Gene-specific regulation of translation—dependence upon eIF2α  
The gene-specific changes in translation noted above likely reflect the under-
lying eIF2α-and eIF4F-dependent mechanisms of translation control during 
hypoxia. We thus analyzed gene-specific translation in WT and S51A MEFs 
to establish the dependence of individual genes on eIF2α regulation (Figure 
7). In contrast to WT MEFs, S51A MEFs show no loss in translation efficiency 
of β-actin or CAIX during acute hypoxia (Figure 7A and B). The loss in trans-
lation efficiency for these genes in the WT cells is similar to that observed in 
HeLa cells and is due primarily to a reduction in the average number of ri-
bosomes per transcript. For both these genes, S51A MEFs show virtually no 
reduction in this parameter during the acute phase of hypoxia. However, in 
contrast to acute hypoxia, the translation efficiency during prolonged hypoxia 
is similar for these two genes in both cell lines. 
 
For ATF4 (Supplementary Figure S2), CHOP (data not shown) and GADD34 
(Figure 7C), acute hypoxia causes a stimulation of translation in WT MEFs 
that is similar to HeLa cells. However, the translational induction is entirely 
absent in S51A MEFs. The increase in translation efficiency for GADD34 in 
WT MEFs during acute hypoxia results mainly from an increase in the aver-
age number of ribosomes per transcript (Figure 7C). Cells that are defective 
in eIF2α phosphorylation show impaired regulation of this parameter. Thus, 
for all genes examined, the observed changes in translation efficiency during 
acute hypoxia are dependent on eIF2α phosphorylation. 
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Figure 7. Dependence on 
eIF2α-P for gene-specific 
translational regulation. WT 
and S51A MEFs were ex-
posed to 0.0% O2 for 0-16 h 
and cell lysates were sepa-
rated on sucrose gradients. 
RNA was isolated from poly-
some fractions and reverse 
transcribed. Thereafter, the 
abundance of (A) β-actin, 
(B) CAIX and (C) GADD34 
was determined using real-
time quantitative PCR. The 
first three panels use black, 
solid grey, hatched grey and 
white bars to represent the 
gene abundance in poly-
some fractions following 0, 
1, 4 or 16 h hypoxia, respec-
tively. The following graph 
depicts one component of 
translation efficiency, that is, 
the average number of ri-
bosomes per mRNA. 
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Discussion 
Rapid and persistent downregulation of protein synthesis is thought to be a 
means of energy preservation and to protect against the lethal effects of hy-
poxia (Koumenis et al, 2002; Wouters et al, 2005). Here we show that the 
inhibition of global mRNA translation during hypoxia exhibits a biphasic re-
sponse (Figure 8). The initial rapid inhibition (i.e. 15 min-4 h) is primarily de-
pendent on eIF2α phosphorylation, whereas inhibition during prolonged hy-
poxia is independent of eIF2α. Phosphorylation of eIF2α under conditions of 
anoxia is extremely rapid, occurring almost as quickly as we can establish 
hypoxia in our system (15-30 min). We have previously shown that eIF2α is 
also phosphorylated under more moderate hypoxic conditions, although to a 
smaller degree and after longer times (Koumenis et al, 2002). We speculate 
that this rapid anoxic response may be especially important during the acute 
exposures to hypoxia/anoxia that frequently occur in tumors due to the tran-
sient opening and closing of blood vessels. This rapid response may explain 
the importance of eIF2α and ATF4 in the tolerance of cells to oxidative 
stress, which also occurs during hypoxia/reoxygenation cycles (Harding et al, 
2003). This hypothesis is supported by a recent study by Bi et al (2005), who 
showed that activation of the PERK-eIF2α pathway during hypoxia contrib-
utes to overall tumor growth. Human tumor cells expressing a dominant-
negative PERK allele as well as MEFs lacking PERK or expressing the S51A 
eIF2α produce smaller tumors with increased cell death in hypoxic areas than 
their WT counterparts (Bi et al, 2005). Thus, although activation of eIF2α 
phosphorylation in response to hypoxia is transient, this response appears 
critical for long-term cell survival within hypoxic regions of tumors. 
 
Inhibition of translation during prolonged anoxia is associated with disruption 
of the mRNA cap-binding complex eIF4F and sequestration of eIF4E by both 
dephosphorylated 4E-BP1 and 4E-T. To our knowledge, this report is the first 
to show a physiological stress-induced regulation of the localization of eIF4E 
and its transporter 4E-T. Accumulation of eIF4E in the cell nucleus or P-
bodies renders it unavailable for cytoplasmic translation. Relocalization of 
eIF4E may have additional roles apart from reducing cap-dependent protein 
translation, including effects on mRNA processing, transport and degrada-
tion. Moderate hypoxia (1%) has also been shown to affect the eIF4F com-
plex through inhibition of mTOR (Arsham et al, 2003). However, the kinetics 
and relative contribution of the eIF4F pathway on inhibition of global and 
gene-specific translation during more moderate hypoxia remain to be deter-
mined (see below). 
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Figure 8. Model of the effects of hypoxia on 
overall mRNA translation. Acute hypoxia 
causes transient eIF2α phosphorylation due 
to PERK activation as a part of the UPR. 
This results in inhibition of the rate of transla-
tion initiation. Following prolonged hypoxic 
conditions, activation of 4E-BP and 4E-T 
causes disruption of eIF4F, which inhibits 
the recruitment of mRNA to polysomes. Both 
molecular mechanisms affect specific 
mRNAs to varying degrees, resulting in dif-
ferential gene expression. 
 
 
 
Analysis of mRNA distribution within polysomes at different times also re-
vealed interesting mechanistic differences during acute and prolonged hy-
poxia. Acute hypoxia caused a substantial drop in the average number of 
ribosomes per translated transcript. This presumably results from a reduction 
in the rate at which ribosomal subunits can be loaded onto mRNA, as each 
subunit requires a new nonphosphorylated eIF2α molecule. Inhibition of 
translation during prolonged hypoxia via eIF4F did not show this effect. In-
stead, translation was suppressed mainly by reducing the fraction of mRNA 
found within the polysomes. These results are consistent with a model in 
which the eIF4F cap-binding complex remains bound to the mRNA allowing 
sequential rounds of initiation by available eIF2α complexes. When transla-
tion is inhibited via eIF4F, many transcripts will lack this cap-binding complex 
and hence will not be competent to initiate translation. However, those tran-
scripts that do contain eIF4F will be translated normally (Figure 8). A similar 
phenomenon has been observed for a subpopulation of mRNAs that contain 
5' terminal oligopyrimidine tracts (5'TOPs), which alternate between transla-
tionally repressed and active states in response to various stimuli (reviewed 
in Meyuhas and Hornstein, 2000). It is thus conceivable that the overall re-
duction in mRNA translation observed during prolonged hypoxia affects a 
subset of genes, such as those with 5'TOPs, to a greater degree than others. 
 
An important issue that arises from our study is the nature of the oxygen-
sensing pathways upstream of eIF2α and eIF4F. Substantial evidence sug-
gests that the oxygen sensors are largely independent of the HIF oxygen-
sensing pathway (Jaakkola et al, 2001; Koumenis et al, 2002). In the case of 
eIF2α, its phosphorylation occurs in an HIF-independent manner. Instead, it 
requires PERK activation (Koumenis et al, 2002) and is associated with acti-
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vation of the UPR in response to ER stress (Romero-Ramirez et al, 2004; Bi 
et al, 2005). The upstream signaling that leads to eIF4F disruption is less 
clear, with perhaps both HIF-dependent and -independent components. Hy-
poxia has been shown to prevent insulin stimulation of mTOR and phos-
phorylation of its substrate 4E-BP1 during conditions of moderate hypoxia 
and serum starvation (Arsham et al, 2003). Similarly, Brugarolas et al (2004) 
showed that induction of REDD1 during hypoxia resulted in activation of the 
mTOR inhibitory complex TSC1/TSC2. As we also observe a decrease in the 
phosphorylation of 4E-BP1 after prolonged hypoxia, the eIF4F-dependent 
changes in translation reported here may also be due in part to inhibition of 
mTOR via REDD1 and TSC1/2. However, it is unlikely that this accounts en-
tirely for eIF4F disruption and translation inhibition during hypoxia. REDD1 is 
a HIF-dependent gene and both mTOR inhibition and translation inhibition 
during hypoxia occur in HIF1α-knockout cells (Koumenis et al, 2002; Arsham 
et al, 2003). Furthermore, our data indicate that eIF4F disruption occurs be-
fore substantial binding of eIF4E to 4E-BP1. Here we have identified redistri-
bution of eIF4E into the cell nucleus via 4E-T as an additional mechanism for 
eIF4F disruption during hypoxia. Further work will be needed to establish to 
what degree inhibition of translation is due to suppression of mTOR/4E-BP1 
phosphorylation and 4E-T activation, as well as to the requirements of HIF in 
both of these pathways.  
 
The fact that both eIF2α and eIF4F independently affect translation during 
hypoxia has important implications for the regulation of gene expression. 
mRNAs preferentially translated during acute hypoxia must be less depend-
ent on eIF2α availability, whereas mRNAs that are actively translated during 
prolonged hypoxia must be less dependent on eIF4F. The translation of 
ATF4, which contains two upstream open reading frames (uORFs) in its 
5'UTR, is perhaps the best example of a mammalian gene that displays this 
type of preferential translation (Harding et al, 2000). When eIF2α availability 
is high, translation begins at the 5' most uORF and re-initiation occurs effi-
ciently at the subsequent uORF, preventing translation from the correct start 
codon of ATF4. When eIF2α is phosphorylated, there is a higher probability 
of skipping the second uORF and re-initiating at the bona fide start codon (Lu 
et al, 2004). Here, we found that in addition to ATF4, the downstream genes 
CHOP and GADD34 are also translationally induced during acute hypoxia. 
The S51A MEFs, which are unable to phosphorylate eIF2α, are defective in 
this translational regulation. This result is consistent with a report showing 
that ER stress-induced expression of GADD34 protein can be prevented by 
keeping eIF2α dephosphorylated (Novoa et al, 2003). The bypass of transla-
tion inhibition may thus facilitate the ability of GADD34 to dephosphorylate 
eIF2α and promote recovery from ER stress.  
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Our results predict that during prolonged hypoxia, gene transcripts with lower 
dependency on eIF4F should be preferentially translated. The translation of 
ATF4 and CHOP was in fact stimulated in HeLa cells after 16 h of hypoxia 
when the eIF4F complex was disrupted. Preferential translation under condi-
tions of limiting cap-binding complex activity can occur through a higher than 
average affinity for eIF4F (Lawson et al, 1988). Another group of mRNAs that 
can be translated independently of the eIF4F complex are those that contain 
an internal ribosomal entry site (IRES) in their 5'UTR (Carter et al, 2000; Hol-
cik and Sonenberg, 2005). The presence of an IRES enables translation ini-
tiation under conditions where eIF4F-dependent translation is inhibited. Im-
portantly, both mouse HIF-1α and VEGF have been shown to contain func-
tional IRESs within their 5'UTR (Stein et al, 1998; Lang et al, 2002), although 
their biological importance is not yet firmly established. This provides a 
mechanism to ensure their translation during prolonged hypoxia where eIF4F 
is disrupted. The mechanism responsible for the selective translation of ATF4 
and CHOP during prolonged hypoxia remains to be identified.  
 
In conclusion, we have shown that mRNA translation is inhibited through mul-
tiple independent pathways with differing activation kinetics during hypoxia. 
These distinct modes of translational control influence the translation of indi-
vidual genes to varying degrees and consequently can influence hypoxia-
regulated protein expression in complex ways. An important finding is that 
inhibition of translation via eIF2α is transient, leading to dynamic changes in 
the translation efficiency of genes over the first 8 h of hypoxia. Our selected 
analysis of gene translation during hypoxia suggests that many genes may 
be differentially regulated by hypoxia. A complete survey of the genome for 
differentially translated genes during various exposures to hypoxia and their 
dependence of eIF2α is possible and will undoubtedly identify novel and im-
portant hypoxia-regulated proteins (Koritzinsky et al, 2005). 
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Abstract 
Background and purpose: EGFRvIII has been described to function as an 
oncoprotein with constitutive activation promoting neoplastic transformation 
and tumorigenicity. The present study was undertaken to test whether 
EGFRvIII also contributes to hypoxia tolerance. 
 
Material and methods: The human glioma cell line U373 was genetically 
modified to stably express EGFRvIII. Western blotting and immunohisto-
chemistry verified the expression of EGFRvIII. Tumor xenografts were pro-
duced by injecting U373 control and EGFRvIII positive cells subcutaneously 
into the lateral flank of recipient mice. Colony formation assays were per-
formed after ionizing radiation at 4 Gy and after exposure to anoxia for 1-4 
days. 
 
Results: EGFRvIII accelerated tumor growth leading to a 3.5-fold increase in 
tumor size compared to control tumors at 40 days after cell injection. 
EGFRvIII promoted clonogenic survival by almost 2-fold and 4-fold after 4 Gy 
and 4 days of anoxia, respectively. EGFRvIII was also associated with a sub-
stantially bigger colony size after anoxic treatment. 
 
Conclusions: EGFRvIII expression stimulates the growth of tumor xenografts 
and strongly promotes survival after irradiation and under hypoxic stress. 
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Introduction 
The epidermal growth factor receptor (EGFR) is a well characterized proto-
oncogene that is expressed in multiple cancers where it has been shown to 
promote tumor progression and therapy resistance [1, 3, 12, 19]. EGFR tar-
geted strategies are actively under investigation and EGFR-specific tyrosine 
kinase inhibitors (TKI) and monoclonal antibodies (mAb) have shown great 
promise [4, 6-8, 17]. This is illustrated by the high number of currently running 
clinical trials investigating anti-EGFR strategies in cancer treatment. How-
ever, some of the first clinical reports failed to corroborate the promising anti-
tumor effects seen in preclinical studies, implicating persistent growth path-
ways despite blockade of wild-type EGFR [5, 21]. The presence of naturally 
occurring mutations of EGFR may account for the limited clinical response to 
EGFR-targeted therapies [10, 13, 18]. A commonly described variant harbors 
an in-frame deletion of exons 2-7 resulting in a truncated version of the re-
ceptor which lacks a portion of the extracellular ligand binding domain. This 
variant, called EGFRvIII, has not been detected in normal tissue, but is found 
in many malignancies, such as glioblastoma, non-small lung cell carcinoma, 
breast cancer, prostate cancer and just recently also in head and neck can-
cer [15,16, 20]. Ligand-independent activation of EGFRvIII may explain the 
relative inability of blocking mAbs to downregulate the receptor [2, 26]. The 
present study was undertaken to test the hypothesis that EGFRvIII express-
ing tumor cells not only contribute to therapy resistance but also to hypoxia 
tolerance. This would have important implications for our understanding of 
the tumor microenvironment and for the optimization of EGFR-targeted 
strategies in cancer therapy. 
Materials and methods 
Generation of a stable EGFRvIII expressing cell line 
U373 human glioma cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA) and cultured in MEMα medium (Invitrogen, 
Breda, NL) supplemented with 10% fetal calf serum (FCS). The 
phβAc.EGFRvIII plasmid, a generous gift from D.Bigner (Duke University, 
NC, USA), was transfected into U373 cells using PolyFect (Qiagen, Venlo, 
NL) according to the manufacturer’s directions. Forty-eight hours after trans-
fection, cells were trypsinized and seeded at low density for selection in 300 
µg/ml Geneticin (Invitrogen, Breda, NL). The plates were incubated for two 
weeks to allow formation of resistant colonies. Several colonies were chosen 
for expansion and labeled U373-vIII clones A-G. 
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Immunoblotting 
The cell pellet obtained from a 6 cm plate was lysed in 50 µl RIPA buffer (150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-
HCl, pH 7.5, 1x protease inhibitor cocktail) and incubated on ice for 30 min. 
Cell debris was removed by centrifugation at 10,000g for 15 min. The protein 
concentration in the supernatant was determined using the DC Assay (Bio-
Rad, Veenendaal, NL). Forty micrograms of each sample was resolved on an 
8% SDS-PAGE gel and blotted onto a Hybond ECL nitrocellulose membrane 
(GE Healthcare, Deigem, BE) by electrotransfer. The membrane was blocked 
with 5% milk-TBST (20 mM Tris–HCl, pH 7.6, 140 mM NaCl, 0.1% Tween 20) 
and incubated overnight in a 1:1000 dilution of EGFR (15F8) rabbit mono-
clonal antibody (Cell Signaling Technology, Danvers, MA, USA). The mem-
brane was washed with TBST and incubated for 1 h with a goat anti-rabbit 
secondary antibody (Cell Signaling Technology) at 1:3000 dilution. Immobi-
lized proteins were detected using SuperSignal West Pico chemiluminescent 
substrate (Perbio, Etten-Leur, NL) and by exposing the blot to X-ray film. 
Immunohistochemistry 
Cells grown in chamber slides in vitro were fixed with 10% formalin and 
stained for EGFR using a 1:200 dilution of EGFR (sc-03) rabbit polyclonal 
antibody (Santa Cruz Biotechnology, Heidelberg, DE). The primary antibody 
was detected by an EnVision peroxidase-linked secondary antibody (DAKO, 
Heverlee, BE) used in combination with DAB+ chromogen and substrate 
(DAKO, Heverlee, BE). Slides were counterstained with hematoxylin and 
mounted in DPX medium (Brunschwig chemie, Amsterdam, NL).  
 
Seven micrometer thick tumor sections were stained using the same primary 
antibody as above at 1:100 dilution. A biotinylated goat anti-rabbit secondary 
(DAKO) was used at a 1:200 dilution followed by Vectastain ABC solution 
(Brunschwig chemie) and detection with DAB. 
Radiation of cells 
Cells were seeded in 6 cm dishes in order to reach ~80% confluence at the 
time of irradiation. Growth medium containing 0.5% FCS was added to cells 
16 h before irradiation. During irradiation, dishes were placed in a Plexiglas 
jig filled with water at 37 °C. Cells were irradiated using an MCN 225 indus-
trial X-ray tube (Philips, Eindhoven, NL) operated at 225 kV and 10 mA to 
deliver a dose of 4 Gy at a rate of 0.85 Gy/min. Immediately following irradia-
tion, cells were returned to the incubator for 24 h at which time they were 
plated in MEMα + 10% FCS for the clonogenic survival assay. 
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Clonogenic survival assay 
Cells were counted using a Coulter Z Series particle counter (Beckman Coul-
ter, Mijdrecht, NL) and seeded in triplicate 6 cm dishes. For hypoxia experi-
ments, cells were seeded for clonogenic survival prior to hypoxic exposure at 
0% oxygen for 1-4 days. After the hypoxic treatment, the plates were re-
moved from the hypoxic chamber (a MACS VA500 microaerophilic work-
station supplied by Don Whitley Scientific, Shipley, UK) and incubated under 
standard culture conditions until colonies formed (~14 days in total). Colonies 
were fixed and stained with 2% bromophenol blue in 70% ethanol. Plating 
efficiency was determined by counting colonies consisting of ≥50 cells and 
correcting for the number of cells seeded. 
Tumor xenograft growth 
Animal experiments were performed using adult NMRI (nu/nu) female mice 
(28-32 g) from the animal facility of the Catholic University of Leuven in Bel-
gium. The animal facilities and experiments were in accordance with local 
institutional guidelines for animal welfare and were approved by the Animal 
Ethics Committee of the university. Three million U373 and U373-vIII(+) cells 
were resuspended in 100 µl growth medium and injected subcutaneously into 
the lateral flank of recipient mice. Tumors were measured with callipers in 
three orthogonal diameters and used to calculate tumor volume based on the 
formula A x B x C x π/6. Animals were followed until the ethically allowed tu-
mor burden was reached, at which time tumors were excised, fixed in 1-4% 
formaldehyde, and embedded in paraffin. Mean tumor volumes were calcu-
lated for each group. 
In vitro growth under aerobic and hypoxic conditions 
For growth under aerobic conditions, 105 cells were seeded in triplicate on 6 
cm dishes. The plates were incubated under normal culture conditions in a 
5% CO2 incubator for 1-6 days. To monitor growth under hypoxia, 5 x 105 
cells were seeded in 10 cm dishes. The following day (day 0), dishes were 
placed in the hypoxic chamber for 1-4 days. Plates were harvested by wash-
ing two times with phosphate-buffered saline followed by trypsinization. Total 
cell numbers were enumerated using a Coulter Z Series particle counter 
(Beckman Coulter, Mijdrecht, NL). Cell numbers were normalized to the 
amount of cells present on day 0. Doubling times were calculated from the 
slope of the best-fit line during the exponential phase of growth. 
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Statistics 
Statistical analysis was carried out using the program SPSS 12.0.1 for Win-
dows (SPSS Inc., 2003, Chicago, IL, USA). A non-parametric Mann-Whitney 
U test was used to assess differences in xenograft tumor growth. A Student’s 
t-test was used to assess differences in radiation survival and a one-way 
ANOVA was used to determine differences in growth under hypoxia. P values 
<0.05 were considered to be significant. 
Results 
Generation of a stable EGFRvIII model 
U373 glioma cells were transfected with an EGFRvIII expression plasmid in 
which EGFRvIII transcription is driven from a human β-actin promoter. Sev-
eral clones with stable integration of the plasmid were selected and screened 
for EGFRvIII protein expression. Clones A, D, and F have high expression of 
EGFRvIII as seen by the presence of two bands corresponding to different 
glycosylated forms of the mutant receptor (Fig. 1a). In contrast, clones B, C, 
E, and G express only wild-type EGFR similar to the parental U373 cells de-
spite displaying Geneticin resistance. We selected clone D as an EGFR-vIII 
positive cell line and clone B as an EGFR-vIII negative control for use in fur-
ther experiments. We will refer to clones B and D as U373-vIII(-) and U373-
vIII(+), respectively. Immunohistochemical staining was performed using an 
antibody that recognizes both wild-type and variant forms of EGFR. The pa-
rental U373 and U373-vIII(-) cell lines show low EGFR expression which is 
localized mainly to the plasma membrane (Fig. 1b). In contrast, U373-vIII(+) 
show higher expression in both the cytoplasm and at the plasma membrane 
with some cells also demonstrating strong nuclear staining. 
Intrinsic radiation resistance imparted by EGFRvIII 
Previous studies have demonstrated a role for EGFRvIII in radiation resis-
tance [10, 11]. We confirmed that our cell line model is also protected from 
radiation induced killing when EGFR-vIII is expressed (Fig. 2). In a clono-
genic survival assay, U373-vIII(+) showed an almost 2-fold increase in sur-
vival after irradiation with 4 Gy (P = 0.005), suggesting that EGFR-vIII is func-
tional in our model and able to activate downstream survival pathways. 
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Figure 1. Stable expression of EGFRvIII in selected U373 clones. U373 cells were transfected 
with phβAc.EGFRvIII and stable integration of the plasmid was selected by growth in Geneticin. 
(a) Untransfected U373 cells, as well as transfected cells, either before (transient) or after selec-
tion (stable pool and individual clones), were screened for expression of EGFRvIII by im-
munoblot analysis. CHO+ indicates lysate from Chinese hamster ovary cells which have been 
engineered to express EGFRvIII and serve as a positive control. Arrows indicate bands at the 
appropriate molecular weight for wild type EGFR and EGFRvIII. (b) EGFR expression was de-
tected by immunohistochemical staining of U373, U373-vIII(-) and U373-vIII(+) cells grown in 
vitro. 
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Figure 2. EGFRvIII increases the intrinsic 
radioresistance of U373 cells. Clonogenic 
survival assays were performed to determine 
the radiosensitivity of U373 and U373-vIII(+) 
cells. Cells were irradiated with 4 Gy and 
plated for colony formation 24 h later. The 
mean values of 3 independent experiments 
are shown. Error bars indicate standard error 
of the mean. *P = 0.005. 
 
EGFRvIII induces growth advantage in vivo  
We established tumor xenografts from U373 and U373-vIII(+) cells to investi-
gate the influence of EGFRvIII on growth in vivo. Both EGFRvIII positive and 
negative cell lines established tumors at a similar rate with palpable tumors 
becoming visible around day 10 after injection (data not shown). Despite 
growing at similar rates under normal culture conditions in vitro (Fig. 4a), 
U373-vIII(+) stimulated the growth of tumor xenografts. On day 40 the aver-
age U373-vIII(+) tumor volume was 948 mm3, a 3.5-fold increase compared 
to the parental U373 tumors (P = 0.011) (Fig. 3a). U373 tumors took an aver-
age of 88 days to reach a similar volume (Fig. 3b). Sections from these tu-
mors that were stained for EGFR expression showed a similar heterogene-
ous staining pattern in both tumor types, however U373-vIII(+) displayed a 
clear increase in the intensity of EGFR staining (Fig. 3c and d). Since the an-
tibody used for immunohistochemistry recognizes both wild-type EGFR and 
EGFRvIII, we conducted immunoblot analysis of ex vivo tumor lysates to con-
firm that the elevated staining seen in Fig. 3d was due to increased EGFRvIII 
expression. Two individual U373-vIII(+) tumors showed dramatically higher 
expression of EGFRvIII than wild-type EGFR compared to U373 tumors 
which displayed variable levels of the wild-type protein (Fig. 3e). Therefore, 
these results show that our cell model retains a high and stable level of 
EGFRvIII expression during tumor growth in vivo. 
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Figure 3. EGFRvIII promotes tumor growth in vivo. Tumor xenografts were established in nude 
mice using U373 and U373-vIII(+) cells. (a)Columns indicate the mean tumor volume ± standard 
deviation at day forty after injection. *P = 0.011. (b) Mean tumor volumes ± standard deviation of 
U373 xenografts at time points after day 40. Tumors were excised and processed for immuno-
histochemical staining of EGFR. Representative sections from U373 tumors (left column) and 
U373-vIII(+) tumors (right column) are shown at 4X (c) and 20X (d) magnification. (e) Im-
munoblot analysis of ex vivo tumor lysates from two individual U373 or U373-vIII(+) tumors was 
conducted using antibodies recognizing EGFR and β-actin. 
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Hypoxia tolerance of EGFRvIII expressing cells 
Due to the growth advantage displayed by EGFRvIII expressing tumors, we 
hypothesized that EGFRvIII may help cells to tolerate the stress of the tumor 
microenvironment. We began by assessing cell growth under both normoxic 
and hypoxic conditions. No significant difference in doubling time was observed 
between the three cell lines under normoxic conditions (Fig. 4a). The doubling 
time was calculated to be ~23 h. Under a low oxygen environment, all cell lines 
displayed decreased growth; however during the first 48 h, U373-vIII(+) cells 
grew more quickly than the cell lines lacking EGFRvIII expression (Fig. 4b). 
During this time U373-vIII(+) cells had a significantly faster doubling time of 34 
h compared to 47 h for U373 (P < 0.002). A decrease in total cell number in all 
cell lines after 2 days of hypoxic exposure indicates that the rate of cell death 
exceeded the rate of proliferation at this time. 
 
 
 
Figure 4. EGFRvIII influences growth under 
hypoxia. The influence of EGFRvIII on cell 
growth was evaluated by counting total cell 
numbers of U373 (■), U373-vIII(-) (●), and 
U373-vIII(+) (▲) after incubation under nor-
moxic (a) or hypoxic (b) conditions. The 
mean cell number relative to day 0 is shown. 
Error bars indicate standard deviation of trip-
licate measurements. (b) The slopes of all 
three curves are significantly different from 
each other during the first two days (P < 
0.002, one-way ANOVA). 
 
 
In order to assess if EGFRvIII could influence the long-term effects of hypoxia 
on cell killing, we performed a clonogenic survival assay. U373-vIII(+) cells 
were more resistant to hypoxia-induced death than parental U373 or U373-
vIII(-) cells after 3-4 days of exposure to 0% oxygen (Fig. 5). Together, these 
results demonstrate that EGFRvIII promotes tolerance of tumor cells to hy-
poxic stress. 
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Figure 5. EGFRvIII improves clonogenic 
survival under hypoxia. Hypoxia tolerance 
was determined by clonogenic survival of 
U373, U373-vIII(-) and U373-vIII(+) after 
exposure to 0% oxygen for 24–96 h. The 
mean surviving fraction ± standard error of 
two independent experiments are shown. 
 
 
Discussion 
In the present report we describe the development of a useful cellular model 
with which to study the contribution of EGFRvIII to tumor growth, response to 
therapy and hypoxia. We confirmed that this cell line displays increased ra-
dioresistance relative to the parental cell line (Fig. 2), as expected based on 
previous studies which emphasize the importance of EGFRvIII as a clinical 
target and mediator of radiation induced survival signaling [9,10]. EGFRvIII 
expression in our model also promotes tumor growth in vivo (Fig. 3a) and 
growth in vitro under hypoxic conditions (Fig. 4b). Thus, under conditions 
where nutrients may be limited or cell stress is apparent, EGFRvIII may im-
part a growth or survival advantage. Supporting this hypothesis, we have 
made the observation that indeed, U373-vIII(+) cells show increased survival 
after hypoxic stress (Fig. 5). 
 
Our results suggest that the growth advantage of EGFRvIII expressing cells 
in xenograft tumors may be related to the EGFRvIII induced proliferation and 
survival observed under hypoxia. Furthermore, the clones derived from the 
EGFRvIII positive cell line were significantly bigger than the controls in the 
colony formation assays presented (Fig. 5; data not shown), which also sug-
gests an induced proliferation under hypoxic conditions. The mechanisms 
underlying the enhanced survival after ionizing radiation and hypoxia are not 
fully understood and warrant further evaluation. We have previously shown 
that EGFRvIII, although constitutively phosphorylated at relatively low levels, 
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responds to ionizing radiation with an immediate activation after clinically 
relevant doses of ionizing radiation [9]. This radiation induced activation pref-
erentially stimulates PI3K-Akt signaling, which is known to be involved in cel-
lular proliferation and apoptosis [9,14, 24, 25]. Whether this can explain the 
difference in clonogenic survival of almost 2- and 4-fold after 4 Gy and 4 days 
of anoxia, respectively (Fig. 2–5), remains unclear. Despite its role in prolif-
eration and antiapoptosis, EGFRvIII may alter the capacity for DNA repair via 
activation of the Akt-mammalian target of rapamycin (mTOR) pathway and 
the subsequent upregulation of translation of DNA repair proteins [19,22,23].  
 
Our results might also indicate a possible selection of EGFRvIII expressing 
tumor cells under hypoxic conditions in growing tumors, which would lead to 
an accumulation of EGFRvIII positive cancer cells in hypoxic areas of the 
tumor. This might, however, impair on the effectiveness of targeted anti-
EGFR drugs due to the biodistribution properties of the drugs in solid tumors.  
 
In summary, we have implicated EGFRvIII as a contributor to cell survival 
under conditions of radiotherapy as well as hypoxic stress. This finding im-
proves our understanding of the contribution of hypoxia on the negative influ-
ence of radiosensitivity in tumor cells. It also highlights the need for monitor-
ing the expression of EGFRvIII in human tumors in order to individualize and 
optimize molecular targeted therapies. The mechanisms underlying these 
vIII-dependent phenotypical changes warrant further investigation. 
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Abstract 
Background and purpose: Rapamycin, a highly specific mTOR inhibitor, has 
shown anti-proliferative and anti-angiogenic properties, as well as an en-
hancement in tumor growth delay when used in combination with radiation in 
mouse xenograft models. Our goal was to determine if rapamycin can also 
have a positive effect on the local tumor control achieved by radiotherapy. 
 
Materials and methods: Nude mice bearing U87 glioblastoma xenografts 
were treated with concomitant rapamycin and radiotherapy over a 5 day frac-
tionation schedule. Animals received graded total doses ranging from 24 to 
100 Gy. Experimental endpoints were tumor growth delay and local tumor 
control. In addition, histological evaluation of tumor sections was performed 
to examine changes occurring within the tumor microenvironment as a result 
of treatment. Analysis of proliferation, mTOR signalling, hypoxia, and vessel 
thrombosis was conducted. 
 
Results: As a single agent, rapamycin reduced the in vitro growth of U87 cells 
by 70% and caused a 4 day growth delay of tumor xenografts. In combination 
with radiation, no further increase in tumor growth delay was observed when 
compared to radiation alone. The tumor control dose 50% (TCD50) was 46.8 
Gy (95% CI 41; 53 Gy) in tumors treated with radiation alone and was slightly 
but not significantly lower at 42.8 Gy (95% CI 36; 49 Gy) after simultaneous 
treatment with rapamycin. Histological evaluation revealed evidence of ele-
vated hypoxia following rapamycin treatment that may be due to vessel 
thrombosis. 
 
Conclusions: The influence of rapamycin on thrombosis and tumor hypoxia 
may be a confounding factor limiting its effectiveness in combination with ra-
diotherapy. 
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Introduction 
The mammalian target of rapamycin (mTOR) kinase has been identified as 
an attractive molecular target for cancer therapy and a number of mTOR in-
hibitors are currently under evaluation in clinical trials [1,2]. mTOR is a key 
component of the PI3K/Akt signal transduction pathway which is stimulated 
by various growth factors upon binding to their respective receptors [3]. In 
addition, mTOR also plays a role in adapting cellular responses to nutrient 
availability and cellular energy levels [3]. When activated, mTOR integrates 
these environmental inputs by phosphorylating two major targets, p70S6K 
and 4E-BP1, which regulate the translation of mRNA into protein thus leading 
to the differential expression of genes that are controlled at the translational 
level [4]. 
 
mTOR activity is frequently upregulated in a wide spectrum of human can-
cers often occurring as a consequence of mutations in PI3K, loss of PTEN 
expression, or overexpression of Akt [5–7]. These genetic alterations pro-
mote proliferation and survival when mitogenic factors and nutrients are limit-
ing, as is often the case within the tumor microenvironment. Many tumor cell 
lines with known mutations within the PI3K/Akt/mTOR pathway are sensitive 
to the growth inhibitory effects of rapamycin, a highly specific mTOR inhibitor 
[8,9]. The anti-proliferative effects of rapamycin are mediated in part by ar-
resting cells in G1 phase of the cell-cycle due to modulation of cyclin D1 [10] 
and p27 levels [11]. In addition, mTOR inhibition may also lead directly to 
apoptosis [12–14] or autophagy (another form of programmed cell death) [15] 
depending upon the genetic make-up of the cell. 
 
Besides its direct action on tumor cells, rapamycin has also been shown to 
have several anti-vascular effects. Guba et al. have demonstrated potent 
anti-angiogenic activity of rapamycin which was attributed to two factors: (1) 
reduced VEGF production by tumor cells and (2) the inhibition of VEGF-
induced proliferation in endothelial cells [16]. Blood vessel function can also 
be impaired by rapamycin via the stimulation of thrombosis within tumor mi-
crovasculature [17]. Thirdly, rapamycin can radiosensitize endothelial cells 
resulting in reduced vascularity and perfusion in glioma xenografts [18]. 
 
These data suggest that mTOR inhibitors may be promising agents in combi-
nation with radiotherapy. Indeed, rapamycin has previously been shown to 
prolong the growth delay of glioma xenografts treated with fractionated radio-
therapy; an effect which was proposed to be caused by inhibition of tumor 
cell repopulation [19]. One might hypothesize that rapamycin could also im-
prove local tumor control by contributing to vascular damage and preventing 
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angiogenesis during radiotherapy. Furthermore, rapamycin may prevent acti-
vation of radiation-induced survival signals that are generated by stimulation 
of the PI3K pathway [20–22]. As a cytostatic drug already used in the clinic 
for the treatment of graft rejection, rapamycin is well tolerated and is not an-
ticipated to complicate normal tissue toxicity.  
 
In the present study we tested the efficacy of combining rapamycin with frac-
tionated radiotherapy on tumor cure using a glioblastoma xenograft model. 
We designed our experiment so as to minimize the effects of rapamycin on 
repopulation and to investigate if there is an additional direct contribution to 
cytotoxicity and tumor cure. We demonstrate variability in the response of 
tumors to the combined therapy, despite being sensitive to rapamycin as a 
single agent. Elevated vessel thrombosis and hypoxia were also observed in 
several rapamycin treated animals. We propose that thrombosis of tumor 
vasculature is playing a role in determining outcome to the combined therapy.  
Materials and methods 
Rapamycin 
Rapamycin was purchased from LC Laboratories (Woburn, MA, USA) and 
stored protected from light at -20°C. For in vitro experiments, a 1 mg/ml stock 
solution was made using dimethyl sulfoxide (DMSO). For in vivo experiments, 
rapamycin was dissolved in ethanol to yield a 10 mg/ml stock solution. Prior 
to injection, the stock solution was diluted to yield a final concentration of 0.4 
mg/ml rapamycin in 5% PEG400, 5% Tween 80 and 4% ethanol. Rapamycin 
was delivered by intraperitoneal (i.p.) injection at a dose of 1 mg/kg body-
weight with control animals receiving vehicle alone. 
 
In vitro growth inhibition 
HeLa (cervix adenocarcinoma, ATCC), MDAMB231 and MCF7 (breast ade-
nocarcinoma, gift from V. Castronovo, Liège University), U251, U118, and 
U87 (glioblastoma, gift from J. Sarkaria, Mayo Clinic), and A549 (lung carci-
noma, gift from J.M. Brown, Stanford University) cell lines were maintained in 
Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum and 
incubated in a humidified 5% CO2 chamber at 37°C. Cells were seeded at an 
appropriate density so as to maintain exponential growth during the course of 
the experiment. 1.5-3.5 x 104 cells were seeded onto 24-well plates in tripli-
cate. The following day, serial dilutions of rapamycin were added to the 
plates. Control wells were treated with an equal volume of DMSO. After 5 
days of incubation, cells were harvested by trypsinization and counted using 
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a Coulter Z Series particle counter (Beckman Coulter, Mijdrecht, NL). The 
relative growth inhibition was calculated by normalizing the average cell 
number in the rapamycin treated wells by the DMSO control. 
Animals 
Animal experiments were performed using 7- to 14-week-old NMRI (nu/nu) 
mice from the specific pathogen-free animal breeding facility of the Experi-
mental Centre of the Medical Faculty of the University of Dresden. The ani-
mal facilities and the experiments were approved according to the German 
animal welfare regulations. To minimize the residual immune response, all 
animals received 4 Gy whole-body irradiation 1-2 days before tumor trans-
plantation. 
Tumor xenograft model 
U87 cells were established as a tumor xenograft as described previously [23]. 
Stock tumors were maintained by serial passage to the back of nude mice. 
For the experiments, source tumors were excised, cleared of necrotic tissue, 
cut into small pieces (~1 mm3), and transplanted subcutaneously into the 
right hind leg of the recipient mice. Tumor diameters were measured twice 
per week and used to calculate tumor volume based on the formula of a rota-
tional ellipsoid π/6 x a x b2, where a is the longer and b is the perpendicular 
shorter tumor axis. Treatment was initiated when tumors reached a volume of 
100 mm3. 
Tumor irradiation 
Animals received injections of rapamycin beginning one day before irradiation 
and continuing daily throughout the fractionation schedule. Irradiation was 
delivered under ambient conditions, without anaesthesia, 2 h after injection 
with rapamycin or vehicle (200 kV X-rays, 0.5 mm Cu, at a dose rate of ~1 
Gy/min). Animals were immobilized in jigs specially designed to hold the tu-
mor-bearing leg in the irradiation field. Five equal fractions were delivered 
over five consecutive days to total doses of 24, 32, 40, 50, 60, 72.5, 85, and 
100 Gy. Animals were randomized into control or rapamycin treatment 
groups, aiming for a total of sixteen animals per dose level. 
Animal follow-up, determination of tumor growth delay and TCD50 
Animals were observed until the tumor diameter reached 12-15 mm, until 
death, or until day 150 after the end of treatment. Median tumor volumes 
were calculated for each treatment arm and dose level as a function of time 
after start of treatment. Regrowth delay was calculated for the dose groups in 
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which less than 50% of tumors were cured (i.e., 24, 32, and 40 Gy). The time 
for tumors to reach 5 times the initial volume was determined for each animal 
and this value was used to calculate the median regrowth time for the treat-
ment group. Regrowth delay was calculated as the difference in median re-
growth time for any pair of treatments. Recurrences were scored when the 
tumor volume increased for at least three consecutive measurements after 
passing a nadir. Tumor control frequency at day 120 after end of irradiation 
was calculated for each dose group using correction for censored animals 
according to the method given by Walker and Suit [24]. Animals were moni-
tored for an additional 30 days to ensure no further recurrences. A binary 
(cure/failure) model was used to fit the individual tumor control data. As re-
ported in previous investigations [25], animals censored later than day 20 
after end of treatment were counted as local controls. Animals censored be-
fore day 20 were omitted from analysis (n = 21). The tumor-control probability 
(TCP) was modeled using the logit model  
TCP = 1 / [1 + exp (-f (x,β) ]  
where x is the vector of covariates that define the treatment, β is the vector of 
parameters describing radiosensitivity of the tumors, and f is a (possibly 
nonlinear) function of these. Parameters were estimated using maximum like-
lihood as implemented in STATA 7.0 software (STATA Corporation, College 
Station, TX). Quoted confidence limits are asymptotic estimates from the re-
sults of the likelihood fits. Comparison of maximum likelihood fits was per-
formed using the likelihood ratio test [26]. TCD50 at day 120 after end of irra-
diation and associated dose-response curve were determined from: 
f (D,β) = β1 (1 – D / β2) where β1 is a constant and TCD50 = β2. 
Immunohistochemistry 
Mice with implanted U87 xenografts were treated with 1 mg/kg rapamycin or 
vehicle alone for 2 days. On the second day, mice in the radiation treatment 
group were irradiated with a single dose of 4.8 Gy (to simulate the treatment 
of the animals in the 24 Gy total dose group of the TCD50 assay). Twenty-four 
hours after irradiation the tumors were excised. Prior to excision, tumors were 
labelled for 1 h with pimonidazole (Natural Pharmacia International Inc., Re-
search Triangle Park, NC, USA), administered i.p. at 0.1 mg/g body weight 
and followed by 3.75 mg bromodeoxyuridine (BrdU) (Serva, Heidelberg, DE) 
for 15 min. Tumors were fixed overnight in 4% neutral buffered formalin and 
embedded in paraffin. Three micrometer thick sections were stained for BrdU 
using monoclonal antibody clone Bu20a (DAKO, Hamburg, DE). The Hy-
poxyprobe-1TM kit (Chemicon International, Hampshire, UK) was used to de-
tect pimonidazole and phospho-S6 ribosomal protein (Ser235/236) was rec-
ognized by a rabbit polyclonal antibody from Cell Signaling Technology 
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(Frankfurt am Main, DE). Staining of tissue sections for thrombosis was per-
formed using the Martius Yellow-Brilliant Crystal Scarlet-Soluble Blue (MSB) 
kit (HD Supplies, UK) according to the method of Lendrum et al. [27]. 
Statistics 
Statistical analysis was carried out using the program GraphPad Prism 4.02 
(GraphPad Software Inc., San Diego, USA). A two-tailed t-test was used to 
assess differences in BrdU labelling. The Kruskal–Wallis analysis of variance 
test was used in combination with Dunn’s multiple comparison post-test to 
establish significance for pimonidazole and MSB staining. Ninety-five percent 
confidence intervals of median values were determined as given by Sachs 
[28]. P values <0.05 were considered to be significant. 
Results 
Anti-proliferative effect of rapamycin in vitro 
We tested the in vitro growth of seven tumor cell lines representing a variety 
of tissue types in response to increasing concentrations of rapamycin. As 
seen in Fig. 1, HeLa and MDAMB231 were resistant to rapamycin with less 
than 30% growth inhibition and an IC50 of >1 µg/ml. In contrast, all other cell 
lines tested showed a marked reduction in growth at very low concentrations 
of rapamycin. The most sensitive cell line in our assay was U87, derived from 
a PTEN-null glioblastoma. U87 displayed a 74% inhibition of growth at 1 
ng/ml rapamycin. Based on these results we selected U87 as a model to fur-
ther study the effects of rapamycin in vivo. 
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Figure 1. In vitro growth inhibition of tumor cell lines by rapamycin. Cells were seeded in 24-well 
plates and treated the following day with vehicle or increasing concentrations of rapamycin. After 
5 days, cells were counted and the growth of rapamycin-treated cells was normalized to that of 
vehicle-treated cells. Results shown are means ± standard deviation of triplicate samples. 
Rapamycin inhibits mTOR signalling and growth of U87 xeno-
grafts 
The ability of rapamycin to inhibit mTOR signalling in U87 xenografts was 
assessed by immunohistochemical staining for S6, a ribosomal subunit pro-
tein that is phosphorylated downstream of mTOR and has been previously 
validated as a marker of mTOR activity [12,29]. After 2 days of treatment with 
1 mg/kg rapamycin, the intensity of phospho-S6 staining was decreased (Fig. 
2B). The proportion of cells with high (+++) phospho-S6 staining decreased 
by ~50% with a corresponding increase in low (+) intensity staining (Fig. 2A). 
This suggests that rapamycin was able to reduce the activation of mTOR tar-
gets in vivo. 
 
Next we investigated the influence of rapamycin on proliferation. Twenty-four 
hours after the last dose of rapamycin, tumors were labelled with BrdU for 15 
min before excision. As seen in Fig. 2C, significantly fewer cells incorporated 
BrdU into replicating DNA when tumors were treated with rapamycin (P = 
0.006). This is consistent with studies that demonstrate an accumulation of 
cells in G0-G1 phase of the cell cycle after rapamycin treatment [19]. Taken 
together these results indicate that our dosing regimen was sufficient to block 
mTOR signalling and reduce proliferation in vivo. This was confirmed when 
we followed the growth of tumors treated daily with rapamycin for 6 days. 
Compared to controls, rapamycin treated tumors grew more slowly and on 
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average required 4 additional days in order to reach the same relative tumor 
volume (Fig. 2D). 
 
 
Figure 2. Rapamycin inhibits mTOR signalling and proliferation in vivo. Nude mice bearing sub-
cutaneous U87 xenografts were treated with 1 mg/kg rapamycin for 2 days. Control animals 
received vehicle alone. On day 3, animals were injected with BrdU and euthanized. Tumors were 
excised and processed for immunohistochemical staining. (A) Phosphorylation of ribosomal pro-
tein S6 was used as a marker of mTOR activity. Staining intensity was scored on a scale from 
zero to +++ in sections from 5 mice per group. (B) Phospho-S6 staining in representative control 
and rapamycin treated tumors. Arrows indicate the various levels of staining intensity. (C) BrdU 
uptake of cells in S-phase. Columns represent the mean labelling index ± standard deviation 
from 5 mice per group. *P = 0.006. (D) Tumor growth delay of animals treated with vehicle (con-
trol) or rapamycin for 6 days. Data points represent the median number of days to reach a fixed 
tumor volume and error bars represent 95% confidence intervals. 
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Tumor growth delay with combination therapy 
We next determined if rapamycin could delay tumor regrowth if used in com-
bination with fractionated radiotherapy. Rapamycin was given for 6 days 
along with equal fractions of radiation on days 2-6. In the lowest dose group 
of 24 Gy, we observed a 26 day growth delay for tumors to reach 5 times the 
starting volume, however there was no additional effect of rapamycin (Fig. 
3A). Tumors treated with the combination therapy began to regress sooner 
but tumor regrowth began at approximately the same time as the tumors re-
ceiving radiation alone. The higher dose groups showed a similar pattern with 
no enhancement of growth delay (data not shown). Interestingly, we ob-
served a large variation in the response of tumors within the rapa + RT 
treatment arm which accounts for the large error bars in Fig. 3A. To illustrate 
this variability, the growth of individual tumors is plotted in Fig. 3B. In the up-
per graph, the majority of tumors treated with 24 Gy alone responded in a 
similar fashion with regrowth beginning around day 25. In contrast, the group 
receiving concurrent rapamycin had 4 out of 8 tumors that behaved similar to 
the radiation only controls, one that had a delayed regrowth, and 3 tumors 
that were cured. The data suggest that some tumors receiving the combined 
treatment may have responded better although the group as a whole did not 
show an improvement in growth delay. 
Local tumor control 
Animals were treated with fractionated radiotherapy as described above for 
the growth delay experiment. A total of eight different doses ranging from 24 
to 100 Gy were given in five equal fractions and the animals were observed 
long-term for local tumor recurrence. Fig. 4 depicts the rate of tumor cure 
(data points) and the predicted probability of tumor control (fitted curves). The 
TCD50 for the control group was calculated to be 46.8 Gy (95% CI 41; 53). 
Concurrent rapamycin treatment shifted the dose-response curve towards 
increased radiosensitivity with a reduction of the TCD50 to 42.8 Gy (95% CI 
36; 49), although this value did not reach significance when compared to ra-
diation alone. 
 
Thesis_Weppler_v12_fc.pdf
Rapamycin and radiotherapy 
 115
 
Figure 3. Rapamycin increases heterogeneity of response to radiation. Mice with established 
U87 tumors received injections of vehicle or 1 mg/kg rapamycin for 6 days, either with or without 
5 fractions of 4.8 Gy. Drug or vehicle was started one day before the fractionation schedule. (A) 
Median tumor volume for each of the four treatment arms is depicted. Arrows indicate time of 
irradiation and the filled bar depicts the period over which rapamycin was delivered. Error bars 
represent standard error. (B) Tumor volume measurements for individual animals treated with 
vehicle plus 5 x 4.8 Gy (upper graph) or rapamycin plus 5 x 4.8 Gy (lower graph).  
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Figure 4. Local control of U87 xenografts treated with rapamycin and radiotherapy. Rate of local 
control (data points) and calculated tumor control probabilities (curves) of U87 tumors irradiated 
with 5 fractions over 5 days with total doses between 24 and 100 Gy. Rapamycin or vehicle was 
administered beginning one day before irradiation and daily 2 h before each fraction. Error bars 
indicate 95% confidence interval of the TCD50 values. 
 
Hypoxia and thrombosis 
We hypothesized that the heterogeneous response of rapamycin treated tu-
mors irradiated with subcurative doses might be a result of differences within 
the tumor microenvironment. In order to assess treatment induced changes, 
we examined tumors after receiving 2 doses of rapamycin either with or with-
out a single 4.8 Gy fraction, thus simulating the conditions on day 3 of the 
TCD50 experiment. Pimonidazole was injected prior to tumor excision in order 
to evaluate the extent of hypoxia. Fig. 5A shows the pimonidazole staining 
pattern observed in representative control and rapamycin treated tumors. 
Control tumors and those receiving radiation alone were typically well oxy-
genated, with the exception of one tumor within the control group that had a 
large hypoxic core. The mean hypoxic fractions were 2.8% and 2.2% for the 
control and RT groups, respectively (Fig. 5B). These data are consistent with 
the highly vascularized nature of glioblastomas [30]. The groups receiving 
rapamycin (both with and without radiation) showed significantly increased 
levels of pimonidazole labelling when compared to control (P < 0.05) or RT 
alone (P < 0.01). 
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Figure 5. Rapamycin influences hypoxia and vessel thrombosis. Mice bearing established U87 
xenografts were treated with vehicle (control) or rapamycin for 2 days either with or without a 
single 4.8 Gy fraction on day 2. Pimonidazole was injected the following day and tumors were 
excised 1 h later. (A) Pimonidazole staining in representative control and rapamycin treated tu-
mors. (B) Percentage of pimonidazole labeled cells was determined from tumor sections. Col-
umn bars represent the mean of 5 tumors. *P < 0.05. **P < 0.01. (C) MSB staining of a rapamy-
cin treated tumor was used to identify thrombotic vessels. Representative fields show an open 
vessel containing yellow erythrocytes (upper figure) and a thrombotic vessel which is occluded 
by a red fibrin deposit (lower figure). (D) The number of both partially and fully occluded vessels 
as a percentage of the total vessel number was calculated. Column bars represent the mean of 5 
tumors. 
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Initial observations of the pimonidazole sections indicated that changes to the 
tumor vasculature might be occurring in the rapamycin treated groups. Sev-
eral recent reports have suggested that rapamycin treatment may influence 
vessel thrombosis. This led us to perform MSB staining on the tissue sections 
in order to easily detect vessels containing fibrin occlusions. Fig. 5C shows 
an MSB stained tumor section from an animal treated with rapamycin with 
both a normal perfused vessel containing yellow erythrocytes (top) and a 
vessel that is almost entirely occluded by a red thrombus (bottom). No differ-
ences were found in total vessel numbers between the experimental arms 
(data not shown) indicating that rapamycin was not affecting vessel density at 
this early time point. The control group had a high basal level of thrombosis 
with an average of 37% thrombotic vessels (Fig. 5D). This is not unusual 
since intravascular thrombosis is a frequent finding in glioblastoma tissue and 
is observed histologically in over 90% of cases [30]. In both groups receiving 
rapamycin, there was an increasing trend in the percentage of thrombotic 
vessels (Fig. 5D). Again, it is interesting to note that some of the rapamycin 
treated tumors show similar levels of thrombosis as controls, but that the het-
erogeneity in thrombosis mirrors the differences seen in both hypoxia and 
tumor response to radiotherapy. 
Discussion 
Rapamycin analogues CCI-779 (Wyeth-Ayest), RAD001 (Novartis), and 
AP23573 (Ariad) are currently in different phases of clinical trials to assess 
toxicity profiles and antitumor activity. CCI-779 is the most advanced com-
pound in development and has shown partial responses in recurrent breast 
and renal cell carcinoma [31,32]. Most interest currently lies in combining 
these mTOR inhibitors with other cytotoxic modalities. Numerous reports 
have demonstrated that rapamycin can sensitize tumor cells to apoptosis-
inducing agents in vitro [33,34]. This has stimulated pre-clinical evaluation of 
CCI-779 in combination with gemcitabine in pancreatic cancer [35]. In our 
study we investigated the combination of rapamycin with a short course of 
fractionated radiotherapy so as to minimize the anti-proliferative effect of ra-
pamycin and thus evaluate its potential to contribute to the direct cytotoxic 
effect of radiation. We find that rapamycin does not significantly improve ra-
diation response as assessed by either growth delay or TCD50. However we 
found that rapamycin did increase variability in tumor response to radiother-
apy, with several individual tumors showing large increases in growth delay. 
This may be a consequence of statistical probability, however these data may 
also suggest that rapamycin provides a benefit to radiation treatment in indi-
vidual tumor cases. If this is the case, then it will be important to determine 
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the biological factors that mediate this differential response in order to poten-
tially identify patients that may benefit from combination treatment. 
 
Differences in the pharmacokinetics of rapamycin have been observed in 
clinical trials [36] and would help to explain a lack of enhancement of radio-
therapy if delivery of rapamycin to the tumor was impaired. Although we can-
not rule out this possibility entirely, it seems unlikely to play a major role since 
animals receiving rapamycin alone responded in a homogeneous manner 
with respect to proliferation and growth delay (Fig. 2C and D). 
 
Our studies point toward changes in the microenvironment as a potential con-
tributing factor in the response to the combination of rapamycin and radiation. 
We found that rapamycin treated animals showed increased amounts of 
thrombosis and also an increase in the hypoxic fraction measured by pimoni-
dazole binding. However, similar to the results observed in individual tumor 
response, these microenvironmental changes after rapamycin treatment were 
also variable amongst the individual tumors examined. It is tempting to 
speculate that the increase in both vessel thrombosis and resulting hypoxia in 
a subset of rapamycin treated tumors may explain the variation in their re-
sponse to radiotherapy. The complete or partial restriction to blood flow by 
thrombotic vessels would produce local areas of acute hypoxia causing an 
increase in radioresistance. If this is the case, then administration of rapamy-
cin prior to radiotherapy, as was done in our study, may decrease radiosensi-
tivity due to transient increases in acute hypoxia and thus offset any potential 
increase in toxicity of the combination treatment. This hypothesis is sup-
ported by the finding that the combination treatment showed a substantial 
gain in the group of animals which received the lowest dose per fraction (24 
Gy group). It is well known that the influence of hypoxia on overall response 
in fractionated therapy increases with increasing dose per fraction. It would 
be interesting to test this hypothesis by administering rapamycin in an adju-
vant setting and/or further reducing the dose per fraction so as to minimize 
the consequences of (acute) hypoxia. It should be pointed out however, that 
at this time we cannot rule out the possibility that rapamycin-induced throm-
bosis may be beneficial if the additional vascular damage translates into in-
creased cytotoxicity to tumor cells, as has been documented using vascular-
targeting agents in combination with radiotherapy [37,38]. 
 
Our analysis of vessel thrombosis was conducted after the initial investigation 
of tumor hypoxia. In hindsight, the hypoxic fraction may have been under-
estimated in our experiment if you take into account the possible inhibitory 
effect of thrombosis on pimonidazole delivery to the tumor. Intrinsic markers 
of hypoxia or oxygen probe measurements would be useful to determine if 
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this is in fact occurring in our system. In addition, sequential measurements 
of hypoxia over time would shed light on the relative effect of rapamycin on 
hypoxia in individual tumors.  
 
The ability of rapamycin to contribute to response through its effects on the 
vasculature may also be influenced by tumor type. Glioblastomas are charac-
terized by frequent thrombosis and areas of necrosis and in addition, these 
patients are at high risk for developing deep-vein thrombosis and pulmonary 
embolism suggesting a systemic dysfunction of coagulation [30]. Therefore, a 
fraction of these tumors may already have high levels of thrombosis making it 
difficult to observe additional thrombosis induced by rapamycin. Previous 
studies documenting rapamycin-induced thrombosis were conducted using 
pancreatic and colon adenocarcinoma models and did not find evidence of 
thrombosis in control tumors [17,39]. It would thus be interesting to evaluate 
rapamycin in combination with radiation in other tumor types showing less 
intrinsic vasculature occlusion. Subsequent studies should also consider in-
cluding tumor lines which are less sensitive than U87 to rapamycin as a sin-
gle agent since the magnitude of this response may mask interactions with 
radiation. 
 
Any variability we observed in tumor response may simply reflect the sto-
chastic nature of thrombus formation and its consequences. Impaired perfu-
sion in a single vessel due to thrombus formation can potentially affect thou-
sands or millions of individual tumor cells and thus have a large impact on 
tumor response. The fact that the hypoxic fraction can vary tremendously 
amongst individual untreated tumors derived from the same cell line and 
grown in the same host supports a role for the stochastic nature of blood 
vessel formation and/or function in determining hypoxia and radiosensitivity 
of individual tumors [40]. 
 
Finally, there is also some recent evidence suggesting that pre-treatment 
levels of hypoxia could contribute to the ability of rapamycin to affect tumor 
response. As described previously, the activity of mTOR is regulated by nu-
merous upstream pathways that monitor growth factors, nutrients, and en-
ergy metabolism. Recently hypoxia was also implicated in the regulation of 
mTOR signalling through two different pathways. Hypoxia causes activation 
of the TSC1/2 complex, which functions to inhibit mTOR. This can occur both 
via induction of the HIF-dependent gene REDD1, and/or through activation of 
AMPK [41,42]. This leads us to speculate that rapamycin may be less effec-
tive in hypoxic regions of tumors since mTOR may already be at least par-
tially inactivated by TSC. Thus the amount of hypoxia present at the start of 
treatment may play a part in determining sensitivity to rapamycin in vivo. 
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Whether this is relevant in our model is subject to debate since Kaper et al. 
argue that hypoxia’s ability to inhibit mTOR is diminished in tumors where 
mTOR activity has been highly upregulated by mutation of the PI3K pathway 
[43]. 
 
It is clear that additional preclinical work is needed to establish the degree 
and consequences of vascular thrombosis and hypoxia on both tumors and 
normal tissues treated with rapamycin and irradiation. It would be interesting 
to monitor perfusion during the course of therapy via in vivo imaging tech-
niques such as DCE-MRI and to compare this with treatment outcome. Also, 
alternative sequencing and timing of rapamycin and radiation delivery should 
be investigated in order to determine if there is an optimal therapeutic win-
dow. Our results suggest that it will be important to consider the effects of 
rapamycin on tumor oxygenation and thrombosis and to use caution in the 
design of future clinical trials combining mTOR inhibitors with radiotherapy. 
Acknowledgements 
This work was supported in part by a grant from the Nederlands Vereniging 
voor Oncologie awarded to S.A.W. and by Grant Ba 1433-4 by the Deutsche 
Forschungsgemeinschaft to M.B. The authors thank Ms. D. Pfitzmann, Ms. K. 
Schumann, and Ms. E. Lootze for their excellent technical assistance with the 
animal experiments conducted in Dresden. We also thank Mrs. S. Balschukat 
(Dresden), and Mrs. Hanna Andrusewicz and Dr. Jan Sir (Department of Pa-
thology in Bydgoszcz) for their help with the histological assessments. 
Thesis_Weppler_v12_fc.pdf
Chapter 5 
 122 
References 
[1]  Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 
2005;14:313–28. 
[2]  Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Curr Opin Investig 
Drugs 2006;7:501–12. 
[3]  Avruch J, Lin Y, Long X, Murthy S, Ortiz-Vega S. Recent advances in the regulation of the 
TOR pathway by insulin and nutrients. Curr Opin Clin Nutr Metab Care 2005;8:67–72. 
[4]  Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: 
implications for cancer and anticancer therapy. Br J Cancer 2006;94:195–9. 
[5]  Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. 
Nat Rev Cancer 2002;2:489–501. 
[6]  Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 30-kinase 
signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63:2742–6. 
[7]  Kang S, Bader AG, Zhao L, Vogt PK. Mutated PI 3-kinases: cancer targets on a silver plat-
ter. Cell Cycle 2005;4:578–81. 
[8]  Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 
2005;11:353–61. 
[9]  Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of 
CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 
2001;8:249–58. 
[10]  Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapa-
mycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and pro-
tein stability. J Biol Chem 1998;273:14424–9. 
[11]  Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T. The upregulation of p27Kip1 by 
rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998;91:561–9. 
[12]  Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, 
Grupp SA. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical 
models of primary adult human ALL. Blood 2006;107:1149–55. 
[13]  Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resis-
tance. Cancer Biol Ther 2003;2:222–32. 
[14]  Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of 
mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer 
Res 1999;59:886–94. 
[15]  Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced 
autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B in-
hibitors. Cancer Res 2005;65:3336–46. 
[16]  Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metas-
tatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. 
Nat Med 2002;8:128–35. 
[17]  Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis 
via tissue factor in the presence of VEGF. Blood 2005;105:4463–9. 
[18]  Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature 
by mTOR inhibitors. Oncogene 2005;24:5414–22. 
[19]  Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the 
mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. 
Cancer Res 2002;62:7291–7. 
[20]  Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin path-
way for radiosensitization of breast cancer. Mol Cancer Ther 2006;5:1183–9. 
[21]  Toulany M, Dittmann K, Baumann M, Rodemann HP. Radiosensitization of Ras-mutated 
human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother 
Oncol 2005;74:117–29. 
 [22]  Gottschalk AR, Doan A, Nakamura JL, Haas-Kogan DA, Stokoe D. Inhibition of phosphati-
dylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mecha-
nism and growth arrest through a PKB-independent mechanism. Int J Radiat Oncol Biol 
Phys 2005;61:1183–8. 
[23]  Taghian A, DuBois W, Budach W, Baumann M, Freeman J, Suit H. In vivo radiation sensi-
tivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995;32:99–104. 
[24]  Walker AM, Suit HD. Assessment of local tumor control using censored tumor response 
data. Int J Radiat Oncol Biol Phys 1983;9:383–6. 
Thesis_Weppler_v12_fc.pdf
Rapamycin and radiotherapy 
 123
[25]  Krause M, Schutze C, Petersen C, et al. Different classes of EGFR inhibitors may have 
different potential to improve local tumour control after fractionated irradiation: a study on 
C225 in FaDu hSCC. Radiother Oncol 2005;74:109–15. 
[26]  Edwards AWF. Likelihood. Expanded edition. Baltimore: Johns Hopkins University Press; 
1992. 
[27]  Lendrum AC, Fraser DS, Slidders W, Henderson R. Studies on the character and staining 
of fibrin. J Clin Pathol 1962;15:401–13. 
[28]  Sachs L. Angewandte statistik. Berlin: Springer; 1992.  
[29]  Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin 
pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 
2002;62:5645–50. 
[30]  Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with 
tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004;84:397–
405. 
[31]  Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel 
inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast 
cancer. J Clin Oncol 2005;23:5314–22. 
[32]  Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose lev-
els of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with ad-
vanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909–18. 
[33]  Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells 
to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 
2005;120:747–59. 
[34]  Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergis-
tically enhances chemotherapyinduced cytotoxicity in breast cancer cells. Clin Cancer Res 
2004;10:7031–42. 
[35]  Ito D, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and 
gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006;118:2337–
43. 
[36]  Gallant-Haidner HL, Trepanier DJ, Freitag DG, Yatscoff RW. Pharmacokinetics and me-
tabolism of sirolimus. Ther Drug Monit 2000;22:31–5. 
[37]  Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM. Augmentation of radiation re-
sponse with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 
2006;64:1458–65. 
[38]  Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-
4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001;60:155–61. 
[39]  Bruns CJ, Koehl GE, Guba M, et al. Rapamycin-induced endothelial cell death and tumor 
vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 
2004;10:2109–19. 
[40]  Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2- Nitroimidazole (EF5) binding pre-
dicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996;56:405–11. 
[41]  Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxia-induced energy 
stress regulates mRNA translation and cell growth. Mol Cell 2006;21:521–31. 
[42]  Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia 
by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18:2893–904. 
[43]  Kaper F, Dornhoefer N, Giaccia AJ. Mutations in the PI3K/PTEN/TSC2 pathway contribute 
to mammalian target of rapamycin activity and increased translation under hypoxic condi-
tions. Cancer Res 2006;66:1561–9. 
 
 
Thesis_Weppler_v12_fc.pdf
Thesis_Weppler_v12_fc.pdf
 125
 
 
 
CHAPTER 6 
Inhibition of 4E-BP1 phosphorylation 
and mRNA translation requires 
simultaneous blockade of mTORC1 and 
PI3K/Akt signaling 
 
 
Manuscript submitted 
 
SA Weppler, M Koritzinsky, JW Voncken, P Lambin, and BG Wout-
ers. 
Thesis_Weppler_v12_fc.pdf
Chapter 6 
 126 
Abstract 
The mammalian target of rapamycin (mTOR) kinase is a central regulator of 
cell metabolism and growth whose activity is often altered in cancer. An im-
portant consequence of mTOR activation is stimulation of cap-dependent 
translation, which is mediated by phosphorylation and inactivation of the eu-
karyotic initiation factor 4E-binding protein 1 (4E-BP1). Here, we demonstrate 
that short exposures to rapamycin, a specific inhibitor of mTOR complex 1 
(mTORC1), has only a modest inhibitory effect on 4E-BP1 phosphorylation 
and mRNA translation despite completely blocking phosphorylation of an-
other mTORC1 substrate p70S6K. We describe a synergistic effect of com-
bined mTORC1 and phosphatidylinositol 3-kinase (PI3K) inhibition that is 
specific for dephosphorylation of 4E-BP1 at both Thr70 and Ser65, and which 
leads to a rapid suppression of translation in a 4E-BP1 dependent manner. 
Similar results are observed using rapamycin in combination with an inhibitor 
of protein kinase B (PKB, also termed Akt), suggesting the existence of a 
PI3K/Akt-dependent signaling pathway sufficient to maintain 4E-BP1 phos-
phorylation in the presence of mTORC1 inhibition. In addition, the differential 
sensitivity of mTORC1 targets to inhibition of PI3K/Akt alone implies that 
mTORC1 complexes may exhibit substrate specificity dependent upon acti-
vation of specific upstream signaling pathways to mTOR. Together these re-
sults suggest that targeting deregulated translation in cancer may be im-
proved by strategies that block both mTORC1 dependent and independent 
signals regulating 4E-BP1. 
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Introduction 
The mammalian target of rapamycin (mTOR) kinase exists in at least two 
distinct complexes with independent functions and regulation (1). mTOR 
complex 1 (mTORC1) consists of the mTOR kinase, LST8 (also known as 
GβL) and raptor, a scaffolding protein that serves to bring mTORC1 sub-
strates in close proximity to mTOR’s catalytic domain (2). The eukaryotic ini-
tiation factor 4E (eIF4E) binding protein (4E-BP1) and p70S6K, both regula-
tors of mRNA translation, are the best characterized targets of mTORC1. 
mTOR complex 2 (TORC2) also contains LST8, but instead of raptor associ-
ates with rictor (3). TORC2 has been shown to phosphorylate Akt at Ser473 
and protein kinase Cα, but to date no evidence of 4E-BP1 or p70S6K phos-
phorylation has been demonstrated (4, 5). 
 
mTOR regulates several processes relevant to cancer including mRNA trans-
lation, ribosome biogenesis, autophagy and metabolism (1). A direct link be-
tween mTOR and cancer was established following discovery that the tuber-
ous sclerosis complex (TSC) functions as a negative regulator of mTORC1. 
Mutations in tsc1 or tsc2 genes thus activate mTOR and are responsible for 
the development of harmatomas in TSC patients. The TSC1/2 complex regu-
lates mTORC1 in response to many upstream signals including amino acid 
and oxygen availability, energy status, insulin and other growth factors (6). 
These signals influence mTOR via TSC1/2 through signaling pathways that 
are also frequently altered in cancer, including the PI3K/Akt pathway. In re-
sponse to insulin and other growth factors, PI3K/Akt signaling activates 
mTORC1 by phosphorylation and inhibition of TSC2 (7). PI3K activation is 
antagonized by the tumor suppressor PTEN, and its importance in cancer 
has been directly linked to its ability to control mTORC1 activity (8). 
 
Regulation of translation is a critical function of mTOR that when deregulated 
contributes to cancer development. This is evidenced by the fact that both 
mTORC1 targets, 4E-BP1 and p70S6K, are involved in regulation of transla-
tion. 4E-BP1 functions as a negative regulator of translation by competing 
with eIF4G for binding to the rate limiting translation initiation factor eIF4E (9). 
Growth promoting signals that stimulate mTOR lead to phosphorylation of 
4E-BP1, which prevents it from binding to eIF4E and therefore stimulates 
translation. The importance of this mTOR effector has been demonstrated in 
a mouse model for cancer in which overexpression of eIF4E can bypass the 
requirement for mTOR activation (8). In addition to its general role in protein 
synthesis, deregulation of translational control by eIF4E and 4E-BP1 is 
thought to differentially alter the expression of cancer related genes in a 
manner that promotes malignant conversion (10). eIF4E is often found to be 
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overexpressed in cancer, and its expression is sufficient to transform cells 
(11). 4E-BP1 also has a demonstrated role in regulating gene expression and 
functions as a potential biomarker of malignant progression and adverse 
prognosis in breast, ovary, and prostate tumors (12, 13). 
 
The binding of 4E-BP1 to eIF4E is regulated by phosphorylation at multiple 
sites. Non-phosphorylated or hypo-phosphorylated 4E-BP1 binds strongly to 
eIF4E and prevents cap-dependent translation, whereas hyperphosphory-
lated 4E-BP1 dissociates from eIF4E, allowing translation to initiate (14). The 
phosphorylation of 4E-BP1 is complex involving at least six phospho-
residues. Four of these sites have been linked to mTOR signaling and are 
phosphorylated in a hierarchical manner, so that phosphorylation at 
Thr37/Thr46 is required for subsequent phosphorylation of Thr70, which in 
turn is required for Ser65 phosphorylation (14-16). Although these sites all 
show dependency on mTOR, their sensitivity to changes in phosphorylation 
by different signals that regulate mTOR are distinct. For example, phosphory-
lation of Thr37/Thr46 is affected significantly by amino acid availability, but 
not by insulin which preferentially stimulates Ser65 phosphorylation (6). The 
ability of 4E-BP1 to bind eIF4E and thus inhibit translation correlates best 
with the phosphorylation status of Ser65, although this is somewhat contro-
versial (6, 9, 17). It remains unclear as to which, if any, of the 4E-BP1 phos-
pho-sites are directly phosphorylated by mTOR and it is likely that other 
kinases are also involved (9, 18). 
 
The importance of mTOR in regulation of mRNA translation, cell growth and 
metabolism coupled with its deregulation in cancer has made it an attractive 
therapeutic target. Rapamycin is a macrolide antibiotic that inhibits mTOR 
with high selectivity (19). Rapamycin interacts with the immunophilin 
FKBP12, which then binds to the FRB-domain of mTOR and in doing so, 
weakens its interaction with raptor. As a consequence, rapamycin prevents 
phosphorylation of the raptor dependent mTORC1 substrates, p70S6K and 
4E-BP1 (20, 21), but not rictor dependent TORC2 substrates like Akt (22) 
although longer treatments may indirectly effect mTORC2 activity by interfer-
ing with assembly of mTOR into new TORC2 complexes (23). 
 
The ability of rapamycin to inhibit proliferation or other cancer associated 
phenotypes is highly variable between tumors and dependent on their genetic 
background (24, 25). For example, loss of PTEN or activation of Akt leads to 
constitutive mTOR activation and can significantly sensitize cells to the ef-
fects of mTOR inhibitors (26, 27). Combinations of rapamycin with other 
small-molecule inhibitors or cytotoxic agents have also shown promising re-
sults, and found to provide better inhibition of targets downstream of 
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mTORC1 (28-30). However, it is unclear whether this beneficial effect results 
from a more complete inhibition of mTORC1, or via mTORC1 independent 
regulation of its targets. Our objective was to examine the ability of mTORC1 
and/or PI3K inhibition to regulate phosphorylation and function of 4E-BP1. 
Surprisingly, our data indicate that 4E-BP1 Ser65 and Ser70 phosphorylation 
and translation initiation is largely resistant to inhibition of either mTORC1 or 
PI3K. However, a strong synergistic effect restricted to the mTORC1 target 
4E-BP1 is observed when these two targets are inhibited in combination. 
These data implicate PI3K/Akt in the regulation of 4E-BP1 and translation in 
an mTORC1 independent pathway and suggest a more effective way of tar-
geting deregulated translation in cancer. 
Materials and methods 
Cell lines 
HT29 and HCT116 colorectal carcinomas, A549 lung carcinoma, and HeLa 
cervix carcinoma were from the American Type Culture Collection, Tig3 hu-
man fibroblasts were a gift from J.Fukami (31), and U87 glioblastoma cells 
were a gift from J. Sarkaria (Mayo Clinic, MN, USA). All the above cell lines 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich, Zwijndrecht, NL) supplemented with 10% fetal calf serum (FCS) 
(HyClone, Logan UT, USA). DU145 prostate carcinoma cells were main-
tained in McCoy’s 5A medium (Invitrogen, Breda, NL) with 10% FCS. U373 
glioma cells were cultured as described (32). U87 cells containing an ecdy-
sone inducible-PTEN construct were generated and validated previously (33). 
Reagents and antibodies 
Rapamycin, LY294002, wortmannin, and Akti-1/2 were purchased from Cal-
biochem (Darmstadt, DE). Ponasterone A was from Sigma-Aldrich 
(Zwijndrecht, NL). The following antibodies were purchased from Cell Signal-
ing Technology (Danvers, MA): Phospho-p70S6K (Thr389), Phospho-4E-BP1 
(Ser65), Phospho-4E-BP1 (Thr70), Phospho-4E-BP1 (Thr37/46), Phospho-
Akt (Ser473), Akt, PTEN, Raptor, and mTOR. The β-actin monoclonal anti-
body (Clone C4) was purchased from MP Biomedicals (Amsterdam, NL). The 
eIF4E monoclonal antibody (Clone 87) was supplied by BD Biosciences 
(Breda, NL), and the eIF4GI antibody was purchased from Abcam (Cam-
bridgeshire, UK). Secondary antibodies were purchased from Sigma-Aldrich 
(goat-anti-mouse) and Cell Signaling Technology (goat-anti-rabbit).  
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Western blot analysis 
Cell extracts were prepared, resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane as described previously (32). The membrane was 
blocked with 5% milk-TBST (20mM Tris-HCl, pH 7.6, 140mM NaCl, 0.1% 
Tween 20) and incubated overnight with the appropriate primary antibody. 
The membrane was washed with TBST and incubated for 1 h with a horse-
radish peroxidase-linked secondary antibody. Chemiluminescence detection 
was carried out using SuperSignal West Pico from Perbio (Etten-Leur, NL). 
m7GTP-agarose affinity chromatography 
eIF4E and associated proteins were isolated as described (34) but with the 
following amendments. 300 μg of cytoplasmic extract was incubated with 50 
μl of m7GTP-Sepharose 4B resin (GE Healthcare Life Sciences) overnight at 
4°C. The resin was washed, boiled in Laemmli sample buffer and the isolated 
proteins were resolved by SDS-PAGE and detected by immunoblotting. 
Polysome analysis 
Polysome-associated mRNA was isolated by sucrose gradient centrifugation 
as described previously (35). The absorbance at 254 nm was recorded con-
tinuously as the gradient was fractionated. 
RNA interference 
4E-BP1 expression was modulated by stably transfecting U87 cells with 
pRetroSuper (36) containing a short hairpin RNA with the targeting sequence 
gtttgagatggacatttaa. The empty pRetroSuper vector was used as a control. 
Effective reduction of 4E-BP1 protein levels using this vector has been vali-
dated previously (37). Pre-designed siRNA against raptor, as well as a non-
targeting negative control siRNA, were purchased from Applied Biosystems 
(Nieuwerkerk a/d Ijssel, NL). Raptor siRNA had the sequence ggattat-
gaggtcgtataatt and was used at a concentration of 20 nM. A SignalSilence 
siRNA kit for mTOR was purchased from Cell Signaling Technology. mTOR 
siRNA was transfected at a concentration of 50 nM. For all siRNA transfec-
tions, cells were transfected in 6-well plates using 12 μl Oligofectamine (Invi-
trogen) in a total volume of 2 ml growth medium according to the manufac-
turer’s directions. Cell lysates were analyzed 72 h after transfection. 
Clonogenic survival assay 
24 hr after treatment with rapamycin and LY294002, cells were trypsinized 
and counted using a Coulter Z Series particle counter (Beckman Coulter, Mij-
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drecht, NL). Cells were seeded in triplicate 6 cm dishes at two different densi-
ties in complete growth medium. The dishes were incubated under standard 
culture conditions for a period of 12 days for colony formation. Colonies were 
fixed and stained with 2% bromophenol blue in 70% ethanol. Plating effi-
ciency was determined by counting colonies consisting of ≥ 50 cells and cor-
recting for the number of cells seeded. 
Statistics 
A two-tailed Student’s t-test was used to assess differences in translation 
inhibition and clonogenic survival. P values less than 0.05 were considered to 
be significant. 
Results 
4E-BP1 phosphorylation is independently maintained by 
mTORC1 and PI3K 
Given the demonstrated influence of mTOR and PI3K signaling on 4E-BP1 
phosphorylation and mRNA translation, we evaluated the consequences of 
inhibiting either or both of these pathways using the mTORC1 inhibitor rapa-
mycin and the PI3K inhibitor LY294002. Two glioma cell lines were treated 
with these inhibitors, either alone or in combination, for a period of 2 h at 
which time we examined phosphorylation of 4E-BP1 and p70S6K (Figure 1a). 
In both U87 and U373 cell lines, treatment with rapamycin alone resulted in a 
complete loss of p70S6K phosphorylation. Consistent with its reported role in 
signaling to mTOR via TSC1/2, inhibition of PI3K with LY294002 was also 
sufficient to block phosphorylation of p70S6K. Despite this clear inhibition of 
mTORC1 activity with either inhibitor, phosphorylation of 4E-BP1 at Ser65 
was only marginally reduced following either of these treatments alone. How-
ever, a strong synergistic effect resulting in near complete loss of 4E-BP1 
Ser65 phosphorylation was observed when the two inhibitors were used in 
combination (Figure 1a, lanes 4 and 8).  
 
No decrease in 4E-BP1 Ser65 phosphorylation similar to that observed with 
the combination treatment was found by increasing the concentration of ra-
pamycin alone from 10nM to 100nM or the concentration of LY294002 alone 
from 5μM to 10μM (Supplementary Figure S1). This suggests that the differ-
ential outcome of mTORC1 and PI3K inhibition on 4E-BP1 and p70S6K does 
not result from dissimilar sensitivities to any residual kinase activity present 
after treatment with the inhibitors (at least not at the concentrations used in 
these experiments). In contrast, a clear dose-dependent decrease in 4E-BP1 
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phosphorylation was observed using LY294002 concentrations ranging from 
1 to 10 μM in combination with 10nM rapamycin. Together these results indi-
cate that unlike p70S6K, 4E-BP1 phosphorylation on Ser65 is maintained 
unless both PI3K and mTORC1 are inhibited.  
 
Because phosphorylation of 4E-BP1 occurs on multiple sites and in a hierar-
chical fashion (15), we further assessed the effects of mTORC1 and/or PI3K 
inhibition on Thr37/46 and Thr70 phosphorylation (Figure 1b). Similar to 
Ser65, treatment with either inhibitor alone showed no effect on Thr70 phos-
phorylation whereas the combination resulted in a near complete loss of 
phosphorylation. In contrast, total levels of Thr37/46 phosphorylation after 
combination treatment were similar to treatment with either inhibitor alone. 
Rapamycin or LY294002 caused an apparent shift to the faster migrating 
hypo-phosphorylated bands of 4E-BP1 which was further enhanced by com-
bining both inhibitors. Therefore, Thr37/46 appear not to be affected directly 
by the combination of mTORC1 and PI3K inhibition and the change in migra-
tion is likely due to the dephosphorylation of Thr70 and Ser65. Assuming the 
reported hierarchy of 4E-BP1 phosphorylation is correct, with phosphorylation 
of Thr70 preceding Ser65, then the synergistic effect of PI3K and mTORC1 
inhibition appears to occur at the point of Thr70 phosphorylation. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Combined PI3K and mTOR inhibition has a co-operative effect on 4E-BP1 phosphory-
lation and global translation. (a) U87 and U373 cells were treated with 10nM rapamycin and/or 
10uM LY294002 for 2 h in complete DMEM. Cells were harvested for protein and Western blot 
analysis was performed using antibodies against phospho-p70S6K (Thr389), phospho-4EBP1 
(Ser65) and actin as a loading control. (b) 4E-BP1 phosphorylation at Ser65, Thr70, and 
Thr37/46 was investigated in U87 cell lysates treated as described in (a). (c) eIF4E was purified 
from U87 lysates treated with rapamycin and/or LY294002 using m7GTP-agarose affinity chro-
matography. The association of 4E-BP1 and eIF4G with eIF4E was detected by subsequent 
immunoblotting. (d) Polysomal mRNA was isolated from U87 lysates by centrifugation through 
sucrose gradients. The absorbance at 254nm was recorded as the gradient was fractionated and 
plotted as a function of gradient depth. Arrows indicate the peaks corresponding to the position 
of 40S, 60S, and 80S ribosomal complexes as well as the location of polysomes. (e) Translation 
inhibition was calculated by comparing the fractional area under the polysome peaks for each 
treatment condition with that of the control. 
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Rapamycin and LY294002 inhibit translation initiation in a 4E-BP1 
dependent manner 
The phosphorylation of 4E-BP1 at Ser65 and Thr70 has been demonstrated 
to correlate with release of its binding partner eIF4E (14), and thus its func-
tional ability to regulate mRNA translation initiation. Consistent with these 
data, we found that treatment with rapamycin and LY294002 resulted in a 
greater increase in the amount of 4E-BP1 associated with affinity-purified 
eIF4E when compared to treatment with either inhibitor alone (Figure 1c). At 
the same time, a similar decrease in the binding of eIF4GI to eIF4E was ob-
served, suggesting that translation initiation could be more effectively inhib-
ited after combined treatment with both inhibitors.  
 
The functional importance of changes in 4E-BP1 phosphorylation and eIF4E 
association to mRNA translation was investigated by analyzing changes in 
polysome distributions after inhibition of mTORC1 and/or PI3K (Figure 1d 
and e). Despite its clear ability to inhibit mTORC1 and block p70S6K phos-
phorylation, treatment with rapamycin for 2 h caused no significant change in 
the amount of polysomal RNA or the distribution of 40S, 60S or 80S ribo-
some subunits. LY294002 alone caused a small (15%) decrease in poly-
some-associated RNA, with a concomitant increase in free ribosome sub-
units. However, the combination of rapamycin and LY294002 resulted in a 
large drop in mRNA translation (a 38% decrease in the area under the poly-
some region of the curve). 
 
Although changes in mRNA translation correlated well with 4E-BP1 Ser65 
and Thr70 phosphorylation upon inhibition of both mTORC1 and PI3K, these 
data do not definitely demonstrate that 4E-BP1 is responsible for this effect. 
The drop in translation was not due to toxicity, since rapamycin and 
LY294002 caused no significant change in clonogenic survival even after a 
24 h treatment (Figure S2). To more directly assess the requirement for 4E-
BP1 in the inhibition of translation we created a stable knock-down of 4E-BP1 
in U87 cells using RNA interference. U87-sh4E-BP1 cells showed no signifi-
cant difference in their polysome profiles compared to U87 cells carrying the 
empty vector (pRS) when grown under normal conditions (Figure 2a and b). 
However when treated with rapamycin and LY294002, we observed a signifi-
cantly smaller decrease (21%) of polysomal RNA in U87-sh4EBP1 cells 
compared with the U87-pRS cells (36%) (Figure 2c). These data indicate that 
translation inhibition caused by rapamycin and LY294002 is largely depend-
ent upon the functional activation of 4E-BP1. 
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Figure 2. The combination of LY294002 and rapamycin inhibits translation in a 4E-BP1 depend-
ent manner. U87 cells expressing either a stable short-hairpin RNA against 4E-BP1 (U87-
sh4EBP1) (b) or the empty pRetroSuper vector (U87-pRS) (a) were treated for 2 h with 10uM 
LY294002 and 10nM rapamycin and subjected to polysome analysis. (c) Translation inhibition 
was calculated as described in figure 1e and is presented as the mean of 4 independent experi-
ments ± standard error. * P=0.01. 
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The response of 4E-BP1 phosphorylation to mTORC1 and PI3K 
inhibition is PTEN independent 
A frequent characteristic of glioblastoma cell lines, including U87, is the loss 
of PTEN expression (38). Since this can lead to upregulation of signaling 
downstream of PI3K, including mTOR activation, we determined whether loss 
of PTEN altered the regulation of 4E-BP1 in this cell line. We assessed 
changes in 4E-BP1 phosphorylation after short treatments with rapamycin 
and LY294002 in U87 cells containing an inducible-PTEN construct. PTEN 
expression could clearly be detected in these cells after 24 h incubation with 
ponasterone A (Figure 3). However, the presence of PTEN did not lead to 
any changes in the response of 4E-BP1 phosphorylation to rapamycin and/or 
LY294002 (Figure 3). 
 
 
Figure 3. PTEN expression does not influence the change in 4E-BP1 phosphorylation elicited 
by LY294002 and rapamycin. U87 cells containing an ecdysone-inducible PTEN expression 
vector were treated with 500 nM ponasterone A to initiate PTEN expression. 24 h later, the 
cells were treated with 10 nM rapamycin and/or 10 μM LY294002 for an additional 2 h. Cell 
extracts were verified for induction of PTEN and analyzed for 4E-BP1 phosphorylation at 
Thr70. 
 
 
We also examined a number of other cell lines from a variety of different tis-
sue types to determine if the cooperative effect of rapamycin and LY294002 
was a common phenomenon. Six out of eight cell lines tested showed an ad-
ditional antagonistic effect on 4E-BP1 phosphorylation when LY294002 was 
added to rapamycin (Table 1). 4E-BP1 phosphorylation in DU145 prostate 
carcinoma and HCT116 colon carcinoma was sensitive to either inhibitor 
alone, and thus the combination had no further effect. The enhanced effec-
tiveness of rapamycin and LY294002 does not seem to be restricted to trans-
formed cells, as it was also observed in diploid Tig3-hTERT fibroblasts (Table 
1). There was no correlation between the presence of PTEN and the co-
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in the panel of cell lines that we 
examined. Therefore, the synergistic response of 4E-BP1 to mTORC1 and 
PI3K inhibition is present in normal cells as well as the majority of tumor cell 
lines investigated, and is not determined by PTEN status. 
 
Table 1. 
Response of 4E-BP1 Ser65 phosphorylation to rapamycin and LY294002 in various cell lines. 
Cell Line Tissue Type PTEN 
status 
Inhibition of 4E-BP1 
Phosphorylation in 
Response to Rapamy-
cin Alone 
Additional 
Effect of Ra-
pamycin + 
LY294002 
Combination 
U87 Glioblastoma Negative partial Yes 
U373 Glioma Negative partial Yes 
DU145 Prostate Carcinoma Positive complete No 
HeLa Cervix Adenocarci-
noma 
Positive partial Yes 
A549 Lung Carcinoma Positive partial Yes 
HT29 Colorectal Adenocar-
cinoma 
Positive partial Yes 
HCT116 Colorectal Carcinoma Positive complete No 
Tig3-
hTERT 
Immortalized Fibro-
blasts 
Positive partial Yes 
 
Specificity of LY294002 and rapamycin as inhibitors of mTORC1 
and PI3K 
LY294002 binds the ATP-binding pocket of PI3K and is known to partially 
inhibit other kinases with a similar catalytic domain such as DNA-PK and 
even mTOR (39). To obtain independent pharmacological proof that the PI3K 
pathway is involved in the observed synergistic inhibition of 4E-BP1 phos-
phorylation, we used rapamycin in combination with other structurally unre-
lated inhibitors of the PI3K/Akt pathway. The PI3K inhibitor wortmannin pro-
duced results similar to LY294002, causing only marginal inhibition of 4E-
BP1 phosphorylation on its own, but complete inhibition in combination with 
rapamycin (Figure 4a). The concentrations of both LY294002 and wortman-
nin that were used in this experiment were sufficient to inhibit phosphorylation 
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of Akt. Rapamycin on the other hand, did not have any appreciable effect on 
Akt phosphorylation at Ser473. More importantly, inhibition of Akt in U87 cells 
with the Akt1/2 inhibitor (Akti-1/2) also resulted in only a small inhibition of 
4E-BP1 phosphorylation on its own, but a near complete attenuation of Ser65 
phosphorylation when given in combination with rapamycin (Figure 4b). 
Taken together, these results reinforce the existence of a PI3K/Akt depend-
ent pathway that signals to 4E-BP1 in an mTORC1 independent manner. 
 
Rapamycin is considered to be one of the most specific small molecule inhibi-
tors known due to its formation of a stable complex with both FKBP12 and 
mTOR. The biological consequences of rapamycin are largely assumed to 
result from inhibition of mTORC1, since it us unable to block mTOR activity of 
the TORC2 complex. However, it remains possible that rapamycin affects 
mTOR activities that are separate from that associated with mTORC1. In or-
der to assess the contribution of combined mTORC1 and PI3K inhibition on 
4E-BP1 regulation independently of rapamycin, we used a genetic approach 
to inhibit the mTORC1 specific protein raptor. Figure 4c shows that we were 
able to attain near complete loss of detectable raptor protein using siRNA. 
Inhibition of raptor reduced the basal levels of 4E-BP1 phosphorylation at 
Ser65 to levels similar to those caused by treatment of the parental cells with 
rapamycin or LY294002 alone (Figure 4c). Importantly, treatment of the rap-
tor knockdown cells with LY294002 resulted in complete loss of 4E-BP1 
Ser65 phosphorylation. These data support mTORC1 as the target of rapa-
mycin in the synergistic effect observed on 4E-BP1 phosphorylation in com-
bination with PI3K inhibition. Knockdown of raptor also led to a small de-
crease in mTOR protein, possibly due to destabilization of the mTORC1 
complex. However, this is unlikely to have influenced 4E-BP1 phosphoryla-
tion since knockdown of mTOR to ~50% of control levels had no significant 
effect on the basal or inhibitor treated levels of 4EBP1 Ser65 phosphorylation 
(Figure S3). Consequently mTOR protein levels do not seem to be rate limit-
ing for mTORC1 activity. As expected, rictor siRNA also did not promote 4E-
BP1 dephosphorylation either basally or after treatment with rapamycin (data 
not shown). 
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Figure 4. Multiple inhibitors of the PI3K pathway act synergistically with mTORC1 inhibition to 
decrease 4E-BP1 phosphorylation. (a) U87 cells were treated for 2 h with 10nM rapamycin in 
combination with 10uM LY294002 or 200nM wortmannin. Western blotting was performed using 
antibodies against phospho-Akt (Ser 473), phospho-4EBP1 (Ser65) and actin. (b) U87 cells were 
treated for 2 h with 10nM rapamycin and/or 25 uM of an isoform specific Akt inhibitor (Akti-1/2). 
(c) U87 cells were transfected with siRNA against raptor or a non-targeting negative control 
siRNA. 72 h after transfection cells were treated for an additional 2 h with 10uM LY294002. Ex-
pression of raptor, mTOR, and actin protein was detected by Western blot, as well as phosphory-
lation of 4E-BP1 at Ser65. 
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Discussion 
Our data demonstrate differential sensitivity of the mTOR targets p70S6K 
and 4EBP1 to inhibition of the mTORC1 and PI3K signaling pathways. 
Whereas inhibition of PI3K or mTORC1 was sufficient to rapidly block 
p70S6K phosphorylation, inhibition of both was necessary to cause complete 
dephosphorylation of 4E-BP1 at Thr70 and Ser65. Inhibition of both targets 
also resulted in a clear functional effect as evidenced by a rapid decrease in 
translation initiation that was largely dependent upon 4E-BP1 expression. 
These data suggest that the phosphorylation and inactivation of 4E-BP1 bind-
ing to eIF4E is maintained so long as either of these signaling pathways is 
activated. This cooperative interaction of PI3K and mTORC1 signaling was 
observed in the majority of cell types investigated, including normal human 
fibroblasts. However, rapamycin was effective as a single agent in two tumor 
types (see table 1) indicating that cancer associated changes may lead to 
defects that can be exploited by single agent treatment. Nonetheless, our 
results suggest that dual inhibition of mTORC1 and PI3K is a far more effec-
tive approach to activate 4E-BP1 and inhibit mRNA translation initiation com-
pared with rapamycin alone. Furthermore, we could reproduce these results 
using various combinations of inhibitors or siRNAs that selectively targeted 
the PI3K or mTORC1 pathways, demonstrating the specificity of the interac-
tion. The fact that phosphorylation of 4EBP1 at Thr70 and Ser65 is main-
tained in cells treated with rapamycin or PI3K inhibitors alone, may explain 
previously reported results demonstrating the requirement for inhibition of 
both PI3K and mTOR to suppress the translational changes mediated by on-
cogenic Ras and Akt (40).  
 
Based on our observations, we propose a model whereby 4E-BP1 phos-
phorylation is mediated independently through both mTORC1 and PI3K/Akt 
pathways (Figure 5). In this model, PI3K/Akt signaling is playing substantially 
different roles in maintenance of the phosphorylation status of individual 
mTORC1 targets. In the case of p70S6K (Thr389), PI3K/Akt signaling func-
tions via its well-described ability to regulate mTORC1, presumably through 
negative regulation of the TSC1/2 complex (Figure 5a). Consequently, inhibi-
tion of either PI3K or mTORC1 is sufficient to block phosphorylation of this 
target. In the case of 4E-BP1 phosphorylation, PI3K/Akt is playing a different 
role that, to a large extent, occurs independently of mTOR. mTORC1 activity 
on 4E-BP1 also appears much less dependent on PI3K signaling compared 
to p70S6K. Although we cannot rule out that some of the effects of PI3K or 
Akt inhibition may be mTORC1 dependent, an important mTORC1 activity on 
4EBP1 remains in cells treated with PI3K or Akt inhibitors. This is evidenced 
by the requirement for rapamycin or raptor knockdown in combination with 
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PI3K inhibition to cause significant changes in phosphorylation and activity of 
4E-BP1. The fact that PI3K inhibition blocks mTORC1 activity against 
p70S6K but not 4E-BP1 suggests that mTORC1 complexes may display 
some degree of substrate specificity that is dependent on the activation 
status of upstream signaling pathways. The activation of pathways regulating 
mTORC1 other than PI3K, such as AMPK or GSK3 (41) may help to explain 
why PI3K inhibitors are ineffective as single agents to block 4E-BP1 phos-
phorylation. 
 
 
Figure 5. Model of the pathways responsible for differential phosphorylation sensitivity of the 
mTORC1 targets p70S6K and 4E-BP1. p70S6K and 4E-BP1 are both phosphorylated by 
mTORC1 dependent activity that is regulated upstream by signaling from PI3K as well as other 
non-PI3K signals. a) In the case of p70S6K, phosphorylation is dependent on both PI3K and 
mTORC1 signaling and is suppressed upon inhibition of either pathway alone. b) 4E-BP1 phos-
phorylation is additionally regulated by PI3K/Akt dependent inputs that do not require mTORC1. 
Phosphorylation of 4E-BP1 on Thr70 and Ser65 is maintained unless both PI3K or Akt and 
mTORC1 are inhibited (new pathway shown in red). The requirement for rapamycin or raptor 
knockdown for inhibition of 4E-BP1 phosphorylation in cells treated with PI3K or Akt inhibitors 
also implies that unlike p70S6K, mTORC1 dependent phosphorylation of 4E-BP1 is not sensitive 
to PI3K inhibition. We speculate that additional upstream regulatory pathways are important for 
this activity (pathway in red arrows). 
 
Although the exact mechanisms responsible for the synergistic effects of 
mTORC1 and PI3K inhibition on 4E-BP1 remain to be elucidated, we envis-
age several possibilities. First, it is possible that both pathways independently 
regulate kinase activity on Thr70 or Ser65 and thus inhibition of either is in-
sufficient to prevent phosphorylation on these sites. Although, there is little 
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evidence that these sites on 4E-BP1 are direct targets of either mTOR or Akt, 
these pathways may regulate an additional kinase that has specificity for 4E-
BP1. Second, it is equally possible that the PI3K and mTORC1 pathways 
regulate a phosphatase complex that acts on Thr70 and/or Ser65. In this 
case, the phosphatase complex would have to be negatively regulated inde-
pendently by these two pathways. The fact that we observed rapid loss in 
phosphorylation without noticeable changes in Thr37/46 phosphorylation 
would support this possibility. Unfortunately, the process of 4E-BP1 dephos-
phorylation is much more poorly understood than its phosphorylation. Third, 
the process of 4E-BP1 phosphorylation occurs in a hierarchical fashion and is 
likely mediated by several independent protein kinases that may or may not 
be associated with mTORC1. The requirement for kinases other than mTOR 
at particular steps during the phosphorylation sequence may also explain the 
requirement for dual inhibition of both pathways. Several publications have 
alluded to an mTOR-associated kinase responsible for phosphorylation of 
4E-BP1 C-terminal residues that can influence the phosphorylation of other 
sites (6, 42). 
 
Recently, it has been reported that silencing or inactivating mTOR can para-
doxically enhance the inhibitory effect of rapamycin (43, 44). This suggests 
yet another possibility, that LY294002, by inhibiting mTOR catalytic activity 
(rather than PI3K), could sensitize cells to rapamycin. While we cannot rule 
out direct effects of LY294002 on mTOR activity, this effect is unlikely to ex-
plain the general cooperative outcome on 4E-BP1 observed in our studies 
since we also found a synergistic interaction with rapamycin and an Akt in-
hibitor. Since Akt1/2 targets the plekstrin homology domain/hinge region of 
Akt and mTOR does not contain any structurally similar domains, we do not 
expect that this inhibitor would bind or inactivate mTOR. Furthermore, target-
ing the mTORC1 complex by knockdown of raptor with siRNA also showed 
co-operativity with PI3K inhibition whereas moderate knockdown of mTOR 
itself did not.  
 
Independent arguments for combining mTORC1 and Akt inhibitors follow 
from previous data demonstrating the existence of a negative-feedback 
pathway from mTORC1 via IRS-1 that regulates Akt activation (45). This 
feedback mechanism can be activated by rapamycin in some cell types and 
can stimulate the phosphorylation of Akt. Although rapamycin has been 
shown to induce Akt activation in U87 cells (46), no increase in Ser473 phos-
phorylation was observed after the relatively short 2 h incubation period used 
throughout our study (Figure 4a and 4b). Therefore, it is unlikely that this 
negative-feedback pathway contributes in any significant way to the synergis-
tic effects on 4E-BP1 reported in this study. However, these data suggest 
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that combining rapamycin with a PI3K or Akt inhibitor may not only co-
operate in blocking 4E-BP1 phosphorylation, but also on blockade of com-
pensatory Akt activation.  
 
The relative importance of different mTOR effectors as determinants or tar-
gets of cancer treatment is not well understood, although 4E-BP1 and its abil-
ity to regulate mRNA translation initiation has been implicated in some situa-
tions (8). Our data demonstrate that combined treatment with rapamycin and 
a PI3K inhibitor results in a rapid inhibition of 4E-BP1 phosphorylation and a 
corresponding inhibition of cap-dependent translation. Rapamycin alone led 
to virtually no change in mRNA translation at this time point, even though 
p70S6K phosphorylation was clearly inhibited. We propose that treatment 
with rapamycin or its analogues may be substantially more clinically effective 
when phosphorylation of 4E-BP1 and thus translation initiation, can be inhib-
ited. In this regards, it would be interesting to determine if changes in 4E-BP1 
phosphorylation at short times after treatment might have predictive value for 
rapamycin efficacy. In view of the fact that deregulation of mRNA translation 
is a common feature of many cancers and represents a critical function 
downstream of commonly mutated oncogenes and tumor suppressor genes 
(47), targeting mTORC1 together with PI3K/Akt represents a promising 
therapeutic strategy. 
 
Supplementary figures 
 
 
Figure S1. Dose response of 4E-BP1 Ser65 phosphorylation to rapamaycin and LY294002. U87 
cells were treated with increasing concentrations of rapamycin (R) or LY294002 (LY) or with the 
two inhibitors in combination (LY+R) for a period of 2 h. Lanes from left to right are: untreated 
cells (C), 10 nM R, 100 nM R, 5 μM LY, 10 μM LY, 10 nM R + 1 μM LY, 10 nM R + 5 μM LY, and 
10 nM R + 10 μM LY. 
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Figure S2. The combination of mTOR and PI3K inhibition yields insignificant toxicity. A549 cells 
were treated for 24 h with 10 nM rapamycin and/or 10 μM LY294002 at which times cells were 
seeded for clonogenic survival. Colonies were counted 12 days later and the surviving fraction 
was normalized to the plating efficiency of untreated cells. The mean surviving fraction ± stan-
dard error (n=6) is depicted. Survival of Control compared to LY+R is not significantly different; P 
= 0.06. 
 
 
 
Figure S3. Partial silencing of mTOR expression does not influence 4E-BP1 Ser65 phos-
phorylation. U87 cells were transfected with siRNA targeting mTOR. 72 h later, cells were 
treated with 10 nM rapamycin and/or 10 μM LY294002. Western blots were performed to vali-
date the knock-down of mTOR protein levels, as well as to investigate the phosphorylation of 4E-
BP1 at Ser65. 
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Abstract 
Birt-Hogg-Dubé syndrome (BHD) is a dominantly inherited disorder charac-
terized by an increased risk of developing kidney cancer, pneumothorax as a 
consequence of lung cysts and benign hair follicle tumors called fibrofollicu-
lomas. It is caused by mutations in the BHD gene, coding for folliculin 
(FLCN), a protein possibly involved in mTOR signaling. BHD syndrome is 
generally considered to be a relatively benign condition for which annual fol-
low-up suffices. However, the possibility that the pre-existing gene defect 
might act to modify the behavior of other cancers that arise in patients with 
BHD syndrome has so far not been considered. 
 
We describe a patient with BHD who succumbed to a malignant neuro-
endocrine tumor of prostatic or bladder origin within 6 months of its discovery. 
He also had a papillary renal cell carcinoma. We propose that the behavior of 
our patient's cancer might have been modulated by absence of the BHD 
gene. We demonstrate loss of FLCN in the tumor and show that it does not 
cause mTOR upregulation, contrary to previous findings in a mouse model. 
Our observation could possibly lead to a different approach towards BHD 
patient surveillance and treatment in the future. 
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Introduction 
Birt-Hogg-Dubé syndrome (BHD, MIM #135150) is an autosomal-dominantly 
inherited cancer syndrome characterized by fibrofolliculomas, lung cysts 
leading to pneumothorax, and mainly chromophobic/oncocytic renal cell car-
cinoma (1). The disease is caused by heterozygous mutations in the BHD 
gene encoding folliculin (FLCN). Almost all human mutations reported so far 
lead to putative protein truncation (2). A conditional kidney-specific BHD 
knockout mouse displays activation of mTOR signaling (3). Thus, loss of 
FLCN may result in inappropriate mTOR activity. Considering that mTOR 
signaling is increasingly implicated in tumor progression (4) the spectrum of 
malignancies associated thus far with BHD syndrome seems limited. Studies 
of multiple extended pedigrees have so far not yielded any firm evidence to 
the contrary. We present a patient with BHD syndrome who developed a neu-
roendocrine carcinoma of prostate or bladder origin that behaved in a highly 
malignant fashion, causing our patient’s demise within 6 months after his ini-
tial diagnosis. He also had fibrofolliculomas, lung cysts and a papillary renal 
cell carcinoma. We find loss of FLCN in the tumor and suggest that this may 
have contributed to tumorigenesis, although we find no evidence for mTOR 
deregulation in our patient’s tissues. 
Materials and methods 
Immunohistochemical stainings were performed on frozen sections according 
to a standard protocol. Briefly, tissue samples were flash frozen in liquid ni-
trogen and transferred to -80ºC within one hour after sampling. 5 µm sections 
were cut with a microtome at -20ºC. For staining, slides were fixed in acetone 
for 10 minutes at -20ºC and washed twice in TBS, followed by an incubation 
with H2O2 (3%) in methanol for 10 minutes. After another washing step, slides 
were blocked (TBS/Triton X-100 0.3%/goat serum 5%) and primary antibody 
was added in a 1:50 dilution to be incubated overnight at 4ºC. Next, secon-
dary antibody (goat anti-rabbit, 1:200) was added and incubated at room 
temperature for 30 minutes. The slides were then washed (3x5 minutes) in 
washing buffer. ABC reagent was then added and incubated at room tem-
perature for 30 minutes, followed by three wash steps with washing buffer. 
DAB was then added in 10 ml washing buffer with 0.1% H2O2 followed by 
rinsing in demineralized water during development of the stain. H&E stained 
slides were used for orientation and histological examination. Photographs 
were taken using a Leica DM-4000 microscope with the Leica Application 
Suite software. 
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Case report 
The patient, a 50 year-old man of Dutch origin, was originally diagnosed with 
Birt-Hogg-Dubé syndrome in 2005 when he visited the outpatient clinic of the 
department of dermatology. Several family members were also found to be 
affected. Our findings in the family are described elsewhere (5). Using direct 
sequencing, we found a novel heterozygous insertion mutation 
1408_1418delGGGAGCCCTGT in the BHD gene in all affected family mem-
bers, including the present patient. Following local guidelines in place at the 
time, we performed abdominal CT imaging and found a homogeneous hypo-
dense mass in the upper pole of the left kidney that the radiologist judged to 
be benign, possibly an oncocytoma. A wait-and-see policy was thus adopted, 
as the patient seemed otherwise healthy. 
 
A year later, he visited the outpatient clinic of the department of urology be-
cause of visible hematuria since six months, particularly after exercise. There 
were no other complaints, with the exception of incidental hematospermia. 
Physical examination at the time showed no abnormalities. Rectal examination 
in particular was unremarkable. Routine lab examination showed the following 
normal results: ESR 11, Hb 8.3 mmol/l, Creatinine 74 µmol/l, alkaline phos-
phatase 83 U/l, gammaGT 23 U/l and PSA 1.0. Routine urinalysis was also 
normal. An abdominal CT-scan was performed and showed the previously 
found lesion in the left kidney, in addition to a hypodense mass in the left pros-
tate lobe (figure 1a). An MRI likewise demonstrated the presence of a mass in 
the left prostate with extension underneath the bladder and into the mesorectal 
fat (figure 1b). At the time, it was interpreted as inflammatory. In an attempt to 
further characterize the process, a transrectal prostate biopsy was taken, which 
revealed only inflammatory changes. A malignancy was considered unlikely 
and the patient was discharged. About five months later, he developed acute 
urinary retention for which he was treated with alpha-sympathicolytic agents 
and a trans-urethral catheter. A trans-urethral prostate resection was attempted 
a month after the initial presentation. During surgery, a mass was seen on the 
posterior bladder wall, blocking the ureteric ostia. Tissue samples were taken 
and a suprapubic catheter was placed. A post-operative MRI of the abdomen 
showed a large pelvic mass and extensive lymphadenopathy (figure 2). The 
tumor invaded pelvic wall muscles, prostate, seminal vesicles and bladder. A 
second large tumor was seen that impinged upon the rectum. In addition, ex-
tensive lymphadenopathy was now present, in particular on the left para-iliacal 
side. A thoracic CT-scan did not show any evidence for intrathoracic metasta-
ses. Histopathological examination of the tissue samples obtained during sur-
gery was consistent with a neuroendocrine carcinoma of unknown origin. Two 
weeks after surgery, the patient developed deep venous thrombosis of the left 
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leg. Venous duplex ultrasound examination showed a thrombus in the left deep 
femoral vein. An abdominal CT scan, which was subsequently performed, 
demonstrated the presence of a mass in the left common iliac vein extending to 
the left renal vein. The patient was treated with LMW heparin for his thrombo-
sis. The oncology department was consulted for chemotherapy, but a day after 
his CT scan the patient collapsed and passed away suddenly. Post-mortem 
examination was performed after the family gave their permission. 
 
Figure 1. (a) CT scan made at initial presentation showing hypodense mass in the left prostate 
lobe (arrow). Contrast was enhanced to better demonstrate the lesion. (b) MRI (T1-weighted) at 
approximately the same anatomical level demonstrating a mass in the left prostate lobe that 
seems to invade the perirectal fat (arrow). 
 
 
Figure 2. MRI (T1 weighted, contrast) made 
5.5 months later illustrating dramatic progres-
sion of tumor growth (more cranial slice with 
respect to 1b). Note that the bladder is almost 
replaced by tumor. 
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Results 
During autopsy, the pulmonary arteries were found to contain multiple blood 
clots in addition to CD56 positive tumor cells. The upper pole of the left kidney 
contained a white-grey solid tumor with a diameter of 1.5 cm. Histopathological 
examination was consistent with a diagnosis of papillary renal cell carcinoma 
(figure 3a). Examination of the pelvic basin revealed a large mostly necrotic 
tumor that almost replaced bladder and prostate with extension into the pelvis 
on the left, probably originating from within the left prostatic lobe. Microscopic 
examination showed a highly cellular tumor process with partly nodular growth. 
The cells had large nuclei of irregular shape and with a sometimes recogniz-
able salt-and-pepper pattern (figure 3b). There were considerable mitotic activ-
ity and a large number of apoptotic cells. Extensive angio-invasive growth was 
seen. Immunohistochemical examination of material obtained during the post-
mortem showed the cells to be weakly positive for the neuroendocrine markers 
CD56 and NSE. Some positive vimentin staining was also observed. All other 
markers including MNF116, keratin 7, keratin 20, 34BE12, EMA, PSA, synap-
tofysin and TTF1 were negative (not shown). Although uncertain, a prostatic 
origin of this apparently highly malignant neuroendocrine tumor was consid-
ered likely. We next examined the patient’s tumors and unaffected tissues for 
evidence of FLCN absence and mTOR activation. Not all samples were of suf-
ficient quality to allow for adequate staining, possibly due to post-mortem deg-
radation. Frozen sections from the neuroendocrine carcinoma showed ab-
sence of FLCN staining in the tumor tissue (figure 4a), while there was clear 
staining of infiltrating lymphocytes, which express FLCN (6). The tumor tissue 
did not stain significantly with an antibody directed against phosphorylated S6, 
a known target of mTOR complex 1 (mTORC1) (7) (figure 4b).  We also exam-
ined unaffected patient and control skin, a fibrofolliculoma, unaffected kidney 
and the papillary renal cell carcinoma for evidence of mTOR activity. The renal 
carcinoma stained for phosphorylated mTOR (serine 2448), but so did unaf-
fected kidney from the patient (figure 4 c, d). Skin gave the same results: basal 
keratinocytes stained in both the patient and a healthy control (not shown). 
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Figure 3. (a) H&E staining of the kidney lesion consistent with papillary renal cell carcinoma 
(x100). (b) Histopathology of the neuroendocrine carcinoma. Highly cellular process with large 
nuclei (x100). 
 
Figure 4. (a) Absence of FLCN staining in neuroendocrine carcinoma (blue nuclei), but presence 
in the lymphocytic infiltrate (x100). (b) Absence of phospho-S6 staining in neuroendocrine carci-
noma. Staining cells are leucocytes (x50). (c) Phospho-mTOR (Ser2448) staining in affected 
kidney (x50). (d) Phospho-mTOR (Ser2448) staining of a tubule in the clinically healthy kidney of 
the patient (x100). 
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Discussion 
We report a patient with Birt-Hogg-Dubé syndrome who died with a poorly 
differentiated neuroendocrine carcinoma of either prostatic or bladder origin. 
Based on the post-mortem findings and the CT scan that showed the mass at 
a relatively early stage, a prostatic origin seems most likely. Small-cell neuro-
endocrine carcinoma of prostate or bladder is very rare but highly malignant 
as evidenced by its rapid growth and metastasis in the present case. Its oc-
currence in the context of Birt-Hogg-Dubé syndrome is intriguing and we hy-
pothesized that loss of FLCN may have contributed to the aggressive behav-
ior of the cancer. Birt-Hogg-Dubé syndrome is caused by heterozygous trun-
cating mutations in the BHD gene. Its strong evolutionary conservation hints 
at an important function of FLCN in cellular physiology. It has been hypothe-
sized that activation of mTOR signaling is a common event that contributes to 
tumor development in disorders such as tuberous sclerosis, Peutz-Jeghers 
syndrome or Cowden’s disease (4). Given the strong similarities between the 
clinical phenotypes of BHD and these hamartoma syndromes, it is not sur-
prising that FLCN is thought to be involved in mTOR signaling. However, 
FLCN’s exact function remains to be determined. The recently published 
conditional BHD knockout in mice shows inappropriate mTOR and Akt activ-
ity, suggesting that FLCN is a negative regulator of mTOR. There are also 
indications of an interaction with AMPK (3). 
 
One of the important pathways regulating mTOR activity is the PI3K/Akt 
pathway, which is frequently upregulated by mutation or gene amplification in 
tumors, leading to mitogen-independent proliferation. Activating mutations 
within the PI3K/Akt/mTOR pathway have been found to occur in 30-50% of 
all human tumors (4). Neuroendocrine differentiation in prostate cancer re-
quires Akt-mTOR signaling and is Akt-dependent (8). Therefore, we hypothe-
sized that increased mTOR signaling caused by FLCN deficiency might have 
contributed to the cancer phenotype that we observed. However, our results 
suggest that absence of FLCN does not coincide with increased phosphoryla-
tion of S6, an established marker of mTORC1 activity (7). Neither does the 
heterozygous state seem to be associated with increased mTOR phosphory-
lation in this patient. Thus, FLCN’s exact role in the regulation of mTOR activ-
ity remains to be determined. Our results contradict earlier findings, but it 
should be noted in this context that rodent models of BHD are not completely 
congruent with the human phenotype. Thus, FLCN may have different func-
tions in humans and rodents, in particular with regard to mTOR regulation. 
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In conclusion, we suggest that our patient’s FLCN mutation may have con-
tributed to the pathogenesis of his small-cell neuroendocrine carcinoma. We 
further propose that follow-up of BHD patients should perhaps be more ag-
gressive than currently recommended because, conceivably, loss of FLCN 
may predispose to more tumor types than renal cell carcinoma alone, or al-
ternatively may render other tumors more malignant. The apparent absence 
of mTOR deregulation in our patient’s tumors might suggest that therapies 
targeting mTORC1 may not be useful for BHD-associated malignancies. 
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CHAPTER 8 
General discussion 
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Discussion 
Tumorigenesis in humans is often a slow and multistep process character-
ized by changes in cell physiology that overcome the inherent defense 
mechanisms that limit tissue growth. Such changes have been defined as the 
‘hallmarks of cancer’ and are thought to be essential steps in the develop-
ment and progression of all solid tumors (1). A number of these hallmarks, 
such as self-sufficiency in growth signals, evading apoptosis, and sustained 
angiogenesis can be achieved through changes in pathways that influence 
signaling to mTOR. As a benign proliferative lesion grows, areas of hypoxia 
develop when tissue demand for oxygen and nutrients exceeds the vascular 
supply. The cellular response and eventual adaptation to hypoxia allows tu-
mor cells to remain viable during long periods with little or fluctuating oxygen, 
and on a tissue-level activates the “angiogenic switch”. Thus hypoxia toler-
ance is also an acquired characteristic of solid tumors that may be necessary 
for tumor progression and could be considered an additional hallmark of can-
cer. 
Regulation of mRNA translation is a biological response to hy-
poxia 
Chapter 2 outlines the clinical importance of tumor hypoxia as a prognostic 
indicator of poor outcome and discusses several ways of targeting hypoxia in 
order to improve cancer therapy. Hypoxia not only impedes the effectiveness 
of radiation or chemotherapy but also promotes a more malignant phenotype 
by stimulating angiogenesis, metastasis, and by selecting for cells with re-
duced apoptotic potential. One way to combat hypoxia in tumors is to inter-
fere with the biological response that is initiated when reduced oxygen levels 
are encountered. 
 
In chapter 3 we investigated one of the main biological responses to hypoxia, 
the control of mRNA translation. We have shown that the inhibition of transla-
tion under hypoxia occurs via two distinct mechanisms, the first involving 
eIF2α which occurs rapidly during the first 4 hours of hypoxia and the second 
involving eIF4E which maintains repression of translation during prolonged 
hypoxic exposure. Different patterns of gene-specific translation efficiency 
were characterized during acute and prolonged hypoxia. For example, actin 
and CAIX are efficiently translated under control conditions but show a rapid 
decrease in the average number of ribosomes per transcript during acute 
hypoxia that partially recovers during prolonged hypoxia. The rapid decrease 
in translation efficiency of these genes was dependent on eIF2α. In contrast, 
ATF4, a transcription factor activated upon ER stress, displays increased 
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translation under hypoxia therefore illustrating that specific genes are able to 
overcome the general repression in global translation under hypoxia in order 
to increase their expression levels. Microarray studies utilizing polysome-
associated RNA have revealed a number of genes that are preferentially 
translated under hypoxia (2, 3). The exact mechanisms responsible for in-
creased translation under hypoxia are still being investigated but seem to 
depend upon gene-specific sequences or secondary structure of the 5’ and 3’ 
UTRs. ATF4 harbors upstream open reading frames (ORFs) in its 5’UTR 
which prevent ribosome initiation at the proper start codon under normal  
conditions; however under ER stress the phosphorylation of eIF2α impairs 
ribosome initiation increasing the probability that ribosomes will read through 
the upstream ORFs and initiate translation at the correct ATF4 start site (4). It 
is probable that the same mechanism regulates ATF4 expression under hy-
poxia. Other genes may rely upon internal ribosome entry sites (IRES) to ini-
tiate cap-independent translation under conditions where the eIF4F initiation 
complex is limiting. A majority of advanced breast cancers overexpress both 
4E-BP1 and eIF4G which facilitates a hypoxia-mediated switch between cap-
dependent to cap-independent mRNA translation (5). This increase in 4E-
BP1 expression enables the inhibition of cap-dependent translation under 
higher oxygen levels while high eIF4G expression allows the selective trans-
lation of IRES-harbouring mRNAs under hypoxia. However the existence of 
IRES mediated translation of endogenous genes remains controversial and 
there is yet no irrefutable evidence that it contributes significantly to the se-
lective translation of particular genes under hypoxia (6, 7). A recent report by 
Zimmer et al. has described a mechanism that increases the translation of 
HIF2α under hypoxia that involves binding of iron regulatory protein 1 (IRP1) 
to an iron-responsive element (IRE) in the HIF2α 5’UTR (8). The IRP1/IRE 
association represses translation under normoxic conditions; however hy-
poxia impairs IRP1 binding therefore allowing efficient translation of HIF2α 
under low oxygen.  
EGFRvIII promotes resistance to hypoxia 
In chapter 4 we investigated a constitutively active tyrosine kinase receptor 
that signals to mTORC1 via the PI3K-Akt pathway, EGFRvIII. We generated 
a glioma cell line that stably expresses EGFRvIII which we used to determine 
the effect of EGFRvIII expression on radiation sensitivity, tumor growth and 
hypoxia tolerance. Despite having no effect on the growth rate of cells grown 
under optimal culture conditions, EGFRvIII stimulated the growth of xenograft 
tumors in mice. This result suggests that EGFRvIII is able to promote prolif-
eration and/or survival under conditions specific to the tumor microenviron-
ment. Indeed, when cultured under hypoxia, EGFRvIII expressing cells had 
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an increased growth rate and were less susceptible to hypoxia-induced cell 
death. Although the mechanism involved has yet to be investigated, it is in-
teresting to speculate that mTOR might play a role. EGFR activation of the 
PI3K-mTOR pathway has been shown to upregulate HIF-1α expression lead-
ing to increased survivin expression and subsequent resistance to apoptosis 
(9). Based on our results, we reason that EGFR over-expressing or EGFRvIII 
positive cells would accumulate in hypoxic regions due to the selective ad-
vantage that increased proliferation and survival under hypoxia imparts to 
these cells. Indeed, a correlation between EGFR expression and regions of 
tumor hypoxia has been reported (10). Treatment of tumors with EGFR in-
hibitors also leads to a decrease in hypoxic fraction (11, 12). Increased cell 
viability within hypoxic regions of tumors would also promote resistance to 
radiation therapy since hypoxic cells require a 3 fold higher radiation dose in 
order to achieve an equivalent amount of toxicity as oxygenated tissue (13). 
Thus, in addition to the effect of EGFRvIII that we found on intrinsic radiosen-
sitivity (as seen by a nearly two-fold increase in survival after irradiation with 
4 Gy in vitro), increased hypoxia in EGFRvIII expressing tumors can signifi-
cantly impair tumor response to radiation therapy.  
 
The relationship between EGFR and hypoxia also works in the reverse direc-
tion with hypoxia stimulating translation of EGFR mRNA (14). Since EGFRvIII 
and wild-type EGFR share the same UTR sequences, it is likely that the 
same regulation would apply to our model. Targeting of mTOR in this situa-
tion could be advantageous if it would block the hypoxia-induced expression 
of EGFR. A number of recent studies have examined the combination of 
mTOR and EGFR inhibitors and have shown promising results (15-17).  
Targeting mTOR in combination with radiotherapy 
In chapter 5 we focused our interest on mTOR as a therapeutic target by in-
vestigating the combination of rapamycin with radiation therapy in a mouse 
tumor xenograft model. We demonstrated that rapamycin was effective both 
in vitro and in vivo to reduce the proliferation of tumor cells. When given in 
combination with fractionated radiotherapy, there was however no additional 
effect of rapamycin on tumor cure or on tumor growth delay. This finding is in 
contrast to two other reports that mTOR inhibitors can enhance the growth 
delay achieved by fractionated radiation (18, 19). However, several key dif-
ferences exist in the design of our study which may explain the conflicting 
results. In our experiment, we delivered the rapamycin treatment over a short 
period of 6 days to look specifically at the interaction with radiation. This lim-
ited the anti-proliferative effect that rapamycin would have on tumor cell re-
population between radiation fractions or on the growth rate of tumor cells 
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surviving radiotherapy. We also used higher radiation doses per fraction than 
the other studies as our primary goal was to measure tumor cure rate. In the 
other studies, rapamycin or RAD001 was given over a prolonged period (> 18 
days). Given the fast doubling time of U87 xenografts (~4 days), overall 
treatment time will play a significant role in the outcome of such a growth de-
lay assay. It still remains to be determined if rapamycin would be beneficial 
with respect to local tumor control and survival in a typical clinical setting 
where radiation is delivered over a 4-6 week period in 2 Gy fractions. 
 
We found a high degree of heterogeneity in the response of individual ani-
mals receiving the combination of rapamycin and radiation which suggested 
that a subset of tumors may have benefited although the group as a whole 
did not. Upon ex vivo examination of tumors we found that rapamycin treat-
ment increased the presence of hypoxia in tumor sections. This may be due 
to an increasing trend in the amount of thrombotic vessels within the tumor 
tissue which could limit perfusion. Alternatively, this may be a result of meta-
bolic effects of mTOR inhibition. Ronellenfitsch et al. show that rapamycin 
can protect glioma cells against hypoxia-induced cell death by maintaining 
ATP levels and thus preserving cell viability (20). Sustaining energy homeo-
stasis by limiting translation may allow tumor cells to better tolerate hypoxic 
stress. This is supported by evidence that the inhibition of translation via 4E-
BP1 is important in order for tumor cells to survive chronic hypoxia (21).  
 
We speculate that these microenvironmental effects of rapamycin may have 
limited any additional increase in cytotoxicity that may have resulted from the 
combination with radiotherapy. Different scheduling of rapamycin and radia-
tion may be useful to alleviate any complications of rapamycin-induced hy-
poxia (ie sequential versus concurrent treatment) as has been demonstrated 
with anti-angiogenic agents (22). 
Differential effects of mTOR inhibition on downstream targets 
In chapter 6, we conducted an in-depth examination of the effects of rapamy-
cin on the downstream targets of mTORC1. We found that p70S6K and 4E-
BP1 responded differently to rapamycin treatment as seen by a more effec-
tive inhibition of p70S6K phosphorylation than of 4E-BP1. Curiously, by com-
bining rapamycin with LY294002, a PI3K inhibitor, 4E-BP1 phosphorylation 
could be blocked more effectively than by either inhibitor alone and there was 
also a greater repression on the biological consequences of mTOR regulation 
as revealed by changes in global translation. This was unexpected given 
what is currently known about the mTOR signaling pathway and the specifici-
ties of these two kinase inhibitors. Previous studies have described both ra-
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pamycin-sensitive and insensitive functions of mTORC1 towards 4E-BP1 and 
have shown that expression of a kinase-inactive mTOR mutant can enhance 
the inhibitory effect of rapamycin towards 4E-BP1 phosphorylation (23). 
These results indicate that rapamycin is not able to block all aspects of 
mTORC1 function in some cell lines. Dose-dependent effects of mTOR inhi-
bition have also been described, with CCI-779 displaying an FKBP12-
independent inhibition of mTOR kinase activity at high micromolar concentra-
tions (24). This suggests that high-dose rapamycin may be more effective to 
inhibit signaling from both mTOR complexes and could overcome the resis-
tance of some cell lines to low-dose rapamycin treatment. 
 
We also saw an enhanced inhibition of 4E-BP1 phosphorylation when using 
rapamycin in combination with an Akt inhibitor, suggesting that there is a 
PI3K/Akt-dependent stimulation of 4E-BP1 phosphorylation that is independ-
ent of mTORC1. This parallel pathway does not influence the phosphoryla-
tion of p70S6K but can maintain phosphorylation of 4E-BP1 and global trans-
lation when mTORC1 is inactive. This parallel pathway may be similar to one 
described by Pore et al. which concerns a PI3K/Akt- dependent regulation of 
HIF-1α translation that does not require mTOR (25).  
 
In conclusion, our results suggest that a more effective inhibition of all 
mTORC1 downstream targets will lead to a better inhibition of translation and 
perhaps a more robust anticancer activity. 
Folliculin dependent regulation of mTOR 
Upregulation of mTOR signaling has been described as a common feature in 
a number of genetic disorders that are associated with the development of 
both benign and malignant tumors referred to as hamartoma syndromes (26). 
The genes which are mutated in these syndromes are tumor suppressors 
such as PTEN, TSC1/2, or LKB1 that all act as negative regulators of the 
various signaling pathways that activate mTOR. The clinical manifestation of 
Birt-Hogg-Dubé syndrome is similar to the phenotypes of the hamartoma 
family of diseases, and mouse models of BHD have established a connection 
between loss of folliculin expression and upregulation of mTOR and MAPK 
signaling (27, 28). Thus, these findings point to a potential function of fol-
liculin in suppressing tumor formation by downregulating mTOR signaling by 
an unknown mechanism. 
 
In the case report presented in chapter 7, we describe a BHD patient who 
died as a result of an aggressive neuroendocrine carcinoma of the prostate. 
This was an unusual case since BHD is not commonly associated with this 
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type of tumor. We hypothesized that increased mTORC1 activity as a conse-
quence of lost folliculin expression in the tumor may have contributed to the 
aggressiveness of this patient’s cancer. However, despite observing loss of 
folliculin expression in the prostate tumor we found no evidence of S6 phos-
phorylation, a target downstream of mTORC1. Interestingly, this finding is 
consistent with recently published results from Hartman et al. who also re-
ported downregulation of S6 phosphorylation in human cell lines expressing 
BHD siRNA (29). Therefore it appears that loss of folliculin does not correlate 
with increased mTORC1 activity in humans, unlike what is observed in vari-
ous mouse models of the disease. This discrepancy may be due to species 
specific differences or may be related to the time during development during 
which folliculin expression is lost (i.e. during embryonic development in the 
conditional knock-out mice or after tissue specific differentiation has occurred 
as in the human situation). 
 
We have continued to explore the mechanistic basis behind these surprising 
observations and have recently obtained preliminary data suggesting that 
mTORC2 may be more relevant for BHD than mTORC1 (figure 1). We have 
expressed either wild-type folliculin or a series of patient-derived folliculin mu-
tants in HEK293 cells. Expression of the wild-type folliculin protein leads to 
reduced phosphorylation of Akt at Ser473 (the site which is phosphorylated 
by mTORC2 (30)). In contrast, expression of mutant folliculin constructs 
which result in the expression of truncated proteins (c.1733insC or Y463X) 
resulted in increased phosphorylation of Akt at the same site. The truncated 
mutants also appear to elevate Akt activity as seen by enhanced FoxO3a 
phosphorylation, a downstream target of Akt. In comparison to these truncat-
ing mutations, the folliculin K508R missense mutant did not have the same 
stimulatory effect on Akt phosphorylation. These new data suggest that the 
C-terminus of folliculin functions as a negative regulator of mTORC2 and that 
these truncating mutations cause activation of mTORC2 and Akt. 
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Figure 1. FLCN dependent regula-
tion of Akt. HEK293 cells stably 
expressing empty vector (Ctrl), wild-
type (WT), or mutant FLCN con-
structs (c.1733insC, Y463X, or 
K508R) were lysed and subjected to 
Western blotting for phospho-Akt 
Ser473 and phospho-FoxO3a 
Ser253. Total Akt serves as a pro-
tein loading control. Expression of 
the constructs is confirmed by the 
FLCN blot. 
 
 
 
Future prospectives 
The development of specific mTOR kinase domain inhibitors (TORKinibs) is 
currently an area of great enthusiasm. New data describing the effectiveness 
of two such inhibitors (PP242 and PP30) in blocking signaling downstream of 
both mTOR complexes has recently been published (31). PP242 has en-
hanced anti-proliferative activity compared to rapamycin, which is due to 
more effective inhibition of mTORC1 and cap-dependent translation rather 
than from additional effects of mTORC2 inhibition on proliferation. This find-
ing also supports our data in chapter 6 which show that the rapamycin-
resistant outputs of mTORC1 are important for the regulation of translation. 
These new agents are yet another tool to improve our understanding of the 
mTOR signaling pathway but furthermore, it will be exciting to follow TORK-
inibs on their journey to the clinic to see if they can indeed improve the effi-
cacy of cancer treatment. Cancers displaying upregulation of either mTORC1 
or mTORC2 activity, and in particular cancers associated with Birt-Hogg-
Dubé syndrome will be excellent candidates for future testing of these new 
agents in the clinic. Nevertheless, attention should be given to potential vas-
culature effects and metabolic consequences of mTOR inhibition as these 
new agents are investigated further in tumor models. 
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SUMMARY 
The mTOR kinase, as a central integration point for sensors of growth fac-
tors, nutrients and energy sources, plays a key role in tumor biology. In the 
cell, mTOR is a part of two different multi-protein complexes, mTORC1 and 
mTORC2. The main function of mTORC1 is to regulate the production of new 
proteins within the cell. In this dissertation I have investigated several key 
aspects of mTOR signaling in cancer with a focus on its role in the tumor mi-
croenvironment. 
 
During the process of tumor development, the normally tight regulation of 
mTOR and protein synthesis is often lost, leading to increased proliferation 
and survival, and alteration of the microenvironment (this thesis). This is illus-
trated in chapter 4 where we show that EGFRvIII, a constitutively active 
kinase receptor that signals through the PI3K/Akt/mTOR pathway, stimulates 
tumor growth and promotes survival after irradiation or under low-oxygen 
conditions (hypoxia). Hypoxia is a common feature of solid tumors and an 
important determinant of poor treatment outcome, thus strategies that can 
reduce or eliminate hypoxic tumor cells are highly desirable (reviewed in 
chapter 2). The ability of cells to repress mTOR activity and protein synthesis 
is an important part of the cellular response to hypoxia. In chapter 3 we show 
that hypoxia inhibits protein synthesis in two separate phases by using two 
distinct mechanisms, one of which requires 4E-BP1, an mTOR substrate.  
 
The ability of 4E-BP1 to inhibit protein synthesis is determined by its level of 
phosphorylation. This prompted us to conduct an indepth study of 4E-BP1 
regulation in chapter 6. We provide evidence to suggest that in addition to 
mTORC1, there is a PI3K/Akt-dependent but mTORC1-independent signal to 
4E-BP1 that must be blocked in order to effectively inhibit protein synthesis 
via this mechanism. Thus, targeting protein synthesis in cancer might be im-
proved by strategies that block 4E-BP1 more effectively.  
 
Due to the attractiveness of mTOR as a therapeutic target in cancer, a num-
ber of mTOR inhibitors are currently being tested, many of which are analogs 
based upon the structure of the original mTOR inhibitor, rapamycin. Previous 
studies have shown that rapamycin can inhibit tumor regrowth when used in 
combination with radiation. However, in chapter 5, we saw no additional ef-
fect of rapamycin to limit local tumor control by radiation, although we did ob-
serve heterogeneity in the response of individual tumors that may have been 
influenced by increased areas of hypoxia and intravascular thrombosis after 
rapamycin treatment.  
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Our knowledge of the mTOR signaling pathway continues to evolve as we 
learn more about the intricacies of its regulatory proteins and feedback path-
ways. Human genetics can be a valuable tool in helping us to dissect the in-
teractions between signaling proteins within a pathway. In chapter 8, we de-
scribe a patient with Birt-Hogg-Dubé syndrome (a familial cancer disease) in 
which the mutant folliculin protein is suspected to promote tumor formation by 
upregulation of mTOR activity through an unknown mechanism. We show 
that tumors associated with this syndrome do not express common markers 
of increased mTORC1 activity, but rather that activation of mTORC2 may be 
more relevant to this disease.  
 
In conclusion, mTOR and protein synthesis are attractive targets for cancer 
therapy. However, the future success of these strategies will depend upon 
both basic and translational research to understand how best to inhibit these 
processes for maximum gain of anti-tumor effect without undesirable activa-
tion of feedback loops or normal tissue side-effects. 
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SAMENVATTING 
mTOR fungeert als centraal integratiepunt voor sensoren van groeifactoren, 
voedingsstoffen en energiebronnen. Op die manier heeft mTOR een erg be-
langrijke rol in tumorbiologie. In de cel kan mTOR deel uitmaken van twee 
verschillende multi-eiwit complexen, mTORC1 en mTORC2. De hoofdfunctie 
van mTORC1 is het reguleren van de productie van nieuwe eiwitten binnen 
de cel. In dit proefschrift heb ik een aantal sleutelaspecten van mTOR-
signalering in kanker onderzocht. De focus lag daarbij op de rol die mTOR 
speelt in de tumor micro-omgeving. 
Gedurende het ontwikkelingsproces van een tumor gaat de strikte regulering 
van mTOR en eiwitsynthese vaak verloren. Dit leidt tot toegenomen prolifera-
tie en overleving van tumorcellen, en tot een verandering van de tumor mi-
cro-omgeving (dit proefschrift). Dit wordt beschreven in hoofdstuk 4 waar we 
laten zien dat EGFRvIII, een constitutief geactiveerde kinase receptor die 
signaleert via de PI3K/Akt/mTOR-route, tumorgroei stimuleert. Expressie van 
EGFRvIII verbetert ook het overleven van tumoren na bestraling of bij bloot-
stelling aan verlaagde zuurstofconcentraties (hypoxie). Hypoxie komt veel-
vuldig voor in vaste tumoren en is een belangrijke determinerende factor voor 
een slechte behandelingsuitkomst. Het is dan ook zeer wenselijk dat strate-
gieën ontwikkeld worden die het aantal hypoxische cellen in tumoren kunnen 
verminderen of elimineren (zoals beschreven in hoofdstuk 2). Het vermogen 
van cellen om mTOR-activiteit en eiwitsynthese te onderdrukken vormt een 
belangrijk onderdeel van de cellulaire respons tegenover hypoxie. In hoofd-
stuk 3 tonen we aan dat hypoxie de eiwitsynthese remt in twee verschillende 
fases, door gebruik te maken van twee verschillende mechanismen. Eén van 
deze mechanismen vereist het mTOR-substraat 4E-BP1. 
 
De mogelijkheid van 4E-BP1 om eiwitsynthese te remmen hangt af van de 
mate waarin het is gefosforyleerd. Dit zette ons aan om de regulatie van 4E-
BP1 in detail te onderzoeken (hoofdstuk 6). Onze data suggereren dat naast 
het mTORC1 signaal wellicht een PI3K/Akt-afhankelijk maar mTORC1-
onafhankelijk signaal naar 4E-BP1 gaat, dat geblokkeerd moet worden om 
via dit mechanisme de eiwitsynthese te kunnen remmen. Zodoende zou het 
aangrijpen op de eiwitsynthese bij kanker mogelijk verbeterd kunnen worden 
met behulp van strategieën die 4E-BP1 effectiever blokkeren. 
 
Omwille van het feit dat mTOR aantrekkelijk is als een therapeutisch doelwit 
bij kanker, worden momenteel een aantal mTOR-inhibitoren getest. Vele van 
deze remmers zijn analogen die gebaseerd zijn op de structuur van de origi-
nele mTOR-remmer, rapamycine. Eerdere studies hebben laten zien dat ra-
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pamycine, in combinatie met bestraling, de hergroei van tumoren kan rem-
men. Echter, in hoofdstuk 5 hebben we geen additioneel effect van rapamy-
cine op lokale tumorcontrole door bestraling gevonden. Wat we wel duidelijk 
observeerden, was een heterogeniteit in respons van individuele tumoren. Dit 
kan mogelijk verklaard worden door een toename van hypoxie en intravascu-
laire thrombose na behandeling met rapamycine.  
 
Onze kennis van de mTOR-signaleringsroute blijft zich verder ontwikkelen 
doordat we steeds meer te weten komen over de gecompliceerdheid van de 
verschillende mTOR-regulatorische eiwitten en de feedback mechanismen. 
Humane genetische informatie kan een waardevol instrument zijn om de in-
teracties tussen verschillende signaleringseiwitten binnen een transductie-
weg in een cel te ontleden. In hoofdstuk 8 beschrijven we een patiënt met het 
Birt-Hogg-Dubé syndroom (een familiale kankeraandoening) waarbij vermoed 
wordt dat het gemuteerd folliculin-eiwit tumorvorming promoot door verhoging 
van de mTOR-activiteit via een nog onbekend mechanisme. Wij tonen aan 
dat tumoren die met dit syndroom geassocieerd zijn, geen merkers van ver-
hoogde mTORC1-activiteit tot expressie brengen, maar dat eerder activering 
van mTORC2 relevanter is voor deze ziekte.  
 
Tot besluit kunnen we stellen dat mTOR en eiwitsynthese aantrekkelijke doe-
len zijn voor kankertherapie. Het toekomstige succes van deze strategieën 
zal afhankelijk zijn van zowel basaal en translationeel onderzoek, dat ons in 
staat moet stellen om te begrijpen hoe we deze processen het best inhibe-
ren, zodat we een maximaal anti-tumor effect kunnen verkrijgen zonder on-
gewenste activering van feedbackmechanismen of neveneffecten op gezond 
weefsel. 
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